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Abstract 
INTRODUCTION: Breast cancer makes up 25% of all cancers diagnosed worldwide. Despite 
an increasing yearly incidence, there has been a significant decrease in mortality owing to 
early diagnosis and advances in treatment. Anthracycline-based chemotherapy is a relatively 
low cost yet highly effective anti-cancer treatment, increasing survival from 30% to >80%, 
presently. However, treatment efficacy is marred by the increased risk of anthracycline-
induced cardiotoxicity (ACT) – estimated at 10-26%. Internationally, there has been evidence 
of ACT having a genetic basis. 
Currently in South Africa, there is little information on ACT in cancer patients and survivors, 
and no information on the genetic basis of this phenomenon. Our recruitment sites in Cape 
Town - Groote Schuur Hospital (GSH) and Tygerberg Hospital (TBH), routinely treat hundreds 
of patients, notably with breast cancer, with anthracycline-based therapy every year, and 
provided the environment to assess ACT, as well as genetic factors which may influence this 
adverse drug reaction.  Left ventricular ejection fraction (LVEF) acts as a surrogate measure 
of cardiac function in the public health-care setting. 
OBJECTIVES: To provide insight into the clinical management of breast cancer patients on 
anthracycline-based treatment with a focus on the prevalence of ACT. To provide an index of 
genetic susceptibility to ACT and potentially contribute to a personalized medicine approach 
for a genetically diverse population. 
METHODOLOGY: In the retrospective part of the study, the clinical records of cancer patients 
treated with anthracyclines from 2011- 2016 at the Oncology Clinic at GSH were analysed. 
Clinical co-morbidities such as hypertension, diabetes, pre-existing cardiac disease and 
smoking as well as type and dose of anthracyclines, cardiac function and patient status were 
assessed.  
In the prospective study, breast cancer patients treated with anthracyclines, with a pre and 
post-treatment LVEF measure were recruited at GSH and TBH from 2013 to 2016. Patients 
were consented for access to both clinical information and biological material. Demographics, 
clinical risk factors and chemotherapeutic regimen data were analysed. LVEF, biomarkers and 
clinical status were also assessed in terms of reflecting ACT. In some instances certain clinical 
information was not available (i.e. LVEF) and out of necessity, a statistical correlation model 
or classifier was created in order to use available clinical data to derive missing clinical 
measures. Patients’ DNA were analysed for seven genetic variants in the following six genes 
ABCC1 (rs246221); ABCC2 (rs17222723; rs8187710); HNMT (rs17583889); NCF4 
(rs1883112): RAC2 (rs13058338) and RARG (rs2229774), and tested for correlation with 
clinical status and cardiac injury. Finally, a corollary study was conducted on a subset of 
patients in an attempt to determine whether cardiac biomarkers may be more sensitive 
measures of cardiotoxicity. 
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RESULTS & DISCUSSION: In the retrospective cohort (n=402) 19.7% of patients showed 
diminished cardiac function. Logistic regression showed that the following predictors: type of 
first line chemotherapy, and total dose significantly contributed to the ACT phenotype as 
measured by change in LVEF. 
In the prospective patients (n=272), 14% were affected with ACT, with an increased likelihood 
of cardiotoxicity in the Indigenous African population. Logistic regression showed that both 
total anthracycline dose and change in LVEF were predictive of ACT. In the association study 
of prospective patients, only the RARG rs2229774 variant was significantly associated with 
patient ACT status (p=0.049, Chi-Square Test). 
Forty-two patients were assessed for the β-Natriuretic Peptide (BNP) biomarker and showed 
limited utility in correlating clinical status and/or LVEF decrease in all patients except 
Indigenous Africans indicating potential increased susceptibility of population group to ACT. 
LVEF was found to be unreliable as significant LVEF decreases did not always correlate with 
cardiac impairment and vice-versa. Changes in routine clinical patient management and 
overburdening of the nuclear medicine department also translated to only one LVEF measure 
being obtained in some instances. The statistically derived classifier for missing indicators of 
heart function was useful, but will require refinement. 
CONCLUSIONS AND RECOMMENDATIONS: Despite the inability of genotype as a predictor 
of ACT in this study, the increased susceptibility in the Indigenous African population to ACT 
as well as increased BNP levels after chemotherapy requires a closer look. The interrogation 
of lndigenous African patient genomes for novel variants of susceptibility to ACT are 
recommended; this requires building up of a substantial cohort from this population group, 
which would likely require collaboration with health care institutions in one of the other 
provinces of South Africa e.g. Eastern Cape, KwaZulu-Natal and/or Gauteng. Both this study 
and literature recommend the need for clinical trials for new and existing drugs on local African 
populations for both safety and efficacy. 
Furthermore, the BNP biomarker may be better suited to the prediction of irreversible cardiac 
damage rather than early cardiotoxicity. Troponin, released in response to cardiomyocyte 
death, may be a more sensitive biomarker in predicting ACT. Similarly, the inherent variability 
and lack of sensitivity of LVEF as a measure of cardiac function warrants the consideration of 
alternatives such as echocardiography or tissue-doppler imaging. 
Findings derived from this study indicate the need for refined patient management of ACT in 
a South African population to potentially allow for treatment with minimised risk and event-free 
breast cancer survival. 
 
 
v 
 
Acknowledgements 
“Courtesies of a small and trivial character are the ones which strike deepest in the 
grateful and appreciating heart.” – Henry Clay 
While this PhD may have my name on it, it would have not been possible without the 
kindness and selfless contribution of others – for which I am both immeasurably and 
eternally grateful.  
Firstly, to my parents Ravi and Shereen, no words can express the gratitude I have 
to both of you for the life you have blessed me with. The hard work and sacrifice 
undertaken and the motivation and love that you have given has resulted in a life with 
endless possibilities and for that I thank you…I only hope that I can one day bestow 
these same kindnesses on both of you for there is no one more deserving. I love you 
both so much. 
Della and Tash, my lovely sisters – one here and one in heaven, thank you for always 
being your big sister’s greatest supporters. Della, thank you for your generosity of 
spirit and being the most fun person I know – being with you is like a holiday and I 
love you for it. 
Michael, my love – in the journey of the PhD, I never expected to find you and I am 
so grateful that I did. Not only have you given me greater resilience in pursuing my 
dreams but you have inadvertently brought out the best version of me and for that I 
thank you. 
To my friends – Amy, Khalil, Lindie, Shareefa, Maryam, Tasneem and Marelize who 
have loyally supported and encouraged me from the side-lines. Our friendship 
transcends distance and time – thank you. Shareefa (Dr Dalvie), thank you for being 
a most trusted PhD ally- without your editing, advice and incredible teaching I would 
be lost. 
To the kindness of the selfless ones, those who take a moment to pause in their busy 
lives to ensure you are assisted is akin to a gratefully received miracle. Alvera, thank 
you for both always dropping everything to help me and your sage advice; Lara, Eve 
and Dr Van Wijk at the Groote Schuur Hospital LE33 Clinic for making my hospital 
visits a happy and productive one; Dr Pieter Barnardt at Tygerberg Hospital for being 
an incredibly proficient research collaborator; Dr Feriel Azibani and Professor Karen 
Sliwa for your kind collaborative efforts; Professors Jacquie Greenberg and Collet 
Dandara for always providing support and a listening ear and Heidi Paulse, our saint 
in the front office – thank you. 
vi 
 
To my supervisors Professor Raj Ramesar and Hannah Simonds, thank you for your 
expertise and support allowing for the completion of my PhD. Professor Ramesar, 
thank you for giving me the opportunity of a lifetime and allowing me to grow – my 
time at HumGen has been an incredibly happy one. Professor Simonds, you are an 
inspiration for women in medicine and science, thank you for all your help in my PhD 
journey. 
To the National Research Foundation and the UCT Funding Office, without your 
steadfast financial contribution this PhD would not be possible – thank you.  
To all the patients and their families who so kindly consented to be a part of this study 
– thank you. I sincerely hope that this work will ultimately contribute to better clinical 
outcomes in the future. 
Finally, I must express my gratitude to God for a life with an abundance of blessings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
Table of Contents 
Declaration ............................................................................................................... ii 
Abstract ................................................................................................................... iii 
Acknowledgements ................................................................................................... v 
List of Figures ......................................................................................................... xii 
List of Tables .......................................................................................................... xv 
Abbreviations ........................................................................................................ xvii 
Chapter 1: Preface ................................................................................................... 1 
1.1 Thesis Statement: ...................................................................................... 1 
1.2 Project Summary: ...................................................................................... 1 
1.3 Motivation: ................................................................................................. 1 
1.4 Research Related Aims and Objectives: .................................................... 3 
Chapter 2: Introduction ............................................................................................ 6 
2.1 Retrospective Patient Analysis .................................................................. 6 
2.1.1 Definition of Breast Cancer ................................................................. 6 
2.1.2 Incidence of Breast Cancer................................................................. 6 
2.1.3 Types of Breast Cancers .................................................................... 8 
2.1.4 Breast Cancer Staging and Classification ..........................................10 
2.1.5 Treatment of Breast Cancer...............................................................15 
2.2 Prospective Patient Analysis .....................................................................16 
2.2.1 Anthracycline-based Chemotherapy ..................................................16 
2.2.2 Modalities to Assess Cardiac Function ..............................................26 
2.2.3 Management of Cardiotoxicity ...........................................................30 
2.3 Genetics of Cardiotoxicity .........................................................................32 
2.3.1 Characterisation of Specific Genes ....................................................38 
2.4 Economic Implications of Cardiac Failure compared to Preventative 
Measures ............................................................................................................41 
2.4.1 Comparison of Preventative Measures, Sensitive Assessment 
Modalities and Treatment for Cardiac Failure ..................................................41 
Chapter 3: Patients, Materials and Methods ...........................................................43 
viii 
 
3.1 Retrospective Cohort ................................................................................43 
3.1.1 Setup of Database .............................................................................43 
3.1.2 Collection of Data ..............................................................................43 
3.1.3 Statistical Analyses ............................................................................44 
3.2 Literature Mining .......................................................................................45 
3.3 Prospective Study: Selecting Genes/SNPs of Interest ..............................45 
3.3.1 Pathway-based Approach ..................................................................45 
3.3.2 Gene Annotation ................................................................................45 
3.3.3 Selected Genes of Interest ................................................................46 
3.4 Prospective Study: Patient Recruitment ....................................................48 
3.4.1 Recruitment Protocol and Ethics ........................................................48 
3.4.2  Procurement of Clinical Information from Patient Folders .................48 
3.5 Patient Sample .........................................................................................49 
3.6 DNA isolation ............................................................................................49 
3.6.1 Principle of DNA Isolation using Promega Maxwell® 16 DNA 
Purification Kit: .................................................................................................49 
3.6.2 Principle of DNA Isolation using ‘Salting-Out’ Technique: ..................50 
3.6.3 Quantification of DNA: .......................................................................51 
3.6.4 DNA Integrity Gels .............................................................................52 
3.7 Polymerase Chain Reaction (PCR) ...........................................................53 
3.7.1 Principle of PCR ................................................................................53 
3.7.2 Primer Design for PCR ......................................................................54 
3.7.3 Optimisation: Singleplex and Multiplex ..............................................57 
3.7.4 Technique of PCR .............................................................................60 
3.7.5 Agarose Gel Electrophoresis .............................................................62 
3.8 Genotyping ...............................................................................................62 
3.8.1 Genotyping by the SNaPshot® Multiplex Assay ................................62 
3.8.2 Genotyping by TaqMan™ SNP Genotyping Assay ............................70 
3.9 Sequencing ..............................................................................................72 
ix 
 
3.9.1 Principle of Sequencing .....................................................................72 
3.9.2 Technique of Sanger Sequencing ......................................................73 
3.10 Statistical Analysis ....................................................................................75 
Chapter 4: Results ..................................................................................................78 
4.1 Retrospective Cohort Analysis .....................................................................78 
4.2 Prospective Cohort Analysis ........................................................................87 
4.2.1 Recruitment ...........................................................................................87 
4.2.2 Procurement of Clinical Information from Patient Folders ......................87 
4.2.3 Statistical Analysis ................................................................................90 
4.3 Patient Sample .............................................................................................93 
4.3.1 DNA isolation ........................................................................................93 
4.3.1.1 Spectrophotometry for quantitation of DNA ....................................94 
4.3.1.2 Assessment of DNA Integrity .........................................................94 
4.4 Selected Genes of Interest ...........................................................................95 
4.4.1 Gene Annotation ...................................................................................95 
4.5 PCR .............................................................................................................95 
4.5.1 Optimisation: Singleplex and Multiplex PCR ..........................................95 
4.5.1.1 Temperature Gradient ....................................................................95 
4.5.1.2 Magnesium Gradient ......................................................................96 
4.5.1.3 Additives ........................................................................................97 
4.5.1.4 Touchdown PCR ............................................................................97 
4.5.2 Optimised Multiplex PCRs .....................................................................98 
4.6 Genotyping ................................................................................................. 100 
4.6.1 Optimisation of the SNaPshot® Multiplex System ............................... 100 
4.6.2 Optimisation of the TaqMan™ SNP Genotyping Assay ....................... 101 
4.6.3 Genotyping of patient samples ............................................................ 102 
4.6.4 Validation Sequencing ........................................................................ 102 
4.7 Statistical Analysis ..................................................................................... 104 
4.7.1 Genotype and Allele frequencies ......................................................... 104 
x 
 
4.7.2 Association testing .............................................................................. 108 
Chapter 5: Discussion ........................................................................................... 112 
5.1 Summary of Main Findings ......................................................................... 112 
5.2 Retrospective Cohort Analysis ................................................................... 113 
5.3 Prospective Cohort Analysis ...................................................................... 116 
5.4 Study Limitations ........................................................................................ 120 
5.5 Recommendations ..................................................................................... 121 
5.6 Future Directions ........................................................................................ 121 
Chapter 6: Supplementary Study – Testing of Biomarkers as a Measure of Cardiac 
Injury ..................................................................................................................... 123 
6.1 Introduction: ............................................................................................... 123 
6.1.1 Brain Type Natriuretic Peptide (BNP) .................................................. 123 
6.1.2 Troponin T........................................................................................... 125 
6.1.3 Suppression of Tumorigenicity 2 (ST2) ............................................... 127 
6.2 Materials and Methods: .............................................................................. 127 
6.2.1 The Study Cohort: .................................................................................... 127 
6.2.2 Determination of cardiac biomarker of injury levels using peripheral blood
 127 
6.2.2.1  Principle of ELISA ....................................................................... 128 
6.2.2.2 Technique of Detection of N-terminal pro B-Type Natriuretic Peptide 
(NT-proBNP) using a Competitive ELISA ....................................................... 129 
6.2.2.3  Statistical Analysis for the determination of NT-proBNP levels .... 129 
6.3 Results: ...................................................................................................... 130 
6.3.1 Determination of cardiac biomarker of injury levels using EDTA-plasma
 130 
6.3.2 NT-pro B-Natriuretic Peptide (NT-proBNP) concentration ................... 130 
6.3.3 Statistical Analysis .............................................................................. 133 
6.3.4 Correlation between Routine Measures, Biomarkers and Cardiac 
Function Decline ............................................................................................... 138 
6.4 Discussion .................................................................................................. 141 
xi 
 
6.4.1 Study Limitations: ................................................................................ 143 
6.4.2 Recommendations: ............................................................................. 144 
Chapter 7: Concluding Remarks ........................................................................... 145 
References ........................................................................................................... 146 
Appendices ........................................................................................................... 155 
Appendix A: Gene Annotation and Primer Design Protocol ............................... 155 
Appendix B: Informed Consent .......................................................................... 158 
Appendix C: Ethics Approval – UCT .................................................................. 160 
Appendix D: Ethics Approval – GSH ................................................................. 161 
Appendix E: Ethics Approval – SUN/TBH .......................................................... 162 
Appendix F: Reagent Preparation ..................................................................... 163 
Appendix G: Multiplex PCR Protocol ................................................................. 165 
Appendix H: Patient DNA Isolations .................................................................. 167 
Appendix I: Spectrophotometric quantitation of DNA ......................................... 174 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
List of Figures 
Figure 1: Graphical representation of the initiation of the PhD project ............. 3 
Figure 2: Experimental steps taken towards fulfilment of aims and objectives 4 
Figure 3: Global incidence and mortality of breast cancer  ................................ 7 
Figure 4: Illustration of breast tissue showing comparison between ductal and 
lobular carcinoma .................................................................................................. 8 
Figure 5: Inflammatory Breast Cancer ................................................................. 9 
Figure 6: Two-dimensional structure of Doxorubicin ........................................17 
Figure 7: Chemical structure of doxorubicin and epirubicin  ............................17 
Figure 8: Comparison of a normal heart and a heart in congestive failure ......19 
Figure 9: Cardiomyocyte showing mechanism of action of anthracycline.......25 
Figure 10: Representation of pathways showing candidate genes involved in 
the metabolism of doxorubicin in a cancer cell  .................................................33 
Figure 11: Representation of transport and metabolism of doxorubicin ..........34 
Figure 12: Representation of candidate genes involved in the metabolism of 
doxorubicin ...........................................................................................................34 
Figure 13: Representation of GeneRulerTM 100bp Plus DNA Ladder (Molecular 
Weight Marker .......................................................................................................53 
Figure 14: Diagrammatic illustration of PCR  .....................................................54 
Figure 15: Diagrammatic representation of touchdown PCR ............................59 
Figure 16: Diagrammatic Representation of SNaPshot® Genotyping  .............63 
Figure 17: GeneScan™ 120 Liz™ Size Standard ................................................69 
Figure 18: Analysis settings on GeneMapper v4.1 software .............................69 
Figure 19: Graphical representation of Taqman™ SNP Genotyping Assay .....70 
Figure 20: Example of an Allelic Discrimination plot .........................................72 
Figure 21: Histogram of retrospective cohort illustrating proportion of patients 
and their age at diagnosis (n=402) ......................................................................78 
Figure 22: Patient Clinical Status (Cardiac impairment/dysfunction: affected vs 
unaffected) of retrospective cohort after chemotherapy ...................................81 
Figure 23: Histogram of the age at diagnosis of patients in the prospective 
cohort (n=272) .......................................................................................................88 
Figure 24: Clinical status (Cardiac impairment/dysfunction: affected vs 
unaffected) of Patients in Prospective Cohort....................................................91 
Figure 25: Difference between actual and predicted post-chemo LVEF measures 
in prospective patients .........................................................................................93 
Figure 26: Assessment of DNA Integrity using agarose gel electrophoresis...94 
xiii 
 
Figure 27: Multiplex optimisation using a temperature gradient .......................95 
Figure 28: Singleplex optimisation using a magnesium chloride (MgCl2) 
gradient .................................................................................................................96 
Figure 29: Singleplex optimisation of ABCC2 rs17222723 using additives ......97 
Figure 30: Multiplex optimisation of ACO1 rs867469, ABCC1 rs246221 and 
ABCC2 rs17222723 ...............................................................................................98 
Figure 31: Optimised multiplex PCR showing the amplification of HNMT 
rs17583889 and ABCC2 rs8187710 ......................................................................98 
Figure 32: Optimised multiplex PCR showing the amplification of RAC2 
rs13058338 and NCF4 rs1883112 .........................................................................99 
Figure 33: Optimised multiplex PCR showing the amplification of ABCC1 
rs246221 and ABCC2 rs17222723 ........................................................................99 
Figure 34: Electropherogram illustrating determination of genotypes for both 
HNMT rs17583889 and ABCC2 rs8187710 ......................................................... 100 
Figure 35: Electropherogram illustrating determination of genotypes for both 
NCF4 rs1883112 and RAC2 rs13058338 ............................................................ 100 
Figure 36: Electropherogram illustrating determination of genotypes for both 
ABCC1 rs246221 and ABCC2 rs17222723 ......................................................... 101 
Figure 37: Quantification & Allelic Discrimination Plots .................................. 101 
Figure 38: Representation of electropherogram, sequence coverage and 
sequence derived from Sanger sequencing ..................................................... 102 
Figure 39: Representation of nucleotide blast results for ABCC2 rs8187710 
validating both the target gene and corresponding SNP ................................. 103 
Figure 40: LD plot and Haplotype analysis generated by the SHEsis program 
 ............................................................................................................................. 108 
Figure 41: Natriuretic peptides involved in Cardiac Failure ............................ 123 
Figure 42: Natriuretic peptides ANP, BNP and CNP ......................................... 124 
Figure 43: Visualization of cardiac muscle and Troponin molecules ............. 126 
Figure 44: Generalized principles of the four types of ELISAs ....................... 128 
Figure 45: Comparison of baseline BNP concentrations in both the MA and IA 
cohorts with the exclusion of hypertensive patients ....................................... 134 
Figure 46: BNP Concentration of the entire cohort before (pre) and after (post) 
chemotherapy ..................................................................................................... 135 
Figure 47: BNP Concentration of the non-hypertensive patients  before and after 
chemotherapy ..................................................................................................... 136 
Figure 48:  Comparison of BNP levels at baseline (pre) and after (post) 
chemotherapy for both MA and IA patients ...................................................... 136 
xiv 
 
Figure 49: Comparison of BNP levels at baseline and after chemotherapy for 
both MA and IA patients ..................................................................................... 137 
Figure 50: Comparison of change in BNP based on both patient status and 
severity score ..................................................................................................... 139 
Figure 51: Comparison of change in BNP in both IA and MA affected and 
unaffected individuals ........................................................................................ 140 
Figure 52: BNP changes in patients with baseline cardiac incidental finding 
 ............................................................................................................................. 141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
List of Tables 
Table 1: Clinical Classification of breast cancer ................................................12 
Table 2: Staging of breast cancer based on TNM Classification .......................14 
Table 3: Types of Anthracycline-Induced Cardiotoxicity ...................................19 
Table 4: Studies illustrating dose-dependent cardiotoxicity .............................22 
Table 5: Left Ventricular Ejection Fraction and its Interpretation .....................27 
Table 6: Genes and SNPs associated with anthracycline-induced cardiotoxicity
 ...............................................................................................................................37 
Table 7:  Details of SNPs for further study of anthracycline-induced 
cardiotoxicity in patient cohort ............................................................................47 
Table 8: Custom-designed PCR Primers .............................................................56 
Table 9: Conditions of PCR reaction required for optimisation of annealing 
temperature ...........................................................................................................57 
Table 10: Conditions of Touchdown PCR reaction ............................................60 
Table 11: Optimised Multiplex Conditions ..........................................................60 
Table 12: Prescribed reagents and concentrations for a standard PCR ...........61 
Table 13: Prescribed reagents and concentrations for a touchdown PCR .......61 
Table 14: Labelled ddNTPs, their fluorescent dyes and colours that determine 
genotype................................................................................................................63 
Table 15: Pre-designed TaqMan™ SNP Genotyping Assay ...............................65 
Table 16: Custom-designed Primers for Genotyping using the SNaPshot® 
Multiplex System ..................................................................................................66 
Table 17: Reagents required for the purification of PCR products ...................67 
Table 18: Reagents required for the SNaPshot Multiplex Assay .......................68 
Table 19: Reagents required for the automated electrophoresis run ...............68 
Table 20: Preparation of reaction mix for the wet DNA method ........................71 
Table 21: Labelled ddNTPs, their fluorescent dyes and colours that determine 
genotype................................................................................................................73 
Table 22: Primers utilised for validation of genotyping using Sanger sequencing
 ...............................................................................................................................74 
Table 23: Reagents required for validation of genotyping using Sanger 
Sequencing ...........................................................................................................74 
Table 24: Demographic characteristics of the retrospective patients cohort ..79 
Table 25: Type and Stage of Cancer of Patients in the Retrospective Cohort .80 
Table 26: Patients classified according to clinical manifestations ...................81 
Table 27: The effect of severity score on LVEF post chemotherapy ................82 
xvi 
 
Table 28: Prediction of LVEF post-chemo measure using population group, type 
of first-line chemotherapy and severity score ....................................................83 
Table 29: Logistic Regression Coefficients used to determine Odds Ratios of 
covariates for Patient Clinical Status ..................................................................86 
Table 30: Demographic characteristics of patients in the Prospective cohort 88 
Table 31: Type and Stage of Cancer of Patients in the Prospective Cohort .....89 
Table 32: Incidental cardiac findings derived from baseline cardiac function .90 
Table 33: Logistic Regression Co-efficients used to determine Odds Ratios 
using Clinical-based Covariates ..........................................................................92 
Table 34: Distribution of genotypes and minor allele frequencies .................. 105 
Table 35: Patient population allele frequencies and Pearson’s Chi-Square test 
for HWE ............................................................................................................... 106 
Table 36: Testing for LD of genetic variants using R and SHESIS .................. 107 
Table 37: Logistic Regression Co-efficients used to determine Odds Ratios 
using Genotype to Predict Outcome ................................................................. 109 
Table 38: Logistic Regression Co-efficients used to determine Odds Ratios 
using Genotype and Dose Covariates ............................................................... 110 
Table 39: Overview of genetic variants, their genetic model and contribution to 
phenotype ........................................................................................................... 111 
Table 40: Clinical, demographic and experimental information for patients 
assessed for BNP levels .................................................................................... 131 
Table 41: Comparison of median baseline BNP concentrations before the 
administration of anthracycline based chemotherapy ..................................... 134 
Table 42: Severity Score established using LVEF measure and patient clinical 
phenotype ........................................................................................................... 138 
Table 43: Patients with baseline cardiac incidental findings analysed for both 
BNP levels and clinical status ........................................................................... 140 
 
 
 
 
 
 
 
xvii 
 
Abbreviations 
 
4PL  Four parameter logistic regression 
5FU  5-Fluorouracil 
ABCC1/2 ATP binding cassette subfamily C member 1/2, gene 
ABCB4 ATP binding cassette subfamily B member 4, gene 
AC  Adriamycin and Cyclophosphamide 
ACE  Angiotensin Converting Enzyme Inhibitor 
ACO1  Aconitase 1, gene 
ACT  Anthracycline-Induced Cardiotoxicity 
ADMET Absorption, Distribution, Metabolism, Elimination and Toxicity of drug 
ADR  Adverse Drug Reaction 
AKR  Aldo/keto Reductase, enzyme 
AKR1A1 Aldo-keto reductase family 1 member A1 
AJCC  American Joint Committee on Cancer 
AT  Adenine-Thymine 
ATP  Adenosine Triphosphate 
BLAST  Basic Local Alignment Search Tool 
BMI  Body Mass Index 
BNP  Brain type Natriuretic Peptide (NT-proBNP, alternate form) 
CAT  Catalase, gene 
CBR  Carbonyl Reductase, enzyme 
CBR3  Carbonyl reductase 3, gene 
CF  Cardiac Failure 
CI  Confidence Intervals 
CMR  Cardiac Magnetic Resonance 
CRAN  Comprehensive R Archive Network 
CT  Computerized Tomography 
CTCAE Common Technology Criteria for Adverse Events 
CYBA  Cytochrome b-245 alpha chain, gene 
DCIS  Ductal Carcinoma In Situ 
DMSO  dimethyl sulfoxide 
DNA  Deoxyribonucleic Acid 
dNTPs  deoxynucleotides 
xviii 
 
ddNTPs dideoxynucleotides  
DOX  doxorubicin (Adriamycin) 
DTT  dithiothreitol 
ECHO  Echocardiography 
EDTA  Ethylenediaminetetraacetic Acid 
EF  Ejection Fraction 
EIA  Enzyme Immunoassays 
ELISA  Enzyme-Linked Immunosorbent Assays 
EPI  Epirubicin (4-Epi-Adriamycin) 
EPR  Electronic Patient Records 
ER  Estrogen Receptor 
ERNA  Equilibrium Radionuclide Angiography 
Exo1  Exonuclease 1 
FastAP Alkaline Phosphatase 
FDA  Food and Drug Administration 
FS  Fractional Shortening 
GC  Guanine-Cytosine 
GSH  Groote Schuur Hospital 
GSTP1 Glutathione S-transferase pi 1, gene 
GTP  Guanosine triphosphate 
GUI  Graphical User Interface 
GWAS  Genome Wide Association Studies 
HER2  Human Epidermal Growth Factor 2 
HFE  Haemochromatosis, gene 
HIV  Human Immunodeficiency Virus 
HNMT  Histamine N-methyltransferase, gene 
HREC  Human Research Ethics Committee 
HRPO  Horseradish Peroxidase, enzyme 
HSP20  Heat Shock Protein 20 
HWE  Hardy-Weinberg Equilibrium 
IDC  Invasive or Infiltrating Ductal Carcinoma 
IDT  Integrated DNA Technologies 
ILC  Invasive or Infiltrating Lobular Carcinoma 
IREB2  Iron Responsive Element Binding Protein 2, gene 
xix 
 
IRES  Iron Responsive Elements 
LCIS  Lobular Carcinoma In Situ 
LD  Linkage Disequilibrium 
LV  Left Ventricle/Ventricular 
LVEF  Left Ventricular Ejection Fraction 
MAPK  Mitogen Activated Protein Kinase 
MGB  Minor Groove Binding 
MgCl2  Magnesium Chloride 
MRD  Minimal Residual Disease 
MRI  Magnetic Resonance Imaging 
MUGA  Multigated Acquisition Scan 
NADPH nicotinamide adenine dinucleotide phosphate, enzyme 
NCBI  National Center for Biotechnology Information 
NCF4  Neutrophil cytosolic factor 4, gene 
NOS  Not otherwise specified 
NTC  No template control 
OD  Optical Density 
PCR  Polymerase Chain Reaction 
PR  Progesterone Receptor 
RAC2  Ras-related C3 botulinum toxin substrate 2, gene 
RARG  Retinoic acid receptor gamma, gene 
RNA  Ribonucleic Acid 
RNS  Reactive Nitrogen Species 
ROS  Reactive Oxygen Species 
RFU  Relative Fluorescent Units 
SDS  Sodium Dodecyl Sulfate 
SLC28A3 Solute Carrier Family 28 Member 3, gene 
SNP  Single Nucleotide Polymorphism 
SQ  Sizing Quality 
ST2  Suppression of Tumorigenicity 2, cytokine 
Taq  Thermus Aquaticus, enzyme 
TBE  Tris-Borate-EDTA, buffer 
TBH  Tygerberg Hospital 
TC  Docetaxel and Cyclophosphamide  
xx 
 
TE  Tris-EDTA, buffer 
Tm  Melting Temperature 
TMB  3,3′,5,5′-Tetramethylbenzidine, substrate 
TNBC  Triple Negative Breast Cancer 
TNM  Staging of Cancer System (Primary Tumour, Regional Lymph nodes, 
Metastasis) 
UMIC Upper Middle Income Country 
UP Uncoupling Proteins 
USA  United States of America 
UV  Ultraviolet
1 
 
Chapter 1: Preface 
 
1.1 Thesis Statement: 
 
Anthracycline-induced cardiotoxicity, while dose-dependent, may be attributed to inherent 
genetic differences in treated patients. 
1.2 Project Summary: 
 
This project focused on the genetic susceptibility of cardiotoxicity in breast cancer patients 
receiving specific types of anthracycline treatment (Adriamycin/doxorubicin and epirubicin). 
Patients were assessed at Groote Schuur (GSH) and Tygerberg (TBH) Hospitals. Variable 
drug response from patients were corrected for co-morbidities and dosage and attributed to 
genetic make-up. Hence, the genetic susceptibility of individual patients to anthracycline-
induced cardiotoxicity was ascertained using variant detection to ultimately allow for the 
individualisation of patient treatment especially focusing on highly-susceptible patients. 
Ultimately, the goal was to identify susceptible patients before treatment towards reducing or 
eliminating anthracycline-induced cardiotoxicity during or after treatment and to prevent long-
term irreparable and sometimes life-threatening cardiac damage in cancer survivors. 
1.3 Motivation: 
 
The motivation for this study was: (i) the record of international findings pertaining to 
differential responses to anthracycline, (ii) reports of the cardiotoxicity of anthracyclines, and 
(iii) the complete lack of information on patients/populations in South Africa (and particularly 
taking into account the widespread use of anthracyclines in the treatment of cancers, 
nationally). Consultations with clinical caregivers e.g. radiation oncologists and surgeons 
revealed both the concerning occurrence of cardiac events in chemotherapy patients as well 
as the lack of means for  clinically stratifying these patients based on risk of adverse drug 
events before chemotherapy exposure. The anecdotal data stemmed from routine clinical 
patient interactions and from interrogating a retrospective database to assess the trend, if any, 
in all patients exposed to anthracycline-based treatment.  
Retrospective data collection (2011-2016) indicated that approximately 20% of all patients 
treated with anthracycline-based chemotherapy at GSH experienced decreased cardiac 
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function (as measured by pre and post treatment left ventricular ejection fraction) or even 
death due to cardiac damage. This prompted an extensive literature review which confirmed 
the incidence of cardiotoxicity due to anthracycline-based chemotherapy in cancer patients to 
be between 10-26% 1,2. 
Chemotherapy, specifically anthracycline-based chemotherapy, has been widely accepted to 
have an increased risk for dose-dependent cardiotoxicity particularly in patients of advanced 
age with pre-existing conditions such as hypertension, diabetes and cardiac disease. 
Therefore, safe administration would be ideally, to patients who have been clinically stratified 
as “low risk” and at doses within a “safe” range. The Food and Drug Administration (USA) 
prescribes a safe range of cumulative dosage at 300-450mg/m2 for doxorubicin 3,4. However, 
approximately 21% of all patients treated with anthracyclines at cumulative doses of less than 
300mg/m2 still experience cardiotoxicity despite the prescribed “safe” dosage threshold 5.  
The stratification of patients with increased susceptibility for developing ACT is still 
considerably challenging despite cognizance of both the clinical risk factors and dose-
dependent association. Consequently, previous studies have been conducted, investigating 
the genetic basis of cardiotoxicity attributed to anthracyclines. Genetic variants involved in the 
absorption, distribution, metabolism, elimination and toxicity of the drug have been implicated 
in the predisposition to ACT 6-10. 
The majority of studies, with the exception of Aminkeng et al. 6,7 have investigated the genetic 
basis of ACT in either European and/or Caucasian populations. Previous studies have shown 
increased adverse drug reactions, reduced drug efficacy and poorer survival in African 
populations for various drugs and attributed this to pharmacogenomic heterogeneity 6,11. The 
positive outcomes of clinical trials and previous genetic ACT associations ought not to be 
readily extrapolated to our unique local populations in South Africa [especially the Indigenous 
African (IA) and Mixed Ancestry (MA) groups]. Therefore, a comprehensive investigation into 
the genetic basis of anthracycline-induced cardiotoxicity in our local populations as well the 
evaluation of routine clinical management was warranted.  
Ideally, this individualized gene-based approach could allow for specific thresholds for 
therapeutic dosage safety and the pharmacological prevention of cardiac deficit 12.  Clinical 
observations of cardiotoxicity during routine clinical management of breast cancer patients 
followed by the establishment of a retrospective database to validate these claims warranted 
the initiation of the PhD study whereby literature was extensively reviewed and a prospective 
cohort established to elucidate the genetic basis of ACT in our local populations. Recruited 
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patients (GSH and TBH) had biological specimens (peripheral blood before and after 
chemotherapy) and hospital records assessed to establish a model of susceptibility to ACT.  
This process is illustrated in Figure 1. 
 
Figure 1: Graphical representation of the initiation of the PhD project 
 
1.4 Research Related Aims and Objectives: 
 To assess the effect of anthracycline treatment, if any, on cardiac function using 
various clinical modalities and patient clinical evaluation using both retrospective and 
prospective patient data 
 To determine the cardiotoxic effects of anthracyclines (both clinical and molecular) in 
the unique local populations – IA and MA, and the genes responsible for this 
susceptibility  
 To provide tools for the creation of a model of risk for susceptibility to anthracycline-
induced cardiotoxicity before the initiation of treatment  
In the fulfilment of the aims and objectives of this study, this study was conducted as illustrated 
in Figure 2:  
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Figure 2: Experimental steps taken towards fulfilment of the project aims and objectives 
The establishment of the retrospective cohort allowed for the collection of clinical data of 
patients at GSH from 2011-2016. The prospective cohort was partially derived from this cohort 
as well as from TBH (from 2013-2016) and peripheral blood from consented patients was for 
purposes of genotyping candidate markers. Genotyping for variants associated with 
anthracycline-induced cardiotoxicity, assessment of levels of cardiac injury using biomarkers 
and evaluation of clinical data allowed for a comprehensive profile on each patient. 
Retrospective cohort data allowed for the creation of a statistical model that allowed for 
inferences to be made in the prospective cohort. Essentially this model may predict risk of 
anthracycline-induced cardiotoxicity specific to population group before the administration of 
chemotherapy. 
It is important to note that all patients in both the retrospective and prospective cohorts have 
cancer and that their clinical status (affected or unaffected) refers to their cardiac 
impairment/dysfunction due to anthracycline-based chemotherapy. 
This thesis is divided into seven chapters: this introductory chapter is followed by a literature 
review with sub-sections on:  
 The elements involved in the analysis of the retrospective cohort such as types of 
breast cancers, staging and classification and treatment regimens, 
  Anthracycline based chemotherapy - efficacy, mechanism of action, risks involved, 
methods of detection of ACT and the genetics of cardiotoxicity, and 
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 The evaluation of modalities used to assess cardiac function.  This is followed by 
Chapter 3: Patients, Materials and Methods where all experimental methods are 
outlined systematically.  
 Subsequently, in Chapter 4: Results will comprise the analysis of the entire cohort 
based on clinical data followed by the analysis of molecular data derived from the sub-
cohort, with biological specimens as well as the development of a correlation model to 
predict cardiac function in lieu of missing clinical data   
 This is followed by Chapter 5: Discussion which will focus on the entire cohort’s clinical 
data and its implications; trends and associations observed from experimental work 
and recommendations for both clinical management and future studies. 
 Chapter 6: Cardiac biomarker study which includes the introduction, materials and 
methods, results and discussion and recommendations, 
 Chapter 7: Conclusions from both the retrospective and prospective study as well as 
the biomarker study 
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Chapter 2: Introduction 
2.1 Retrospective Patient Analysis 
Breast cancer patients in the Western Cape follow a fast track referral service from both public 
(government) and private hospitals in the province.  
Government or public hospital patients attend a breast surgical outpatient clinic and are 
urgently referred to the Radiation Oncology Outpatient clinics at both GSH and TBH if found 
to have a breast carcinoma. Private hospital patients undergo a full workup, mammogram and 
histology before being referred to these outpatient clinics. Private patients utilise this facility if 
their medical insurance funds are depleted or if they require a second medical opinion.  
Once referred to the Oncology Clinic, the patients are reviewed by a multi-disciplinary team 
and a decision is made regarding treatment options. This may include surgery with a 
mastectomy or lumpectomy followed by adjuvant chemotherapy, radiotherapy, and hormonal 
therapy, where appropriate. Alternatively, patients are treated with neoadjuvant chemotherapy 
which is usually followed by a surgical intervention. Patients are followed up after 
chemotherapy is complete to assess if they need further treatment, alternative treatment or 
palliative options. 
This review will elucidate the intricacies of a patient’s cancer diagnosis and management, with 
a focus on breast cancer and anthracycline-based chemotherapy and its association with 
cardiotoxicity. There will be further exploration into the modalities used for the assessment of 
cardiac function and the genetics of anthracycline-induced cardiotoxicity. In addition the 
economic implications of a cancer diagnosis with the eventuality of a potentially fatal adverse 
drug reaction will be considered. 
2.1.1 Definition of Breast Cancer 
Breast cancer is defined as uncontrolled cellular growth culminating in a malignant tumour 
with the ability to metastasize to different parts of the body13. Breast cancer occurs most 
frequently in women, however it does also occur in men (i.e. approximately 1% of all cases of 
breast cancer)14. 
2.1.2 Incidence of Breast Cancer 
In 2012, global statistics indicate that about 14.1 million people are diagnosed with cancer 
annually, with a mortality of 8.2 million per annum15.  
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Breast cancer was reported to be the second most common cancer, occurring in 25% of 
cancer diagnoses, worldwide, and the most common cause of cancer-related death in women  
in both developing and developed nations15.  
 
Figure 3: Global incidence (blue) and mortality (red) of breast cancer according to the 
World Health Organization15 
Despite the increased incidence, there has been a significant decrease in mortality owing to 
early diagnosis and recent advances in treatment16. Mortality of breast cancer patients in the 
USA for the periods 1975-1977 compared to 1999-2005 decreased from 68% to 50%, per 
annum17. Nearly 90% of all women diagnosed with breast cancer will have a survival period 
of 5 years or longer18. 
8 
 
Developing nations are reported to have more cases and deaths due to breast cancer 
compared to developed nations (Fig. 3). 
Currently, approximately 500 new cases of breast cancer are diagnosed and/or treated 
annually at each of the oncology facilities at GSH and TBH. 
Patients’ breast tissue are biopsied to determine the type, grade and stage of breast cancer 
which are informative for subsequent clinical management and may have prognostic 
implications. 
2.1.3 Types of Breast Cancers 
Variants of breast cancer are attributed to cellular morphology. Specifically, carcinomas initiate 
in the epithelial cells in breast tissue, adenocarcinoma initiates in glandular tissue and 
sarcomas originate in muscle, fat or connective tissue cells13. 
2.1.3.1 Carcinoma In Situ 
Carcinoma in situ may be regarded as non-invasive or pre-invasive breast cancer; the majority 
of women with early diagnoses have either ductal carcinoma in situ (DCIS) or lobular 
carcinoma in situ (LCIS)13. DCIS originates in the cells lining the milk ducts whereas LCIS 
originates in the milk-producing glands of the breast tissue. Carcinoma in situ, by definition, 
does not metastasize but does possess the capacity to develop into invasive disease.  
 
Figure 4: Illustration of breast tissue showing a comparison between ductal and lobular 
carcinoma in situ (Image adapted from13) 
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2.1.3.2 Invasive or Infiltrating Ductal Carcinoma (IDC) 
IDC is the most common type of breast cancer. It has the capacity to initiate in the milk duct, 
breach the wall of the milk duct, and to subsequently grow in the surrounding fatty tissue 
ultimately metastasizing to other parts of the body by utilizing the lymphatic system or blood 
stream13. 
2.1.3.3 Invasive or Infiltrating Lobular Carcinoma (ILC) 
Approximately 1 in 10 of all invasive breast cancers are ILC 13, which like IDC, have the ability 
to metastasize to other parts of the body. 
2.1.3.4 Inflammatory Breast Cancer 
Inflammatory breast cancer is rare occurring in 1-3% of all breast cancer cases and is 
challenging to diagnose as there is no discrete tumour mass present13. Instead, the skin on 
the breast appears to be thick and pitted like an orange peel (“peau d’orange”) and this is 
attributed to cancer cells blocking lymph vessels in the skin. Difficulty in diagnosis due to its 
atypical presentation may negatively impact prognosis13. 
 
Figure 5: Inflammatory Breast Cancer presenting with the “peau d’orange” appearance 
(Image adapted from 13) 
2.1.3.5 Paget Disease of the Nipple 
This type of cancer accounts for only about 1% of all breast cancer diagnoses and originates 
in the milk ducts, progresses to the skin of the nipple and areola resulting in red, itchy, bleeding 
or oozing nipples13. Paget’s disease is optimally treated with a mastectomy. 
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2.1.3.6 Phyllodes Tumour (PT) 
PT is a fairly rare type of tumour that develops in the connective tissue of the breast. Malignant 
phyllodes tumours are treated with surgery and chemotherapy if they are metastatic13. 
2.1.3.7 Angiosarcoma 
This type of cancer originates in the blood or lymph vessels, very rarely in the breast tissue 
and can spread rapidly. Angiosarcomas may occur as a complication of radiation therapy, or 
in some cases, in the tissues of the arms of women who have had lymph node surgery and 
subsequent lymphoedema13.  
2.1.3.8 Invasive Breast Carcinoma 
The following types of invasive cancer have a good prognosis compared to IDC: Adenocystic 
carcinoma, adenosquamous carcinoma (low-grade), medullary carcinoma, mucinous 
carcinoma, papillary carcinoma and tubular carcinoma 13. 
However the following types of invasive cancers have a poor prognosis compared to IDC: 
Metaplastic carcinoma, Micropapillary carcinoma and Mixed Carcinoma (both ductal and 
lobular) 13. 
Nevertheless all these subtypes are treated similarly to IDC. 
Breast cancer may also be classified according to rate of growth and ability to metastasize, as 
well as molecular markers in or on cells. While tumour grading and staging determine whether 
or not neoadjuvant or adjuvant therapy will be utilised, the presence/absence of hormone 
receptors may direct appropriate treatment.  
2.1.4 Breast Cancer Staging and Classification 
Breast cancer grading is based on histological features which indicate the rate of growth and 
the likelihood of metastasis. Grade 1 indicates well-differentiated cancer cells, Grade 2 
indicates moderately-differentiated cells whereas Grade 3 indicates poorly-differentiated 
cancer cells that grow and metastasize rapidly 13.  
While grading is informative, breast cancer staging is crucial as it quantifies the extent of 
‘spread’ of the cancer, which, in turn, has ramifications on prognosis and treatment options. A 
standardized staging system that is used routinely is the American Joint Committee on Cancer 
(AJCC) TNM Staging System 19. Clinical staging is determined using physical examination, 
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biopsy and imaging test results. Pathologic staging includes clinical staging as well as surgical 
and histological results and is therefore more accurate. 
The T, N and M staging/classification of cancers denote the following: 
Primary Tumour (T), numbered 0-4, describes tumour size and spread to the skin or chest 
wall whereby higher T numbers describe larger tumours or a greater degree of spread. 
Regional Lymph Nodes (N), numbered 0-3, describes whether cancer has spread to axillary 
or internal mammary lymph nodes and how many are affected. 
Metastasis (M), numbered 0 or 1, indicates whether distant metastases has occurred (i.e. 
M=1). 
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Table 1: Clinical Classification of breast cancer allowing for determination of T,N and M 
TNM Clinical Classification 19,20 
  
Primary Tumour  
Tx Unable to assess primary tumour  
T0 No primary tumour found 
Tis Carcinoma in situ (ductal or lobular) or Paget’s Disease of the nipple 
without tumour 
T1 
 
T1a 
T1b 
T1c 
Tumour dimension ≤ 2cm: 
  
Tumour dimension ≤ 0.5cm 
0.5cm < Tumour dimension < 1cm  
1cm < Tumour dimension < 2cm 
 
T2 2cm < Tumour Dimension < 5cm 
T3 Tumour Dimension > 5cm 
T4 
 
T4a 
T4b 
T4c 
T4d 
Tumour with extension to the chest wall or skin: 
 
Extension to chest wall 
Oedema, ulceration of the skin or satellite skin nodules on the same 
breast 
Both T4a and T4b 
Inflammatory carcinoma 
Nearby Lymph 
Nodes 
 
Nx Unable to assess regional lymph nodes  
N0 
N1 
 
 
N1mi 
N1a 
N1b 
N1c 
No regional lymph node metastasis 
Metastasis to 1-3 axillary lymph node/s and/or detectable number of 
cancer cells in internal mammary lymph nodes 
 
Micrometastases in 1-3 axillary lymph nodes <2mm across 
Metastasis to 1-3 axillary lymph nodes with at least one area >2mm 
across 
Metastasis to internal mammary lymph nodes 
N1a and N1b apply 
N2 
 
 
N2a 
 
N2b 
Metastasis to 4-9 axillary lymph node/s or cancer-enlarged internal 
mammary lymph nodes 
 
Metastasis to 4-9 axillary lymph nodes with at least one area >2mm 
across 
Metastasis to internal mammary lymph nodes causing enlargement 
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Table 1 continued.  Clinical Classification of breast cancer allowing for determination of T,N and M 
N3a 
 
 
N3b 
 
 
 
 
N3c 
Metastasis to 10/+ axillary lymph nodes with at least one area >2mm 
across or metastasis to lymph nodes under clavicle with at least one 
area >2mm across 
Metastasis in at least 1 axillary lymph node >2mm across and enlarged 
internal mammary lymph nodes or 
Metastasis in 4/+ axillary lymph nodes with at least one area >2mm 
across and detectable amounts of cancer in internal mammary lymph 
nodes (determined by sentinel node biopsy)  
Metastasis to lymph nodes above clavicle with at least one area >2mm 
across 
Metastasis  
MX Unable to assess distant metastasis 
M0 No distant metastasis present  
M1 Distant metastasis present 
The T, N and M numbers allow for the determination of stage grouping whereby therapeutic 
decisions can be made. The staging ranges from Stage 0 (non-invasive cancer) to Stage I 
(least advanced) to Stage IV (most advanced). 
After the comprehensive classification of breast cancer using clinical/pathological staging 
(Table 1 and 2), it is further characterised by the utilisation of hormone receptors and Human 
Epidermal Growth Factor 2 (HER2/neu) status. 
Hormone receptors are intracellular proteins that have an effect on cancer cell growth 13. 
Breast cancer cells may have oestrogen receptors (ER positive) and/or progesterone 
receptors (PR positive). Breast cancers may also be ER and PR negative. While hormone-
receptor positive cancers have slower growth, they tend to recur; they are however amenable 
to hormonal therapy whereas hormone-receptor negative cancers are not 13. Menopausal 
women are more likely to have hormone receptor-positive cancers while hormone receptor-
negative cancers are more likely to occur in premenopausal women 13. 
A cell surface receptor protein routinely tested for, is HER2/neu which promotes cancer cell 
growth at increased levels 13. HER2 positive cancers result in cancers that grow and spread 
aggressively, however, they generally respond favourably to therapies targeting the HER2/neu 
protein 13.  
Low levels of HER2 coupled with the absence of both ER and PR hormone receptors result in 
triple negative breast cancer (TNBC) which not only favours younger women of African 
American/Latina descent but also tends to proliferate and metastasize rapidly 13. Patients with 
14 
 
TNBC have limited therapeutic options as they are not responsive to both hormonal and 
HER2-targeted therapies, however chemotherapy can still be utilised. 
Table 2: Staging of breast cancer based on TNM Classification 
Staging TNM Classification 20 
  
Stage 0 Tis, N0, M0 
Breast carcinoma in situ (DCIS & LCIS): pre-cancer or early cancer of the breast  
 
Stage IA 
 
 
Stage IB 
T1, N0, M0 
Tumour dimension < 2cm across with no lymph node or distant metastasis  
 
T0 or T1, N1mi, M0 
Tumour dimension < 2cm across with micrometastasis in 1-3 axillary lymph nodes 
and no distant metastasis  
 
Stage IIA 
 
 
 
 
 
 
 
Stage IIB 
 
 
 
 
 
 
 
Stage IIIA 
 
 
 
 
 
 
 
Stage IIIB 
 
 
 
 
 
Stage IIIC 
T0-1, N1, M0 
Tumour dimension < 2cm across and metastasis in 1-3 axillary lymph nodes or 
detectable number of cancer cells in internal mammary lymph nodes 
or both of the above 
 
T2, N0, M0 
2cm < Tumour Dimension > 5cm with no lymph node or distant metastasis 
 
T2, N1, M0 
2cm < Tumour Dimension > 5cm with metastasis in 1-3 axillary lymph nodes or 
detectable number of cancer cells in internal mammary lymph nodes but no distant 
metastasis  
 
T3, N0, M0 
Tumour Dimension > 5cm with no lymph node or distant metastasis 
 
T0-2, N2, M0    
Tumour dimension <5cm with metastasis in 4-9 axillary lymph nodes or detectable 
number of cancer cells in internal mammary lymph nodes but no distant metastasis  
 
T3, N1-2, M0 
Tumour dimension >5cm with metastasis in 1-9 axillary lymph nodes or internal 
mammary lymph nodes but no distant metastasis  
 
T4, N0-2, M0 
Tumour grown into chest wall or skin and no metastasis to lymph nodes (N0) or 
metastasis in 1-3 axillary lymph nodes and micrometastasis in internal mammary 
lymph nodes (N1) or metastasis in 4-9 axillary lymph nodes and internal mammary 
lymph nodes (N2). No distant metastasis (M0) 
 
T(any), N3, M0 
Tumour dimension of indeterminate size or cannot be located and one of the 
following: metastasis to 10/+ axillary lymph nodes or to lymph nodes above clavicle 
or below clavicle or axillary lymph nodes and enlargement of internal mammary 
lymph nodes or 4/+ axillary lymph nodes and micrometastasis to internal mammary 
lymph nodes (N3). No distant metastasis 
Stage IV T(any), N(any), M1 
Metastasis to organs or lymph nodes away from the breast 
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2.1.5 Treatment of Breast Cancer 
Factors such as breast cancer type, stage and patient clinical comorbidities generally 
determine the type of treatment administered. Breast cancers may be treated locally (direct 
involvement of only the tumour) and/or systemically (therapy is effected via the bloodstream) 
13. Patients will often receive combination therapies to eradicate cancer cells and/or prevent 
recurrence. 
Treatment strategies may include 13: 
1. Surgery –  
Surgical treatments involve either breast-conserving surgery whereby only the tumour is 
removed and normal breast tissue is conserved, or a mastectomy whereby the entire breast 
and surrounding tissues are removed. Axillary nodes are cleared at the time of surgery. 
2. Radiation Therapy –  
Radiation therapy is often utilized after surgery. High energy gamma rays with the capacity to 
eradicate cancer cells are delivered from outside the body from a linear accelerator. 
3. Hormonal Therapy –  
Patients with hormone receptor-positive breast cancers are treated with systemic therapies 
that prevent oestrogen from attaching to hormone-receptors thereby either slowing or stopping 
further cancer cell growth. Hormone therapy may be used before and after surgery as well as 
for cancer recurrence.  
4. Targeted Therapy –  
Targeted therapies leverage specific qualities of cancer cells i.e. cell-surface protein to prevent 
further growth and metastasis. While chemotherapy destroys all rapidly growing cells, 
including normal cells, targeted therapy has greater anticancer specificity, and they tend to 
have less severe side effects. 
5. Chemotherapy –  
Chemotherapy is administered either orally or intravenously and can be effected in a multitude 
of ways in breast cancer patients: before surgery to reduce tumour mass to allow for a more 
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successfully operable tumour (neoadjuvant); after surgery to minimise recurrence via minimal 
residual disease (MRD) (adjuvant) and as palliative therapy in patients with advanced disease 
to alleviate symptoms and prolong survival 13,21.  
Routinely used chemotherapies include: Anthracyclines, Taxanes, 5-fluorouracil (5FU), 
Cyclophosphamide and Carboplatin. Combinations of the various types of chemotherapy are 
administered to increase their anti-neoplastic activity - however this also increases the 
propensity of developing adverse drug reactions (ADRs). 
2.2 Prospective Patient Analysis 
2.2.1 Anthracycline-based Chemotherapy 
Currently, anthracyclines are one of the most widely used and effective anti-cancer treatments 
and have been used routinely for more than 50 years 22. While neoadjuvant chemotherapy is 
frequently recommended in sub-Saharan Africa (67%), first-line chemotherapy consisting of 
anthracycline-based chemotherapy is used in 60% of breast cancer patients, which translates 
to approximately 60,000 patients in Africa per year 15,23. Not only are they are first-line 
regimens for breast cancer but also for leukaemia, lymphoma and sarcomas 12. Anthracyclines 
are a class of anti-tumour drugs administered to both adult and paediatric patients with soft-
tissue sarcomas, and solid or haematologic cancers 24.  
2.2.1.1 Types of Anthracyclines 
Anthracycline-based regimens include: doxorubicin (Adriamycin®), 4-Epi-doxorubicin or 
epirubicin (Ellence®), Daunorubicin, L-asparaginase, and Mitoxantrone 3.  
 Doxorubicin 
Doxorubicin was first extracted in the 1960’s from the bacterium, Streptomyces peucetius var. 
caesius, and was utilised from the 1970’s for routine clinical use 25-27. The drug is used in the 
treatment of various cancers which include: breast, lung, gastric, ovarian, thyroid, Hodgkin’s 
and non- Hodgkin’s lymphoma, multiple myeloma, sarcoma and paediatric cancers 27.  
The doxorubicin compound has an aglyconic and sugar moiety – the aglycone consists of a 
tetracyclic ring and quinone-hydroquinone groups, a methoxy substituent and a side chain 
with a carbonyl group 22. The daunosamine sugar molecule is attached by a glycosidic bond 
to a ring and consists of a 3-amino-2,3,6-trideoxy-L-fucosyl moiety 22.  
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Figure 6: Two-dimensional structure of Doxorubicin 28 
 Epirubicin 
Epirubicin is a semi-synthetic derivative of doxorubicin and is created by the epimerization of 
the hydroxyl group in a daunosamine carbon 22. The effect of this change is a shorter terminal 
half-life and increased total body clearance, however the mode of action and antineoplastic 
activity remains the same as doxorubicin 22,26.  
 
Figure 7: Chemical structure of structurally similar doxorubicin and epirubicin – 
Reorientation of the hydroxyl group (OH) in the 4’ position of the daunosamine ring 
contributes to different pharmacological effects and safety profiles 29 
This allows for the use of higher cumulative doses of epirubicin compared to doxorubicin 30. 
 Daunorubicin 
Daunorubicin, isolated from the bacterium Streptomyces peucetius, is used in the treatment 
of leukaemia and other neoplasms. Daunorubicin’s antineoplastic activity may be attributed to 
DNA intercalation and the inhibition of topoisomerase II. Additionally Daunorubicin may affect 
the regulation of gene expression and produce free radical damage to DNA 31. 
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 Valrubicin 
Valrubicin, a semi-synthetic analog of doxorubcin, is primarily used to treat bladder cancer 32. 
It is administered via direct infusion into the bladder where it easily penetrates into cells. Its 
anti-tumour activity is due to its ability to cause chromosomal damage and arrest cell cycle in 
G2 achieved by DNA intercalation and the inhibition of nucleosides into nucleic acids 32.  
 Mitoxantrone 
Mitoxantrone is an antineoplastic agent used to treat leukaemia, lymphomas and multiple 
sclerosis. It has the ability to intercalate into DNA, interfere with RNA and inhibit 
topoisomerase II enabling it to be used in treatment of progressive or relapsed leukaemia, 
lymphoma and multiple sclerosis 33. 
2.2.1.2 Efficacy 
Anthracyclines are arguably one of the most effective anticancer therapies ever developed 30. 
Doxorubicin is particularly effective in treating aggressive lymphomas, Hodgkin’s disease, soft 
tissue carcinomas, childhood solid tumours and breast cancer 34. 
Routine anthracycline administration has resulted in cancer survival increasing from 30% in 
the 1960’s to about 80% presently 26,35. More than 70% of childhood cancer patients will 
survive at least five years as a result of the use of anthracyclines 36. 
However tumour resistance and drug toxicity may hinder antineoplastic activity. 
2.2.1.3 Risks 
Although generally efficacious, chemotherapy may cause patients to exhibit signs of toxicity 
or cancers may be refractory to treatment 21. While some common side effects attributable to 
doxorubicin may be managed with medical intervention e.g. nausea, vomiting, stomatitis, 
alopecia, gastrointestinal disturbances, pyrexia, hyperpigmentation of the nails and 
conjunctivitis; some reactions to the drug are far more serious, namely: neurologic impairment, 
cumulative cardiotoxicity and bone marrow aplasia with subsequent granulocytopaenia, 
neutropaenia, thrombocytopaenia and anaemia 22. Undoubtedly, one of the most challenging 
sequelae of anthracycline-based chemotherapy is cardiotoxicity 9,16,18,24. 
The risk of anthracycline-induced cardiotoxicity (ACT) is reported to be between 10-26% with 
a mortality rate of more than 20% 1,2. ACT can be identified in the following ways: either as 
acute, early or late cardiotoxicity 22,24-26,37. Acute ACT, occurs in 11% of patients, is dose-
independent, clinically manageable and generally reversible 9,38. It may present during 
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treatment as arrhythmias which include sinus tachycardia, premature ventricular contractions 
and ventricular tachycardia, bradycardia, coronary syndromes, dilated cardiomyopathy or 
rarely, acute cardiac failure. Early cardiotoxicity is defined as occurring within one year of 
treatment whereas late cardiotoxicity is defined as occurring after one year of treatment. Both 
early and late-onset cardiotoxicity (also referred to as chronic cardiotoxicity) are dose-
dependent 39,40. Chronic ACT may present as progressive left ventricular dysfunction, 
cardiomyopathies and subsequent death due to cardiac failure (CF) 9,25,26,37,39,41.  
 
 
 
Figure 8: Stylised comparison of a normal heart and a heart in congestive failure (Image 
adapted from 42). Progressive muscle weakness in a congested heart results in the 
inability of a dilated left ventricle to pump adequate blood throughout the body 
Table 3 below compares the types of ACT, hallmark clinical features and prognosis in both 
adults and children. 
Table 3: Types of Anthracycline-Induced Cardiotoxicity – Features and Prognosis 
 
Acute 
Cardiotoxicity 
Early 
Cardiotoxicity 
Late Cardiotoxicity 
Onset 
Within 1st week of 
treatment 
<1 year after 
treatment 
≥1 year after 
treatment 
Clinical Features 
in Adults 
Arrhythmias, acute 
cardiac failure 
Dilated 
cardiomyopathy 
Dilated 
cardiomyopathy 
Clinical Features 
in Children 
 
Restrictive and/or 
dilated 
cardiomyopathy 
Restrictive and/or 
dilated 
cardiomyopathy 
Prognosis Generally reversible May be progressive May be progressive 
Adapted from Raj et al. (2014) 24 
Clinical cardiac phenotypes referred to in Table 3 are described below in greater detail: 
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Arrhythmias describe abnormal heart rhythm that can either be too fast (tachycardia) or too 
slow (bradycardia or brachycardia) that may result in symptoms of fatigue and dizziness 43. 
Dilated cardiomyopathy occurs when the left or both ventricles dilate resulting in impaired 
systolic function that may present with symptoms of CF and/or arrhythmia and systemic 
embolism. Symptomatic therapy which includes diuretics, beta blockers and angiotensin 
converting enzyme (ACE) inhibitors may be administered. Extreme cases may warrant cardiac 
transplantation 43. 
Restrictive cardiomyopathy is characterised by both normal or reduced diastolic or systolic 
volumes and normal thickness of the ventricular wall. While restrictive cardiomyopathy of the 
left ventricle may present with pulmonary congestion and/or mitral regurgitation, restrictive 
cardiomyopathy of the right ventricle may present with increased jugular venous pressure, 
hepatomegaly and tricuspid regurgitation 43. Diuretics may improve the condition but advanced 
disease has a poor prognosis. 
Cardiotoxicity may range from the fairly innocuous swelling of the sarcoplasmic reticulum, 
cytoplasmic vacuolization, myofibrillar degeneration, myocyte disruption to the severity of 
fibrosis, systolic/diastolic dysfunction and CF 26,39. The range of cardiac damage may explain 
the types of ACT – while cardiac remodelling and subsequent contractile dysfunction, largely 
due to fibrosis, accounts for both chronic and acute ACT; late onset ACT may be attributed to 
cumulative cardiac damage coupled with the inability of cardiomyocytes to rebound from 
toxicity 12.  
The progressive nature of irreversible cardiotoxicity may be of greatest burden to children, 
adolescents and long term cancer survivors 36,41. Approximately one out of eight childhood 
cancer survivors have been reported to experience severe cardiac disease later in life – with 
an average time between diagnosis and cardiomyopathy  of  9.4 years; this risk increases 
significantly with increased cumulative dose 24,44. When childhood cancer survivors were 
compared to their siblings, they were found to have a significantly higher incidence of CF, 
myocardial infarction, pericardial disease and valvular abnormalities – cardiac events which 
increased in likelihood over a 30 year period after initial cancer diagnosis 45. Specifically, a 
study by Grenier et al. 46, showed that almost 65% of all long term childhood cancer survivors, 
treated with anthracyclines, showed left ventricle (LV) contractile dysfunction and that heart 
transplantation was common in young adults who experienced cardiotoxicity.  
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In terms of breast cancer, increased survival due to therapy translates to a significant number 
of survivors with impaired cardiac function or the potential to develop cardiomyopathies. 
Currently, in the USA alone, it is estimated that there may be more than 2 million cancer 
survivors at risk of delayed anthracycline cardiotoxicity 17. This increased risk combined with 
family history of cardiovascular heart disease and unhealthy lifestyle choices can severely 
compromise quality and quantity of life. 
The incidence and severity of ACT may be increased due to a multitude of risk factors such 
as higher cumulative dose, increased individual dose, younger or older age at diagnosis, 
female sex, pre-existing cardiovascular disease such as hypertension, ischaemic, myocardial 
or valvular disease, metabolic disorders, genetic factors (i.e. trisomy 21, African Ancestry), 
mediastinal radiation therapy, and shorter infusion time 9,10,24,26,36,47,48. Risk factors worth 
consideration due to their effect on cardiac health include: smoking, consumption and/or use 
of alcohol, energy drinks, stimulants, prescription and illegal drugs 24. Impaired cardiac 
function may be caused by complications arising from viral infection, pregnancy, arrhythmia, 
and anaemia – therefore, a combination of predisposing medical conditions coupled with 
cardiotoxic chemotherapy increases the risk of developing ACT. 
Nevertheless, cardiovascular disease (CVD) is a leading cause of long-term morbidity and 
mortality amongst cancer patients 49,50. 
2.2.1.4 Dose 
Numerous studies have shown that cumulative dose is strongly associated with the risk of 
developing ACT 3,5,9,24,25,36,40,44,51-53.  
While the USA’s Food and Drug Administration (FDA) has stipulated that total cumulative 
doses exceeding 550 mg/m² results in permanent cardiac damage, there are still patients who 
experience symptoms of cardiac failure below this prescribed “safe” anthracycline dose 3,53. 
Conversely, there are also patients who can tolerate anthracyclines (without cardiotoxicity) 
with cumulative doses exceeding 1000 mg/m2. 
Table 4 which is a summary of previously published work shows the risk of cardiotoxicity 
attributed to varying cumulative doses and in some instances the type of anthracycline-based 
therapy. 
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Table 4: Studies illustrating dose-dependent cardiotoxicity experienced by patients 
treated with anthracyclines 
Study Therapy Cumulative Doses and Subsequent Risk of Cardiotoxicity  
  ≥ 150 
mg/m2 
250 
mg/m2 
 350 
mg/m2 
(+/-) 
450 
mg/m2 
550 
mg/m2 
(+/-) 
>600 
mg/m2 
Raj et al. 2014 
24 
 7% 9% 18% 38% 65%  
Volkova et al. 
2011 25 
 0.2% 
(CF) 
 1.6% 
(CF) 
3.3% 
(CF) 
8.7% 
(CF) 
 
Von Hoff et 
al. 1979 40 
DOX   3% (CF)  7.5% 
(CF) 
 
Swain et al. 
2003 53 
DOX   5% (CF)  26% 
(CF) 
48% 
(CF) 
Ryberg et al. 
1998 52 
EPI      1.9-4% 
(CF) 
Kumar et al. 
2012 5 
DOX  21%     
Deng et al. 
2007 9 
     26% 
(CF) 
 
        
 
It is important to clearly delineate how cardiotoxicity and/or CF was defined – Von Hoff et al.54 
described the event as clinical symptoms of CF exhibited by the patient after the administration 
of doxorubicin 40,51. Swain et al. 53 defined CF as fulfilling two of the following requirements: 
cardiomegaly on chest x-ray, basilar rates, S3 gallop, or paroxysmal nocturnal dyspnoea, 
orthopnoea or significant dyspnoea following exertion 53. Ryberg et al. 52 specified that patients 
deemed as having CF fulfilled the following requirements: a history of breathlessness, clinical 
signs of CF such as dyspnoea and/or congestion on the chest X-ray and/or peripheral 
oedema, cardiomegaly with/without pulmonary congestion/pleural effusion on an X-ray and/or 
abnormal left ventricular ejection fraction (LVEF) where LVEF < 46% or a decrease of > 15% 
(post–treatment compared to pre-treatment) and if possible, an abnormal echocardiography 
(ECHO).  
While risk of CF and/or cardiotoxicity risk is inconsistent between studies, it shows that there 
is no “safe” dose of anthracyclines and furthermore that the dose-dependent association with 
cardiomyopathy may limit therapeutic potential 44. The disparities in some instances (as shown 
in Table 4) in terms of cardiac risk at specific cumulative doses can be explained by the varying 
definitions of CF and/or cardiotoxicity adopted by the authors, as well as the type of 
anthracycline-based treatment administered. 
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While doxorubicin is effective against a wide variety of tumours, 4-epi-doxorubicin or epirubicin 
is estimated to be about 30% less cardiotoxic due to differences in the manner in which they 
are metabolized 10,26,35 – this is discussed in greater detail later in the chapter. 
While anthracycline-based therapy alone is damaging to the cardiac muscle structure and 
function, the combination of anthracyclines with other therapies (i.e. combination therapy) may 
carry a greater risk of cardiac failure in cancer patients 24. 
2.2.1.5 Combination Therapy 
The overall risk of ACT may be significantly increased when radiation therapy and/or other 
agents such as targeted drugs are utilized together with an anthracycline-based regimen.  
Radiation therapy, if administered in an irradiation field covering parts of the heart, may 
exacerbate symptoms of ACT and long term cardiac risk – this has been shown to be 
associated with a high cumulative anthracycline dose with radiation 16,24,51. Wang et al.44 
demonstrated that the risk of cardiomyopathy may be increased by up to 3-fold if 
anthracycline-based therapy was combined with chest irradiation. However, more recent 
modes of chest wall irradiation such as intensity-modulated radiation therapy may avoid 
significant damage to the heart 51. 
Targeted drugs including the anti-HER2 antibody (trastuzumab) and inhibitor (lapatinib) when 
combined with anthracyclines have increased anti-cancer activity but potentially significant 
cardiotoxic effects. The risk of cardiac dysfunction increases from 10% to 28% when 
anthracyclines are combined with trastuzumab 16,17,39. Trastuzumab administered alone, 
impairs myocyte contractility causing short-term, reversible damage; however in combination 
with anthracyclines, it causes impairment to myocytes’ homeostatic mechanisms and survival 
pathways ultimately contributing to myocyte loss and causing long term cardiac damage 17. 
Other potential contributors to cardiotoxicity include taxanes, platinum drugs, 
fluoropyrimidines, vinca alkaloids and nitrogen mustard analogues 27. While combination 
therapy is often necessary in cancer patients with a poor prognosis, this has to counterbalance 
with the increased risk of ACT 18. 
While ACT generally presents with symptoms indicative of cardiac dysfunction, numerous 
studies have found cancer patients with subclinical damage that could not be routinely 
detected yet later manifested as cardiovascular heart disease 9,40,48,55. Patients with subclinical 
damage still receiving doxorubicin may have severely compromised left ventricular function 
that can contribute to further damage and CHF 17,39. Compensatory mechanisms such as 
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tachycardia or shortness of breath after minimal exertion may precede CF, and are signs to 
be looked out for 17. It has been reported that subclinical cardiac abnormalities may occur in 
more than 50% of all patients treated with anthracyclines, suggesting that reported rates (10-
30%) may be underestimating actual cardiotoxicity rates 9,40,55. 
Previous attempts to stratify patients based on co-morbidities and clinical factors into risk 
groups for developing ACT have proved to be unsuccessful.  It is therefore necessary to take 
a comprehensive patient history to avoid exacerbating existing cardiac damage with 
anthracycline based treatment, but also to attempt to elucidate the underlying mechanisms of 
drug-related injury 9,10,24,26,47,48. 
2.2.1.6 Mechanism of Action 
The mechanism of action of anthracyclines involves damage to tumour DNA via intercalation 
of the drug between bases and effectively blocking the synthesis of DNA and/or RNA 2,24. 
Furthermore, anthracyclines inhibit the action of topoisomerase II, an enzyme necessary for 
DNA replication, which contributes to both cellular apoptosis and the inhibition of cancer cell 
replication 56. The subsequent generation of semiquinone free radicals and oxygen-free 
radicals further damages DNA, proteins and cellular membranes 21,24.  
The mechanism of action of anthracyclines may also explain the damage inflicted on 
cardiomyocytes and subsequent chronic cardiomyopathies and CF (Fig. 9) 2,16,22,27,48,56.  
Anthracyclines are able to bind to both nuclear and mitochondrial DNA and interfere with the 
transcription of genes and cellular replication. While Topoisomerase  II inhibition is effective 
for tumour eradication, it is detrimental for healthy cardiomyocytes 56. The inhibition of 
Topoisomerase II in cardiomyocytes activates DNA cleaving caspases (caspase 3 and 
caspase 9), which contribute to myofibril and troponin damage 56. Troponin is a myofibrillar 
protein that regulates cardiac muscle contraction 57. Dysfunction and/or damage may result in 
impaired cardiac function.  
The metabolism of doxorubicin may additionally explain further cardiac insult whereby 
doxorubicin  undergoes a two-electron reduction to the alcohol metabolite – doxorubicinol and 
a one electron reduction to the semiquinone radical coupled with the generation of reactive 
oxygen species (ROS) 26,27. The two-electron reduction of the carbonyl group in the 
anthracycline side chain is catalysed by nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent reductases, carbonyl reductases (CBR) and aldo/keto reductases (AKR) 
and results in the accumulation of alcoholic metabolites. These alcoholic metabolites not only 
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impair cardiomyocyte contractility by inhibition of the Ca²+ and Na+/K+ pump and depleting 
Adenosine Triphosphate (ATP) but also disturb cardiac iron homeostasis 47,56,58. This 
disturbance occurs when anthracyclines bind cellular iron resulting in a doxorubicin-iron 
complex that generates free radicals and is damaging to DNA, intracellular proteins and 
membrane lipids 25,39. Consequently, there is a direct correlation between the myocardial 
accumulation of alcoholic metabolites and the onset of cardiomyopathy 25,26,47,58. 
Furthermore, the one electron reduction of the quinone moiety in the tetracyclic ring of the 
anthracycline is catalysed by oxidoreductases and produces a semiquinone radical capable 
of regeneration and production of ROS. ROS has been previously implicated in contributing 
to membrane and DNA damage, oxidative stress and cellular apoptosis and ultimately, to the 
progression of cardiomyopathies to CF 26,27,39,41,47. 
Increased nitric oxide production due to doxorubicin metabolism also results in the creation of 
reactive nitrogen species (RNS) which together with ROS may further impair cardiac function 
by: (i) contributing to the disruption of cardiac gene expression and apoptosis, and (ii) affecting 
mitochondrial function and energy generation 16,17,26. The intercalation of anthracyclines into 
mitochondrial DNA and their affinity for cardiolipins (inner mitochondrial-membrane specific 
phospholipid) further compromises mitochondrial enzyme activity and subsequent function 
22,59. The oxidation of cell membrane lipids, DNA degradation, mitochondrial defects and 
dysfunction of enzymes containing sulfhydryl groups may all be attributed to ROS and 
contribute to chronic cardiotoxicity 34. The initiation of apoptosis is also due to the release of 
cytochrome C due to oxidant stress as well as p38 MAPK activation 25.  
 
Figure 9: Illustration of a cardiomyocyte showing mechanism of action of anthracycline 
and potential cellular damage (Image adapted from Sandhu et al. 2014 56 and Volkova 
et al. 2011 25) 
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As previously mentioned, epirubicin is less cardiotoxic than doxorubicin due to differences in 
their intracellular distribution and metabolism. While doxorubicin localises in the mitochondria, 
epirubicin is found in cytoplasmic organelles where it undergoes a one-electron reduction with 
little ROS produced and limited two-electron reductions further reducing the amount of 
alcoholic metabolites produced 26,35. Despite these advantages, epirubicin does still 
accumulate in the heart allowing for direct interaction with vulnerable cardiomyocytes 26.  
Cardiac cells are vulnerable due to their high metabolic activity, weak antioxidant defences 
and high cardiolipin concentration for which anthracyclines have a great affinity 17,22,26,37,39. 
Cardiomyocytes are also post-mitotic cells with limited regeneration ability, therefore, 
anthracycline-induced cardiac damage is often irreversible 22. A barrage of cardiac insults 
including: depleted cardiac stem cells, impaired DNA synthesis, gene expression and cell 
signalling contributing to damage in the sarcoplasmic reticulum, mitochondria and sarcomeres 
inevitably results in chronic cardiomyopathy 24. 
These mechanisms of action and pathways may aid in the differentiation of cardiovascular 
phenotypes based on the type of damage inflicted on cardiomyocytes ultimately allowing for 
a delineation between genetic and ischaemic cardiomyopathy that could be utilized in the 
genetic determination of cardiac risk 16,24. Therefore, ACT can be categorized as either Type 
I or II, where Type I consists of irreversible, cardiac damage contributing to cardiomyocyte 
death, compared to Type II which includes damage caused by combination therapies and may 
be reversible due to benign myocyte impairment 25,60. Type I damage is attributed to ROS 
generation by anthracyclines resulting in cardiac cell damage and myocyte loss compared to 
Type II damage which may be due to competition for binding therapeutic targets (i.e. HER2 
protein by trastuzumab) therefore affecting cardiomyocyte growth, repair and survival 10,25,60. 
As a result, Type I damage is often associated with long-term cardiotoxicity. 
2.2.2 Modalities to Assess Cardiac Function 
Not only does reduced  reporting of cardiac events and inherent clinical differences in cancer 
patients contribute to determining accurate estimates of ACT but the variance and low 
sensitivity of routinely used detection modalities may further compound the issue 24. 
In the routine clinical setting cardiotoxicity is detected using LVEF derived from a number of 
modalities, including ECHO and clinical examination. However these methods are rarely able 
to detect early stage or subclinical cardiotoxicity 39. Other tests utilised to monitor 
anthracycline-induced cardiotoxicity include: equilibrium radionuclide angiocardiography 
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(ERNA), endomyocardial biopsy and indium-111 antimyosin imaging, magnetic resonance 
imaging (MRI), tissue-doppler imaging and biomarkers 39,61-64. 
2.2.2.1 Left Ventricular Ejection Fraction (LVEF) 
LVEF is a measure of the amount of blood being pumped out of the main pumping chamber 
of the heart, the left ventricle with each contraction. A healthy heart pumps more than half the 
heart’s blood volume with each beat and is quantified as a percentage 64. 
Table 5: Left Ventricular Ejection Fraction and its Interpretation 64 
Ejection Fraction Interpretation 
55-70% Normal/ Healthy heart 
40-55% Below Normal 
<40% May indicate heart failure 
≤35% Risk of life-threatening irregular 
heartbeats 
Table 5 shows ejection fraction measurements and their interpretations – while a lowered 
LVEF indicates compromised cardiac function due to damaged cardiac muscle or disease, a 
patient with diastolic failure can have a normal or preserved ejection fraction 17. CF can either 
be attributed to systolic CF whereby the left ventricle muscle contracts inadequately resulting 
in reduced oxygenated blood being pumped throughout the body or to diastolic CF where 
contraction of the heart is normal but ventricles are impaired not allowing sufficient blood into 
the heart 64. Nevertheless, a patient with an EF of less than 35% is at risk of sudden cardiac 
arrest or cardiac death due to irregular heartbeats 64. 
In the context of anthracycline-based chemotherapy, baseline LVEF is determined prior to 
treatment and again after three or four cycles where patients with an LVEF greater than 50% 
at baseline are deemed healthy and subsequently amenable to treatment 10,39. However, a 
decrease in LVEF of greater than 10% from baseline to after treatment, or an LVEF of less 
than 50% may indicate the onset of cardiotoxicity and treatment should either be discontinued 
or substituted 37,39. Moderate decreases (≤10%) in LVEF do not necessarily denote CF or 
impaired muscle function and may be stabilized with the discontinuation of treatment 25. 
LVEF is therefore a commonly utilised and accepted physiologic measure of cardiac function 
in patients receiving anthracycline-based chemotherapy and may be determined using ERNA 
or a multigated acquisition scan (MUGA), ECHO, cardiac catheterization, computerized 
tomography (CT) scan or an MRI 39,64. 
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 Equilibrium Radionuclide Angiography (ERNA) 
ERNA came into prominence in the 1970s as a reliable method for the quantification of LVEF 
65. ERNA also known as a MUGA scan, involves the use of a radionuclide agent such as 
technetium-99m to tag patient red blood cells which are then re-injected followed by gated-
image acquisition 65.  
Gated-image acquisition occurs when the patient’s cardiac rhythm is at rest and 300-600 
heartbeats are assessed over a period of 5-10 minutes – this together with 3 standardised 
views of the heart and a count-based algorithm allows for the determination of LVEF 65. 
The advantages of this technique are its non-invasive nature and high reproducibility, whereas 
its disadvantages include the limitation of clinical benefit compared to exposure to radiation, 
difficulty in obtaining image acquisition angles and problematic gating due to patient 
arrhythmias 65. 
 Echocardiography (ECHO) 
ECHO is a modality for the determination of LVEF that is similarly non-invasive, more sensitive 
and avoids radiation exposure 65,66.  
ECHO employs the use of sound waves or ultrasound to visualise the heart in real time and 
may be two dimensional (2D ECHO) or three dimensional (3D ECHO). Doppler ECHO or 
tissue doppler imaging makes use of pulsed wave Doppler 61. 2D ECHO enables the 
visualization of real-time motion of the heart’s structures whereas 3D ECHO enables the 
visualization of the heart’s structure and function in greater depth 67. The more sensitive 
Doppler ECHO shows the flow of blood through the heart’s chambers and valves allowing for 
the quantitation of blood pumped out with each beat and subsequent function of the heart 67. 
While ECHO is a technique that can be used to detect structural abnormalities and evaluate 
cardiac function, determinations of LVEF are often an approximation 39. Generally an LVEF, 
derived using an ECHO, of less than 40% and/or fractional shortening (FS) of less than 28% 
is regarded as left ventricular dysfunction 68. Childhood cancer survivors’ echocardiograms 
have shown reduced LV fractional shortening related to the cumulative dose of doxorubicin, 
however significant reductions in LV fractional shortening were also observed in some treated 
with low doses, emphasising that there was no safe dose of doxorubicin 24. 
Even though studies have found Doppler ECHO to be a highly sensitive measure of 
myocardial strain and 3D ECHOs to be superior to 2D ECHOs; echocardiography was prone 
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to intra- and inter operator variability as well as being fairly expensive (to be taken into account 
especially in a resource-poor setting) 16,66,67.  
Nevertheless, 3D ECHOs were found to be comparable to cardiac magnetic resonance 
techniques. 
2.2.2.2 Cardiac Magnetic Resonance (CMR) Imaging 
Cardiac Magnetic Resonance (CMR), utilises a magnetic field together with radio frequency 
impulses to produce a highly detailed image of the heart. 
Although infrequently used, it is both non-invasive, highly sensitive and superior to cardiac 
nuclear imaging (ERNA/MUGA) and therefore considered the gold standard for the 
assessment of LV function 65,69. The determination of LVEF and volumes using CMR have 
been found to be highly reproducible and accurate 65,69. Limitations, however, include the high 
cost and expertise required to operate an MRI machine, irregular heartbeats affecting the 
image quality and the time taken to perform the imaging 70. 
Despite the various modalities to assess LVEF, it has low sensitivity as an early predictor of 
cardiomyopathy especially when patients have acute reversible damage that may be 
timeously treated 18,37,65,69. A number of alternatives exist for assessing cardiac function with 
greater sensitivity; similarly alternative measures of early cardiac dysfunction need to be 
assessed – these include endomyocardial biopsies, Indium-111 antimyosin and cardiac 
biomarkers. 
2.2.2.3 Endomyocardial Biopsy 
An endomyocardial biopsy consists of the invasive removal of a right ventricular 
endomyocardium sample 39. Biopsies performed after early doxorubicin treatment may show 
cell disruption and loss with histopathologic changes as previously observed in specimens of 
patients treated with doses as low as 240mg/m2 17,25. However this technique can be 
expensive, risky and may confer inconclusive findings 39. 
2.2.2.4 In-111 Antimyosin 
In-111 antimyosin is a tracer used for the imaging of conditions such as myocarditis, 
cardiomyopathy, cardiac transplant rejection and doxorubicin-induced cardiotoxicity; while it 
is highly sensitive to early onset cardiotoxicity, it can be expensive, technically challenging 
and time-consuming 39,65.  
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Therefore there is a need for a sensitive yet fairly inexpensive and efficient, non-invasive 
measure of cardiac injury.  
2.2.3 Management of Cardiotoxicity 
ACT can be reduced or prevented in a number of ways which include: drug dose control; the 
use of less toxic natural derivatives, tumour-targeted formulations or cardio-protective agents; 
continuous infusion to reduce peak plasma drug levels; the delayed administration of 
trastuzumab after anthracycline treatment and administering a non-anthracycline based 
regimen 17,26,39,71. 
2.2.3.1  Dose Control 
As previously discussed, the recommended cumulative dose for doxorubicin is 240-360mg/m² 
and 450-600mg/m² for epirubicin; as is obvious – different individuals may tolerate relatively 
low doses – below the optimum therapeutic range 17,39. Therefore, despite the setting of an 
arbitrarily low dosage to prevent cardiotoxicity, there is no safe dose of anthracycline. Also, 
despite the association between high cumulative doses and increased risk of ACT, long-term 
follow-up studies have shown subclinical dysfunction and CF in cancer survivors administered 
even at low doses of anthracyclines 12,24. 
2.2.3.2  Natural Derivatives 
While doxorubicin is naturally occurring, a semisynthetic derivative – epirubicin, was 
discovered to be less cardiotoxic yet equally efficacious in both animal models and in vivo 
studies. However clinical trial data has not been definitive in relative cardiotoxicities of the two 
anthracyclines 22,72-74. 
As previously discussed in this chapter, epirubicin has been utilized in high risk patients and 
often at higher cumulative doses. 
2.2.3.3  Tumour-targeted Formulations 
Tumour-targeted formulations endeavour to prevent the uptake of anthracyclines by cardiac 
cells and improve tumouricidal activity 37,72,75. These formulations have two modes of action: 
active targeting - whereby there is specific tumour recognition by the carrier, and passive 
targeting, where there is preferential drug distribution such as the liposomal encapsulation.  
This process prevents interaction of anthracyclines with the heart, by virtue of the large size 
of their liposome ‘covers’, making them unable to fit into tight capillaries, thereby reducing 
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cardiotoxicity 75,76. Studies of the liposomal formulations of doxorubicin have shown promise 
in reducing cardiotoxicity in the clinical setting, while also suggesting it may be a better 
alternative to both conventional doxorubicin and epirubicin 22,37,72. 
2.2.3.4  Cardio-protective Agents 
Numerous agents may confer cardio-protection to patients who are at risk of ACT and 
subsequent HF. Dexrazoxane, a derivative of ethylenediaminetetraacetic acid (EDTA), is an 
iron-chelator that has emerged with the most promise 10,24,27,37,76. Dexrazoxane binds free 
and/or loosely bound cellular iron or iron from anthracycline-iron complexes therefore 
preventing iron-catalysed ROS damage.  Cardio-protection is evidenced by the stable or non-
increased Troponin T levels in patients treated with anthracyclines 17,22,26.  
There has been evidence of an association between dexrazoxane use and impaired efficacy 
of anthracyclines, lower response rates, and significant haematologic and gastrointestinal tract 
toxicity, however other studies have found that dexrazoxane conferred long-term cardio-
protection without compromising oncologic efficacy 17,24,27,39. Based on this contentious 
evidence, dexrazoxane is cautiously administered only when the cumulative dose of 
anthracyclines is maximized 17,27,39. 
Routinely prescribed cardiac medications for asymptomatic left ventricular dysfunction or 
cardiac failure which include: β-blockers, angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, diuretics, nitrates and hydralazine may, if prescribed early 
enough achieve complete cardiac recovery 16. Another agent, heat-shock protein 20 (HSP20), 
has shown protection against doxorubicin-induced apoptosis and may have potential as a 
cardio-protector 22. Angiotensin-converting inhibitors such as enalapril, which usually improve 
both LV structure and function, had a temporary effect on patients with CF, as well as 
worsened long-term cancer survivors’ conditions after 6-10 years 24. 
Despite the challenges associated with cardio-protective agents, they may confer benefit 
given the progressive nature of ACT evidenced by the significant number of cancer survivors 
suffering from cardiac failure refractory to treatment or needing cardiac transplantation 10,37. 
2.2.3.5  Continuous Infusion 
Due to risk of ACT being dose-dependent, another strategy to decrease risk of cardiac injury 
is to reduce peak plasma levels of doxorubicin by increasing the duration of infusion without 
reducing the overall dose i.e. continuous infusion 77. While continuous infusion compared to 
32 
 
bolus infusion of doxorubicin has been shown to reduce cardiotoxicity in adults; this was not 
the case in children even when it was combined with the cardio-protectant, dexrazoxane 24,77. 
2.2.3.6  Delayed Administration of trastuzumab 
While trastuzumab markedly improves breast cancer survival, it also aggravates ACT 
increasing cardiac risk by 27% when combined with anthracyclines; this is why its delayed 
administration is recommended  16,78. 
The reason for not administering trastuzumab with anthracyclines is that trastuzumab acts as 
a modulator of ACT when administered at the same time as anthracyclines and has the ability 
of further damaging already vulnerable myocytes 78. 
2.2.3.7  Non-Anthracycline Based Regimen 
In patients where the risk of cardiomyopathy and/or CF is too high without compromising 
treatment efficacy [with risk mitigation strategies such as dose control], other non-
anthracycline based regimens may be considered 76. Studies have shown superior disease-
free survival and lower rates of CF in patients treated with four cycles of TC (docetaxel and 
cyclophosphamide) compared to four cycles of AC (adriamycin and cyclophosphamide) 76. 
The prevention of anthracycline-induced cardiotoxicity while maintaining anti-tumour efficacy 
is an important consideration especially in long term cancer survivors such as childhood 
cancer patients. However, since the mechanism of drug-induced cardiac damage is not fully 
understood, understanding the process of metabolism of anthracyclines may explain 
cardiotoxicity. It is therefore not unreasonable to presume that that the genes coding for 
enzymes involved in anthracycline metabolism may be determinants of cardiac damage 34. 
2.3 Genetics of Cardiotoxicity 
Since there is compelling evidence that genetic factors play a role in the effectiveness of 
chemotherapy as well as adverse drug reactions, there is strong motivation to investigate 
pharmacogenetic associations with treatment outcomes 7,8,55. The field of pharmacogenetics 
seeks to explain the genetic contribution to variable drug responses - in this instance the 
variability in an individual’s response to anthracyclines 9,13. Observed variability in patient drug 
response as well as fairly inconclusive risk associations with clinical co-morbidities suggests 
that there is very likely to be a genetic predisposition/susceptibility to ACT. Therefore, 
polymorphisms in pathway-based genes involved in drug absorption, distribution, metabolism, 
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elimination and toxicity (ADMET) may allow for the elucidation of genetic response to 
cardiotoxicity and subsequently allow for the individualisation of treatment and to minimise 
event-free survival 10,55,79. 
The function of proteins involved in drug ADMET may be affected by amino acid changes due 
to genetic alterations. However, not all genetic mutations trigger an amino acid change- these 
changes may range from them being functionally neutral to deleterious 80. A synonymous 
genetic variant comprises a sequence change without any change to the encoded amino acid 
81. Missense variants result in a sequence change where the encoded amino acid is changed 
but the length is preserved 81. An intronic variant may have the potential to also affect gene 
regulation 81.  There is growing evidence that variants which are not overtly functional (e.g. 
nonsense or missense) may well occur in intergenic and intronic regions, but be very important 
from a regulatory perspective 82. 
Returning to ACT - previously genetic variants have been found to potentially modify the 
association between dose-dependence and cardiotoxicity as indicated by inter-individual 
variability 44.  
Candidate genes involved in the metabolism of doxorubicin were first investigated (Fig.10) 
followed by anthracycline-based drug transport within a cell (Fig.11) and its metabolism in a 
cardiomyocyte and subsequent adverse drug reactions (Fig.12). 
 
Figure 10: Representation of pathways showing candidate genes involved in the 
metabolism of doxorubicin in a cancer cell 83- courtesy of www.pharmgkb.org  
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Figure 11: Representation of transport and metabolism of doxorubicin83 – courtesy of 
www.pharmgkb.org 
 
Figure 12: Representation of candidate genes involved in the metabolism of 
doxorubicin and subsequent adverse reactions in a cardiomyocyte83 – courtesy of 
www.pharmgkb.org 
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Therefore, a candidate gene approach that focused on genes involved in drug ADMET as well 
as in the mechanism of cardiomyocyte injury would allow for a plausible investigation into the 
following: 
1. Aldo-keto reductases are NADPH-dependent oxidoreductases involved in the 
metabolism of Doxorubicin 34. They are involved in the reduction of aldehydes and 
ketones into primary and secondary alcohols that are eventually eliminated from the 
body 34. The formation of doxorubicinol (an alcohol metabolite) therefore requires input 
from the following genes: AKR1C3, AKR1A1, CBR1 and CBR3 27,34. 
2. CBRs are also involved in converting anthracyclines to alcohol metabolites which may 
be cardiotoxic. Therefore, the CBR3 V244M variant (rs1056892) may be associated 
with ACT 26,47,68. This single nucleotide polymorphism (SNP) encodes for a valine to 
methionine substitution at position 244 and has been found at varying frequencies in 
different population groups 26. While CBR3 and HAS3 (rs2232228) may have a dose-
modifying risk of ACT- patients homozygous for the CBR3 V224M G allele and the 
HAS3 A allele were previously shown to be susceptible to cardiotoxicity, even at fairly 
low doses (101-150mg/m²), ACT was also induced at high doses of anthracyclines 
(>250mg/m²) irrespective of the CBR3 genotype but not for the HAS3 AA genotype 
44,68. CBR3 expression is regulated by the transcription factor, nuclear factor like-2 
(nrf2), which controls genes that protect against oxidative stress and may provide the 
link between ROS-cardiomyocyte damage and CBR3 expression. 
3. Genes involved in the oxidation reaction and production of ROS and deactivation of 
ROS include NADPH dehydrogenases, namely NCF4, CYBA and RAC2, nitric oxide 
synthases, xanthine oxidase, glutathione peroxidase, catalase and superoxide 
dismutase 27. NADPH oxidases may play a crucial role in oxidative cardiac damage, 
remodelling and contractile dysfunction, and are therefore of importance for the 
development of ACT 12. Specifically, NCF4 rs1883112, was found to be strongly 
associated with cardiac interstitial fibrosis (a common feature of cardiomyopathy) while 
patched myocardial necrosis (infarcted myocardium causing a necrotic patch) was 
associated with CYBA rs4673 12.  
4. Due to  the ability of doxorubicin to destroy topoisomerase II , leading to  DNA damage 
and cell death, genes involved in the DNA repair pathway may be of interest and 
include: TOP2A, MLH1, MSH2, TP53 and ERCC2 27.  
5. Uncoupling proteins (UCP) are members of the family of mitochondrial transport 
proteins that maintain the mitochondrial membrane. Decreased UCP expression was 
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found to be associated with both increased mitochondrial ATP production and ROS 
production; potentially increasing the likelihood of ACT 24. Therefore polymorphisms in 
the genes coding for UCPs may have a bearing on genetic predisposition to 
cardiotoxicity. 
6. Recently, it was found that African American ancestry and mutation in the 
Haemochromatosis gene (HFE) may increase predisposition to ACT 24.  
Due to the advances in the development of bioinformatics tools and ever decreasing costs of 
next generation genomic technologies, genome wide association studies (GWAS) have 
helped to identify novel SNPs that may predict ACT 44. Wang et al. 44 focused on the validation 
of a novel SNP involved in a gene-environment interaction; specifically its ability to modify the 
dose-dependent risk of cardiomyopathy. SNP rs1786814 in the CELF4 gene was successfully 
associated, validated and replicated and showed that cardiomyopathy was rare and not dose-
dependent in patients with the AA genotype 44. Patients with the GG genotype however, 
exposed to a cumulative anthracycline dose of 300 mg/m2, had a more than 10-fold risk of 
cardiomyopathy compared to their GA/AA counterparts 44. Furthermore, an association was 
found between the CELF4 (rs1786814) GG genotype and more than one splicing variant of 
TNNT2; the gene that encodes cardiac troponin T, a biomarker of myocardial damage 44. More 
than one cardiac troponin T variant results in a temporally-split myofilament response to 
calcium and subsequent decreased myocardial contractility and ventricular function 44. 
Splicing of TNNT2 during development results in the inclusion of alternative exon 5 which 
subsequently results in an additional 10 amino acids into the protein ultimately pre-empting 
cardiac dysfunction 44.  
Similarly, Aminkeng et al. 7 conducted a GWAS study on childhood cancer patients treated 
with anthracyclines and found a novel variant, RARG rs2229774, to be associated with ACT. 
The RARG variant impairs transcriptional regulation of Top2b, which encodes DNA 
topoisomerase – a target of anthracyclines 7,84. A study by Zhang et al.85 showed that in mice, 
the cardiomyocyte-specific deletion of Top2b which encodes for topoisomerase IIB resulted in 
a protective effect. Cardiomyocytes were safe from DNA double-strand breaks and 
transcriptome changes generally inflicted by doxorubicin thereby preventing defective 
mitochondrial biogenesis and ROS formation. This ultimately protected these mice from 
developing doxorubicin-induced progressive cardiac failure. 
Other SNP risk variants include: SLC28A3 rs7853758  which was found to be strongly 
associated with ACT; UGT1A6 rs6759892; ABCB4 rs1149222; ABCC1 rs4148350 and HNMT 
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rs17583889 10. Specifically, SLC28A3 rs7853758 (L461 L) and UGT1A6 rs17863783 (V209 
V) have been previously associated with ACT in paediatric cancer patients 84. While neither of 
these variants are expressed in the heart, it is surmised that their associations with ACT may 
indicate indirect effects on cardiac tissue 84. The variant UGT1A6 rs17863783 (V209 V) has 
been linked to impaired drug metabolism possibly due to its reduced glucuronidation activity 
in vitro 84. A reduction in glucuronidation results in the accumulation of reactive oxygen species 
and toxic alcohol metabolites. The variant SLC28A3 rs7853758 (L461 L) has been shown to 
have reduced expression in cell lines and subsequent reduced exposure to anthracyclines 
which may confer a protective effect 84. This is due largely to SLC28A3’s role as a drug 
transporter. 
A number of genes and SNPs or variants within or in the vicinity of these genes, as shown in 
Table 6, have been associated with either a protective or increased risk effect related to 
anthracycline-induced cardiotoxicity 8,10,27,55,79 : 
Table 6: Genes and SNPs that have been previously associated with anthracycline-
induced cardiotoxicity 
Gene Variant CHR Position Functional Annotation Alleles 
            
ABCC1 rs45511401 16 16173232 Exon Missense G/T 
 
rs4148350 16 16170477 Intron G/T 
 
rs246221 16 16138322 Exon   T/C 
ABCC2 rs17222723 10 101595996 Exon Missense T/A 
 
rs8187710 10 101611294 Exon Missense G/A 
ABCB4 rs1149222 7 87073775 Intron G/T 
ACO1 rs867469 9 32383708 5' near gene G/A 
AKR1A1 rs2229540 1 46032311 Exon Missense A/G 
CAT rs10836235 11 34460704 Intron C/T 
CBR3 rs1056892 21 37518706 Exon Missense G/A 
CYBA rs4673 16 88713236 Exon Missense T/C 
GSTP1 rs1695 11 67352689 Exon Missense A/G 
HFE rs1800562 6 26092913 Intron A/G 
HNMT rs17583889 2 138746039 Intron C/A 
IREB2 rs17483548 15 78730313 5' near gene G/A 
NCF4 rs1883112 22 20219009 5' near gene G/A 
RAC2 rs13058338 22 20597907 Intron A/T 
RARG rs2229774 12 53211761 Exon Missense G/A 
SLC28A3 rs7853758 9 86900926 Exon G/A 
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2.3.1 Characterisation of Specific Genes 
 ABCC1 
ATP binding cassette subfamily C member 1 (ABCC1) is located on chromosome 16p13.11 
and encodes for a transporter involved in intra- and extra- cellular membrane transport 81,86. 
ABCC1 also confers anti-cancer drug resistance due to its role in the transmembrane 
movement of substances.  
ABCC1 acts as both a transporter and inhibitor for 69 clinically approved drugs including 
doxorubicin, methotrexate, lamivudine and docetaxel utilized in diverse clinical applications 
ranging from cancer to HIV 86.  
 ABCC2 
ATP binding cassette subfamily C member 2 (ABCC2) is located on chromosome 10q24.2 
and similar to ABCC1, encodes for the transmembrane transport of substances and 
additionally contributes to drug resistance 81,86. 
ABCC2 has a role as a transporter in the metabolism of 102 approved drugs including 
doxorubicin, docetaxel, methotrexate and cisplatin 86. 
 ABCB4 
ATP binding cassette subfamily B member 4 (ABCB4) is located on chromosome 7q21.12 and 
encodes for a membrane-associated protein involved in both the transport of substances 
across the cellular membrane as well as the transport of phospholipids from liver hepatocytes 
into bile 81,86. 
ABCB4 has a role as an antagonist and transporter in the metabolism of drugs 86. 
 ACO1 
Aconitase 1 (ACO1) is located on chromosome 9p21.1 and encodes for a protein with 
enzymatic functions essential to the regulation of iron levels inside cells. ACO1 protein binds 
to iron-responsive elements (IRES) to target mRNA when iron levels are low 81,86.  
 AKR1A1 
Aldo-keto reductase family 1 member A1 (AKR1A1) is located on chromosome 1p34.1 and 
encodes for an aldo/keto reductase that catalyzes the NADPH-dependent reduction of 
aldehydes to their specific alcohols 81,86.  
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AKR1A1 plays a role in the metabolism of various drugs including both doxorubicin and 
daunorubicin 86. 
 CAT 
Catalase (CAT) is a gene located on chromosome 11p13 that encodes for a key antioxidant 
enzyme involved in defence against oxidative stress 81,86. This enzyme converts ROS to water 
and oxygen thereby preventing toxicity. CAT also promotes the growth of T-cells, B-cells, 
myeloid leukaemia cells, melanoma cells, mastocytoma cells and fibroblasts 86. 
CAT plays a role in the metabolism of substances including ethanol and anthracyclines 86. 
 CBR3 
Carbonyl reductase 3 (CBR3) is located on chromosome 21q22.12 and encodes for a NADPH-
dependent oxidoreductase involved in the catalysis of carbonyl compounds to specific 
alcohols 81,86.  
CBR3 is involved in the metabolism of doxorubicin and other anthracyclines in both the 
cardiomyocyte and in cancer cells 86. 
 CYBA 
Cytochrome b-245 alpha chain (CYBA) is located on chromosome 16q24.2 and encodes the 
light chain (alpha subunit) of cytochrome b which is a critical component of the membrane-
bound oxidase of phagocytes that generate superoxide 81,86. 
CYBA plays a role in the metabolism of drugs that includes doxorubicin as well as in oxidative 
stress and the response to ROS 86. 
 GSTP1 
Glutathione S-transferase pi 1 (GSTP1) is located on chromosome 11q13.2 and encodes 
enzymes that play a critical role in detoxification, xenobiotic metabolism as well as 
susceptibility to cancer and other diseases 81,86. 
GSTP1 has an enzymatic role in the metabolism of drugs as well as in cellular response to 
stress and the detoxification of ROS 86. 
 HFE 
Hemochromatosis (HFE) is located on chromosome 6p22.2 and encodes for a protein that 
regulates iron absorption by binding the transferrin receptor 81,86. Defects in this gene result in 
the recessive condition, hereditary haemochromatosis, which is an iron-storage disorder 86. 
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HFE has been implicated in ACT due to its role in the regulation of iron levels – HFE deficient 
cells allow for increased levels of doxorubicin-iron complexes and subsequent cardiac injury 
87. 
 HNMT 
Histamine N-methyltransferase (HNMT) is located on chromosome 2q22.1 and encodes for 
an enzyme involved in methyl group transfer; the dysregulation of which contributes to the 
development of cancer 81,86. 
Due to its role in regulating histamine levels and subsequent regulation of the airway response 
to histamine, HNMT is involved in the metabolism of drugs as diverse as amodiaquine (anti-
inflammatory and anti-malarial) as well as anthracyclines 86. 
 IREB2 
Iron Responsive Element Binding Protein 2 (IREB2) is located on chromosome 15q25.1 and 
encodes for an RNA-binding protein that binds to iron-responsive elements in ferritin thereby 
inhibiting mRNA degradation 81,86. 
The role of IREB2 in cellular iron homeostasis and as a modifier for HFE, influences 
haemochromatosis as previously mentioned, and may therefore contribute to ACT due to the 
regulation of cellular iron and its propensity to form doxorubicin-iron complexes 86-88. 
 NCF4 
Neutrophil cytosolic factor 4 (NCF4) is located on chromosome 22q12.3 and encodes for a 
regulatory protein component of the NADPH-oxidase that produces superoxide and plays a 
crucial role in host cell defence 81,86. 
Furthermore, due to NADPH-oxidase being involved in oxidative cardiac damage and 
remodelling, NADPH-oxidase polymorphisms have been implicated in the predisposition to 
ACT, as discussed earlier in the chapter 12,86. 
 RAC2 
Ras-related C3 botulinum toxin substrate 2 (RAC2) is located on chromosome 22q21.3 and 
encodes for small, plasma membrane-associated guanosine triphosphate (GTP) proteins 
where it regulates various cellular responses such as secretion, phagocytosis and cell 
polarization as well as the generation of ROS together with NADPH-oxidase 81,86. 
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 RARG 
Retinoic acid receptor gamma (RARG) is located on chromosome 12q13.13 and encodes for 
retinoic acid receptors involved in various biological processes including the regulation of gene 
expression 81,86.  
 SLC28A3 
Solute Carrier Family 28 Member 3 (SLC28A3) is located on chromosome 9q21.32 and 
encodes for a nucleoside transporter that regulates multiple cellular processes including the 
transport and metabolism of nucleoside drugs such as anthracyclines 81,86. 
Measures to either prevent or mitigate the onset of ACT have been discussed in detail in this 
chapter – while they have advantages and disadvantages, it is often their financial cost that 
prevent many of them being utilized in favour of managing the patient’s cancer as a first 
priority. The next section will discuss the long term cost of employing this strategy. 
2.4 Economic Implications of Cardiac Failure compared to Preventative 
Measures 
South Africa, as a developing nation (UMIC) with a stretched healthcare budget and a 
discrepancy between private and public healthcare, needs an approach that is financially 
feasible without compromising patient need 89,90. As previously mentioned, CVD is a leading 
cause of non-cancer related morbidity and mortality which can significantly increase the public 
health financial burden 49,50. 
2.4.1 Comparison of Preventative Measures, Sensitive Assessment Modalities 
and Treatment for Cardiac Failure 
In 2004 medical imaging was one of the highest costs claimed from medical insurance – this 
was attributed to both high patient demand and increased diagnostic accuracy 89. 
Picano et al. 89 showed that by using an echocardiogram as a cost comparator of 1, the CT is 
3.1x,  cardiac MRI 5.51x and 19.96x for a right or left heart catheterization. The cost of an 
echocardiogram is approximately $2275 in the United States 91 (+/- R31 631.00 in SA, 
according to the current exchange rate, although  SA costs were not available. The cost of 
determining LVEF using ERNA or MUGA is approximately $573 (+/- R7984.00) per scan. 
Economic costs aside, each modality must be carefully considered in terms of sensitivity, inter-
operator variability and if applicable, radiation dose. 
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Comparatively, the cost of assessing cardiac injury using biomarkers were as follows: BNP 
was found to be between $200- $1000 per test (+/- R2790- R13 948) and Troponin was found 
to be between $45- $95 per test (+/- R628- R1325) 92,93.  
While lower and middle income countries struggle to manage chronic diseases such as 
hypertension and diabetes, the subsequent health and economic burden of cardiac disease 
increases 94. Adverse drug reactions such as ACT may add considerable strain to this.  
Breast cancer screening together with a mastectomy, chemotherapy, radiation and targeted 
therapy (inpatient and outpatient treatment) is incredibly expensive and can be upwards of 
R500 000 per patient 95. The average cost of anthracycline was estimated at approximately 
R1300.00 compared to the relatively cardio-safe alternative, liposomal encapsulated 
doxorubicin at approximately R131 575 per patient 96,97. Dexrazoxane, the cardio-protector 
that would be administered together with the anthracycline-based chemotherapy costs 
approximately $5661.77 per patient (+/- R78 960.00) and may be a cheaper alternative to the 
liposomal encapsulated doxorubicin 98. 
However, in comparison to the estimated lifetime cost of the implications of CF of $109 451 
(+/- R1 526 639), the more expensive therapeutic options may be comparatively cheaper 
when faced with the risk of HF due to ACT 99. Especially since it is estimated that amongst 
breast cancer survivors, CVD is the largest contributor to non-cancer related mortality – 
approximately 35% in cancer survivors over the age of 50 years 50. 
The Present Study 
With the above narrative setting the scene for the need to do further research on ACT in the 
diverse populations of South Africa, the objectives that were targeted for the research were 
as follows: 
• To assess the effect of anthracycline treatment, if any, on cardiac function using 
various clinical modalities and patient clinical evaluation, using both retrospective and 
prospective patient data 
• To determine the cardiotoxic effects of anthracyclines (both clinical and molecular) in 
the unique local populations – IA and MA, and the genes responsible for this susceptibility  
• To provide tools for the creation of a model of risk for susceptibility to anthracycline-
induced cardiotoxicity before the initiation of treatment 
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Chapter 3: Patients, Materials and Methods 
 
3.1 Retrospective Cohort 
This study was initiated following anecdotal reports of cardiotoxicity during or after routine 
anthracycline-based treatment for patients with cancer. Adequate evidence had to be found 
from patients who were previously treated to necessitate a comprehensive study involving 
patient recruitment and subsequent biological specimens. 
  
3.1.1 Setup of Database 
Ethical approval was granted from both the University of Cape Town (UCT) and GSH (HREC 
Ref 650/2012) for this review. A Microsoft Excel database was established utilising records 
derived from GSH Pharmacy of all patients prescribed anthracyclines from 2011-2016, 
regardless of type of cancer. Patient information was limited to patient name, demographics, 
hospital number, prescription date and type of anthracycline administered. Hospital numbers 
were imported into the spreadsheet and duplicates were tagged and removed. The database 
was password protected and only accessed by the principal investigator. All data analysis was 
presented after patients were de-identified. 
 
3.1.2 Collection of Data 
Demographic information, patient history and clinical management details are recorded in 
paper-based patient folders specific to the clinic where the patient is receiving treatment. 
Therefore, imported hospital numbers in the patient database were used to find ID numbers 
specific to patient folders in the outpatient Oncology Clinic at GSH. Hospital Radiotherapy (RT 
ID) numbers are managed electronically on ‘Clinicom’ and Electronic Patient Records (EPR). 
RT ID numbers enabled the physical location of patient folders which are divided according to 
year and patient surname; deceased and alive patient folders are filed separately.  
Data was collected from patient folders, EPR and ‘Clinicom’ to populate the following fields: 
age, sex, population group, type and stage of cancer, HIV status, type of 
chemotherapy/regimen, number of cycles and cumulative dose, LVEF before and after 
chemotherapy using ERNA, body surface area (BSA) and whether the patients experienced 
any signs or symptoms related to cardiotoxicity or CF. 
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Baseline cardiac assessments together with clinical history were utilized to eliminate cardiac 
impairment unrelated to cardiotoxicity. Acute cardiotoxicity, which is both rare and reversible, 
typically occurs within a week of treatment and while transient, may present as sinus 
tachycardia, ventricular tachycardia, transient arrhythmia, pericarditis-myocarditis syndrome 
and acute LV failure 76. Early onset ACT which occurs within a year of treatment, and late 
onset ACT, which occurs more than a year after treatment, presents with ventricular 
dysfunction, CF and arrhythmias 7,36.  
Furthermore grading of the ACT was based on the Common Technology Criteria for Adverse 
Events v3.0 (CTCAE) and definitions in the literature 7,10,51. Patients with no signs or symptoms 
of cardiac impairment were graded as 0. Whereas, patients with chest pain, shortness of 
breath and/or palpitations without LVEF decline were graded as 1; patients with chest pain, 
shortness of breath and/or palpitations with LVEF decline <10% were graded as 2; patients 
with a suspected CCF, LV dilation and increased Troponin T were graded as 3; and patients 
with CF, MI and/or decline in LVEF ≥10% were graded most severe, as 4. Therefore, early or 
late onset ACT was determined by a LVEF decrease of more than 10%76 determined by ERNA 
and/or clinical symptoms pertaining to cardiac impairment (shortness of breath, chest pain, 
and effort intolerance) or cardiac failure and/or the grading determined by the CTCAE report. 
The association of cumulative anthracycline dose with ACT was also utilized to further stratify 
patients as low risk (≤250mg/m2 for doxorubicin and <400mg/m2 for epirubicin) and high risk 
(>250mg/m2 for doxorubicin and >400mg/m2 for epirubicin), the type of anthracycline was also 
taken into account - with doxorubicin denoting increased toxicity compared to epirubicin 7,26,58. 
This data contributed to the building of the correlation model discussed later in the chapter. 
 
3.1.3 Statistical Analyses 
Data from folders, specifically for patients treated for cancer from 2011-2015, were collected 
and analysed using GraphPad Prism 5 100 and R programming language and scripting 101. 
Graphs were generated using both Microsoft Excel, GraphPad Prism 5 and R programming 
language.  
Analysis of variance (ANOVA) type II tests were used to determine significance of certain 
variables (i.e. age, pre-existing clinical conditions, type of chemotherapy etc.) to the post LVEF 
measures. 
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3.2 Literature Mining 
 
Literature was extensively mined focusing on textbooks and journal articles. Google Scholar 
alerts were established using keywords “anthracycline”, “cardiotoxicity” and “anthracycline-
induced cardiotoxicity” to allow for the procurement of updated literature. Abstracts from 
conference proceedings were also useful in keeping the literature current.  
 
3.3 Prospective Study: Selecting Genes/SNPs of Interest 
The value of SNPs in this study were to elucidate whether heritable genetic variation had an 
association with ACT 102. SNPs are distinguished from rare variations by having a minor allele 
frequency (MAF) of more than 1% 102,103. 
This candidate gene study utilized both, SNPs found to have an association with risk of 
anthracycline-induced cardiotoxicity from previous studies, as well as genes of interest derived 
from PharmGKB (www.pharmgkb.org, date accessed 2014/07/10).   
 
3.3.1 Pathway-based Approach 
Genes involved in the metabolism of anthracyclines, especially those with cardiomyocyte 
involvement, were selected for further interrogation. Hence the pathway-based approach was 
utilized. PharmGKB (www.pharmgkb.org, date originally accessed 2013/09/11) was 
extensively accessed to better understand the metabolism of both doxorubicin and epirubicin, 
and to select the genes and variations that impact drug response. 83. 
 
3.3.2 Gene Annotation 
The purpose of gene annotation is to provide gene descriptions, identify coding regions and 
to relay functional significance. 
Gene annotation in this instance was performed by using two online databases, the National 
Centre for Biotechnology Information (www.ncbi.nlm.nih.gov) and Ensembl 
(www.ensembl.org) as well as a specifically designed script 104 using Practical Extraction and 
Report Language (Perl Version 5). The information derived from gene annotation allowed for 
the design of polymerase chain reaction (PCR) primers described later in the chapter. 
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NCBI and Ensembl were used to gather information, specifically the gene and transcript ID, 
DNA sequence of interest, as well as the orientation of the strand. This information was edited 
and saved as SEQ files. The PerlV5 script 104 was then run on these files using command line 
programming and the output analysed for both gene characterisation and primer design 
(Appendix A). 
 
3.3.3 Selected Genes of Interest 
Table 7 details the 19 SNPs that were interrogated further in prospectively recruited patient 
samples. 
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Table 7:  Details of SNPs for further study of anthracycline-induced cardiotoxicity in patient cohort  
*Absorption, Distribution, Metabolism and Elimination (ADME)
Gene Gene Name rs ID Variant Genomic Location/ Co-
Ordinates 
Functional Significance Pharmacokinetic/ dynamic effect 
       
ABCB4 ATP-Binding Cassette, Sub Family B, Member 4 rs1149222 G 7: 87073775(+) ADME* processes  
ABCC1 
ATP-Binding Cassette, Sub Family C, Member 1 
rs45511401 T 16: 16173232(+) 
ADME processes 
Resistance to anticancer drugs 
ABCC1 rs4148350 T 16: 16170477(+)  
ABCC1 rs246221 C 16:16138322 (+)  
ABCC2 
Multidrug Resistance Protein 2 
rs17222723 A 10: 101595996(+) Efflux Transporter of cytotoxic agents out of 
cell 
 
ABCC2 rs8187710 A 10: 101611294(+) Increased risk ACT105 
ACO1 Aconitase 1 rs867469 A 9:32383708 (+) Regulation of cellular iron levels Affects iron homeostasis83 
AKR1A1 Aldo-Keto Reductase Family 1, Aldehyde 
Reductase 
rs6690497 C 1:46032321(+) NADPH-dependent reduction of substrates 
to alcohols 
Altered efficiency of metabolism of 
anthracyclines86, 34 AKR1A1 rs2229540 G 1:46032311 (+) 
CAT Catalase rs10836235 T 11: 34460704(+) Defence against oxidative stress 
Impaired catalase activity increases 
ROS damage86; CC genotype 
associated with ACT106 
CBR3 Carbonyl Reductase 3 rs1056892 A 21: 37518706(+) 
Enzymatic reduction of compounds to 
alcohols 
Associated with ACT associated CF47 
CYBA Cytochrome b-245, alpha polypeptide rs4673 T 16: 88713236(+) 
Critical component of NADPH oxidase (p22-
phox) that produces superoxide 
Missense mutation; Minor allele (T) 
associated with ACT8 
GSTP1 Glutathione S-Transferase Pi 1 rs1695 G 11: 67352689(+) Role in detoxification  
HNMT Histamine N-Methyltransferase rs17583889 A 2: 138746039(+) Metabolism of Histamine  
IREB2 Iron-Responsive Element Binding Protein 2 rs17483548 A 15:78730313 (+) Regulation of cellular iron levels Affects iron homeostasis 
NCF4 Neutrophil cytosolic factor 4 rs1883112 A 22: 20219009(+) 
Component of NADPH oxidase (p40-phox) 
that generates reactive oxidant intermediates 
Downregulation of oxidase 
RAC2 Ras-related C3 botulinum toxin, substrate 2 rs13058338 A 22: 20597907(+)  Increased risk ACT105 
RARG Retinoic Acid Receptor, Gamma Integrin, Beta 7 rs2229774 A 12:53211761(+) Ligand dependent transcriptional regulator86 Impaired Top2B regulation7 
SLC28A3 Solute Carrier Family 28, Member 3 rs7853758 A 9: 86900926(+) 
Nucleoside transporter in many tissues 
including the heart10 
Minor allele (A) protective against 
ACT10 
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3.4 Prospective Study: Patient Recruitment 
3.4.1 Recruitment Protocol and Ethics 
Patients were recruited from outpatient breast cancer clinics at GSH for the period 
from May 2013 – March 2016 and TBH for the period from May 2015 – March 2016. 
Patients eligible for the study were anthracycline-treatment naïve who were to 
commence anthracycline-based chemotherapy for breast cancer. Informed patients 
were consented (Appendix B), peripheral blood samples were procured at specific 
time points (before the commencement of chemotherapy and after 3 or 4 cycles of 
chemotherapy) and patients’ clinical management was closely monitored for the 
duration of the study.  
Ethical approvals (Appendix C, D and E) were received from the Human Research 
Ethics Committees (HREC) at the UCT and GSH (HREC 650/2012) and the University 
of Stellenbosch and TBH (HREC S15/02/032) and the study was conducted in 
accordance with the Declaration of Helsinki 107. 
3.4.2  Procurement of Clinical Information from Patient Folders 
Recruited patients’ clinical information were collected from treating oncologists, 
patient folders and online data management systems specific to each hospital (for 
GSH – ‘Electronic Patient Records’ and ‘Clinicom’; and at TBH – Enterprise Content 
Management). Patients were de-identified and assigned laboratory numbers - only 
the principal investigator had access to identifying patient information. 
Demographic information (age, sex, population group, family history of cancer or 
cardiac disease, weight, height), pre-existing conditions (hypertension, diabetes, 
cardiac disease, cholesterol), lifestyle factors (smoking and HIV status, chronic 
medication) and factors pertaining to the cancer diagnosis and treatment (type and 
stage of cancer, post or pre-operative status, treatment regimen and dose, cardiac 
monitoring) – was recorded in an access controlled database.  
Transient acute ACT was excluded as patients had follow-up cardiac measures 
assessed more than 21 days after treatment. Baseline cardiac assessments together 
with clinical history were utilized to eliminate cardiac impairment unrelated to 
cardiotoxicity. 
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Furthermore, grading of the ACT was established using the CTCAE and literature 
findings. As with the retrospective cohort, patients with a grading of higher than 3 after 
administration of anthracyclines were deemed as serious ACT. Early or late onset 
ACT was determined by a decrease of more than 10% in LVEF 76 determined by either 
ERNA, MUGA or ECHOs and/or clinical symptoms pertaining to cardiac impairment 
(shortness of breath, chest pain, effort intolerance) or cardiac failure and/or the 
grading determined by the CTCAE Report and literature findings. This data together 
with the data from the retrospective cohort, was utilised to create the correlation model 
to extrapolate cardiac function in the absence of a clinical measure/function (i.e. 
missing LVEF). 
3.5 Patient Sample 
Peripheral whole blood (3ml) was collected in Greiner Bio-One Vacuette Venous 
Blood Tubes (Lavender K3EDTA) from patients. The additive, EDTA, binds calcium 
ions resulting in the inhibition of the coagulation cascade 108. These blood tubes 
enable an intact and stable specimen to be collected for both DNA and RNA isolation. 
3.6 DNA isolation 
3.6.1 Principle of DNA Isolation using Promega Maxwell® 16 DNA Purification 
Kit: 
The Promega Maxwell® 16 Instrument (Promega, USA) together with the DNA 
Purification Kit enable the isolation of DNA by the utilisation of paramagnetic particles 
allowing for the subsequent capture, washing and elution of DNA. The prepared 
reagent cartridges and automated purification allowed for DNA isolation to be 
completed in approximately 45 minutes. 
3.6.1.1 Technique of DNA Isolation using Promega Maxwell® 16 DNA 
Purification Kit: 
DNA was isolated using the Promega Maxwell® 16 DNA Purification Kit (Promega, 
USA) according to manufacturer’s instructions. Briefly, the peripheral blood sample 
was centrifuged at 2500 rpm for 10 minutes resulting in the separation of three layers 
– plasma, buffy coat and erythrocyte layers. The utilisation of the buffy coat enables 
an enrichment of the white blood cells, however, the yield may be affected by other 
factors such as sample quality and patient total white blood cell count. 
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A volume of 1ml of the buffy coat layer was centrifuged at 3000 rpm for 10 minutes. 
A total of 500ul of the leukocyte-enriched fraction was then added to the first well of 
the Maxwell extraction cartridge and a plunger was added to the last well. The 
cartridge was placed on the Promega Maxwell® 16 platform and blue elution tubes 
were placed in the elution tube slots as indicated on the instrument. The elution tubes 
were filled with 300ul of Elution Buffer and the automated purification run was 
selected.  
After the isolation, the blue elution tubes were placed in a Magnetic Elution Tube Rack 
where residual Magnesil® particles were removed. Eluted sample was then pipetted 
into a clean 1.5 ml microfuge tube, quantified and its integrity assessed before being 
stored at -12°C for downstream applications. 
The Promega Maxwell® 16 DNA Purification Kit, while time-efficient, resulted in 
purified DNA of a relatively low concentration.  
3.6.2 Principle of DNA Isolation using ‘Salting-Out’ Technique: 
The majority of samples in this study were extracted using the ‘salting-out’ technique 
109 to ensure highly concentrated DNA samples that would be utilisable for 
downstream applications involving PCR, genotyping and sequencing. 
This technique, adapted from Miller’s salting out method 109, involves the removal of 
erythrocytes from the DNA-containing leukocytes in a peripheral blood sample, which 
are then lysed using cell-lysis solution. The cell-lysis solution contains detergents and 
salts that disintegrate the cellular membrane and subsequently liberate the DNA. The 
denaturation of proteins occurs by the addition of Sodium Dodecyl Sulfate (SDS) and 
Proteinase K. Specifically a detergent, SDS, results in the solubilisation of proteins 
and lipids that make up the cellular membrane; Proteinase K, an enzyme, is used to 
digest proteins thereby eliminating protein contamination from DNA samples as well 
as preventing DNA degradation by the inactivation of nucleases.  Subsequent 
incubation at 37°C for 48 hours allows for complete cell lysis. Sodium Chloride (NaCl) 
was then added to precipitate DNA – the neutralization of the negative charge of DNA 
decreases the solubility of DNA in water. The availability of Na+ monovalent cations 
allows for further precipitation of the nucleic acids. Excess salts were removed by the 
addition of 70% ethanol and then air dried to remove excess ethanol. The pellets were 
resuspended in Tris-EDTA (TE) buffer (Appendix F) to prevent further degradation to 
the DNA. 
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O.D = c x l x ɛ 
 
Briefly, the peripheral blood sample was centrifuged at 2500 rpm for 10 minutes 
forming distinct layers of plasma, buffy coat containing leukocytes and platelets and 
erythrocytes. A volume of 500ul of the buffy coat together with 900ul of Red Blood 
Cell Lysis Buffer (RBC Lysis Buffer) (Appendix F) were vortexed. After incubation at 
37°C for an hour, and further centrifugation at 2500 rpm for 10 minutes the resulting 
supernatant was discarded. A further 2ml of the RBC Lysis Buffer was added to the 
pellet, vortexed and centrifuged at 2500 rpm for 10 minutes with the supernatant again 
discarded. 600ul of Cell Lysis solution, 20ul of 20% SDS and 2ul of Proteinase K 
(20mg/ml) was added to the pellet, incubated at 37°C overnight and then vortexed to 
dissolve the pellet. A total of 400ul of 6M NaCl was added, the sample was vortexed 
and then centrifuged at 2500rpm for 15 minutes. The supernatant was then 
transferred to a clean microfuge tube and 100ul of absolute ethanol was added and 
the tube inverted until the DNA was visibly aggregated. The sample was then 
centrifuged at 10000 rpm for 2 minutes, the subsequent supernatant discarded and 
the pellet left to air dry for 2 hours. The pellet was finally resuspended in 200ul 1x TE 
Buffer (Appendix F), quantified spectrophotometrically, and integrity assessed before 
downstream applications. 
3.6.3 Quantification of DNA: 
Concentration and purity were determined using the NanodropTM ND-1000 
Spectrophotometer (Nanodrop Technologies, USA). DNA concentration is 
determined by the measurement of ultraviolet light absorbance at 260nm with an 
absorbance unit or OD being determined using the following formula: 
 
 
where c = concentration, l = path length and ɛ = extinction co-efficient 
The purity of DNA was assessed using ratios based on the following: A230 is the 
wavelength for maximum organic solvent absorbance; A260 is the wavelength for 
maximum DNA absorbance and A280 is the wavelength for maximum protein 
absorbance. Therefore, protein and organic solvent contamination are detected by 
measuring the ratios of A260/A280 and A260/A230 respectively. An A260/280 ratio 
of ≈1.8 and an A260/230 ratio of 2-2.2 are representative of DNA of adequate purity.  
Non-degraded DNA samples were diluted to a working concentration of 100ng/ul and 
stored at 4°C for downstream experiments. 
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3.6.4 DNA Integrity Gels 
3.6.4.1 Principle of Agarose Gel Electrophoresis 
The integrity of DNA was assessed using agarose gel electrophoresis 110. Agarose, 
derived from seaweed, forms a matrix composed of interlinking polysaccharide 
chains. When in an electric field negatively charged DNA molecules travel through 
matrix pores toward the anode. Tris-Borate-EDTA (TBE) buffer (Appendix F) is the 
medium in which the gel is run. 
DNA fragments may be separated by size as a result of larger fragments migrating 
slower across the gel than smaller ones. The separation of fragments with similar 
sizes may be achieved with a higher percentage agarose gel – the increased 
resolution is due to pores in the matrix being smaller. A nucleic acid stain allows for 
the visualisation of DNA fragments by fluorescing under ultraviolet light while a 
specific molecular weight marker or ‘ladder’ electrophoresed alongside the samples 
of interest allows for the determination of DNA fragment size in neighbouring wells. 
Sharp, well-defined bands close to the well indicated DNA of adequate concentration 
and integrity whereas blurry bands indicated potential degradation. 
Potentially degraded DNA samples were not discarded due to the high sensitivity of 
downstream applications such as PCR. Failure to amplify, or in other downstream 
application, in some cases, could be correlated with degradation of DNA as evident 
on the gel. 
3.6.4.2 Method of Agarose Gel Electrophoresis 
Briefly, 500ng of DNA and 2ul of 6x Loading Dye (ThermoScientific, USA) were loaded 
onto a 1% agarose (Seakem® LE Agarose, Lonza, USA) gel immersed in 1x TBE 
Buffer. The gel was solidified with the addition of nucleic acid stain, SYBR®Safe (Life 
Technologies, USA) (1ul/10ml). 10ul of molecular weight marker, GeneRulerTM 100bp 
Plus DNA Ladder (ThermoScientific, USA) together with 2ul of loading dye was loaded 
separately to gauge the size of genomic fragments in adjacent lanes. Electrophoresis 
of the fragments at 90V for 60 minutes allowed for adequate resolution of fragments 
for their visualisation under UV light using the UVIPro Gold transilluminator and 
UVIPro version 12.3 software (UVITec Limited, UK).  
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Figure 13: Representation of GeneRulerTM 100bp Plus DNA Ladder 
(ThermoScientific, USA) Molecular Weight Marker and its utilisation in the 
estimation of nucleotide fragment size 111 
3.7 Polymerase Chain Reaction (PCR) 
3.7.1 Principle of PCR 
PCR allows for the specific amplification of regions of DNA using two flanking 
oligonucleotide primers, a thermostable Taq polymerase derived from the 
thermophilic microorganism Thermus aquaticus, and repeated cycles of heat 
denaturation, annealing of primers to complementary regions and subsequent 
extension of the primers using deoxynucleotides (dNTPs) which act as the building 
blocks of the new strands 112. The region of amplification lies between the two primers 
and each cycle of amplification effectively doubles the number of products achieving 
exponential, highly specific amplification of a specific DNA region 112. Taq, is heat-
resistant and therefore able to withstand repeated cycles of denaturation at high 
temperatures without its function being compromised 112. Generally 25-30 cycles with 
denaturation at 95°C, annealing at 50-60°C and extension at 68-72°C ensure optimal 
Taq polymerase function (Fig. 14) as well as reaction yield 112,113. 
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Figure 14: Diagrammatic illustration of PCR and subsequent exponential 
doubling of amplified DNA 113 
The high rate of efficiency of amplification also requires the addition of a negative 
control (sterile H2O instead of template DNA) as a measure of contamination with an 
extraneous source of template DNA. A successful PCR free from contamination will 
have an unamplified negative control. 
3.7.2 Primer Design for PCR 
As previously mentioned, primers are crucial to the successful and specific 
amplification of a DNA region of interest. Primers are short oligonucleotide sequences 
that are complementary to flanking regions of a sequence of interest and their 
competent design significantly contributes to both specificity and yield of the PCR 
reaction. 
Primers were designed by using the following databases: Primer3 version 0.4.0 
(http://bioinfo.ut.ee/primer3-0.4.0/, date accessed 2013/11/06), Integrated DNA 
Technologies (IDT) OligoAnalyzer version 3.1 (http://eu.idtdna.com/calc/analyzer, 
date accessed 2013/11/06) and NCBI Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/, date accessed 2013/11/06).  
Primer3 is an automated program that identifies primer pairs that may be utilised to 
amplify a specific DNA region of interest. These primer pairs are determined using 
certain specifications such as primer melting temperature (Tm), primer size and the 
molar concentrations of Guanine and Cytosine in a sequence (GC% content). 
Specifically, conditions adhered to for primer design in this study were as follows: 
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α ul of TE buffer required  = 10 x nanomoles of  oligonucleotide 
 
primer size of 20-24 base pairs in length, primer melting temperature of 50-60°C with 
a maximum temperature difference between the two primers of no more than 3°C, a 
GC content of 50-60% and a maximum permitted mononucleotide repeat length of 3 
(Max Poly-X). 
IDT OligoAnalyzer was then utilized to detect secondary structures such as hairpins, 
self-dimers and heterodimers that may be produced during the PCR reaction. The 
forward and reverse primers are both individually assessed, specifically for primer 
sequence complementarity that may hinder the efficient extension of the PCR 
product. Primer pairs were rejected if: the hairpin Tm was close to the primer Tm and 
if the Delta G (ΔG) is smaller than -4. The ΔG represents the amount of energy 
required to break a secondary structure and the lower the value, the higher the energy 
requirement. 
Primer pairs that met specific criteria after Primer3 and IDT OligoAnalyzer analyses 
were then submitted to NCBI Primer-BLAST to ensure that primer pairs would bind 
specifically to the target region and that the likelihood of mismatches to other regions 
in the genome were unlikely. 
Often singleplex PCR reactions, where one target region is amplified at a time, can 
be both time-consuming and expensive. Therefore multiplex PCR reactions are a 
feasible alternative, primer design however has to be minimally amended whereby: 
primer pairs at the same Tm are grouped together and their product size ranges 
altered so that there can be an approximately 100bp size difference that can be 
elucidated on a gel. These multiplex primers are then analysed using IDT 
OligoAnalyzer for complementarity to each other by assessing the forward primer of 
one of the pairs together with the reverse and other primer pairs for potential 
secondary structures. 
Primers were resuspended in 1x TE buffer. 100uM stock solutions were made using 
1x TE buffer whereas 10uM working solutions were made using sterile H2O.  
 
 
Primer working solutions were stored at 4°C and stock primer solutions were stored 
long-term at -20°C.  
Table 8 lists the seventeen primer pairs that were designed for PCR using the 
approaches previously described. 
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Table 8: Custom-designed PCR Primers for the Amplification of Target Regions containing the SNP of interest 
*TM= melting temperature
GENE dbSNP ID FORWARD PRIMERS TM GC% REVERSE PRIMERS TM GC% PRODUCT 
SIZE 
ABCB4 rs1149222 CATGTTGTAGCCAGACTGAG 54.28 50 GGACCTGGAATGTCACAA 54.95 50 703 
ABCC1 rs246221 AGGACCTTGTCTGAAGTCAC 54.13 50 TGGAGACATCTGGCTATGAG 56.31 50 595 
ABCC1 rs4148350 GACTTAGCTTACCCATCTGGAC 57 50 CTCCTAACAGTGGGATACACAG 56.37 50 333 
ABCC1 rs45511401 GTCCTCTCCTTTCAGACCTT 54.98 50 GTCCTCATCCTACCTTGATAGC 56.94 50 492 
ABCC2 rs8187710 GCTGTTTGGAGATGATAGGC 57.36 50 GGTAGTAGGTTCATGGGTGTTC 57.46 50 572 
ABCC2 rs17222723 CCTTAGGAGGTTTGGAGACT 55.04 50 CCTGTGAGATAGGGTGTGTT 54.97 50 761 
ACO1 rs867469 CAGTATGACAGGGAAGGTGTAG 56.37 50 CTAGATGAAAGGTGGTGAGG 54.78 50 307 
AKR1A1 
rs2229540 
rs6690497 
GGTGACAGTAGAAGGCTGAA 55.45 50 TCAGGTACAGGTCCAGATACTC 55.85 50 489 
CAT rs10836235 CCAATCAGAAGGCAGTCCTC 59.8 55 GTGCTGGAGACCTCAAGATT 56.86 50 699 
CBR3 rs1056892 CCAGTGGTTGTACCTCTGTGA 58.63 52.38 CTCCGAAGCAGACGTTTACC 59.88 55 505 
CYBA rs4673 GAGCTTGGTTTCTCACTTGG 57.51 50 GTGTTCTCAGCCTTGATGTG 56.76 50 680 
GSTP1 rs1695 ACTGAGACCCACTGAGGTTA 54.65 50 AGGAGATCAGAAACCACCAG 56.71 50 637 
HNMT rs17583889 GACCTGAATAAGAGCACAGC 55.09 50 GACCTCAAGTGATCTGCCTA 55.36 50 325 
IREB2 rs17483548 GACAGGAGATAATGCTGGGTAG 57.84 50 GGGAGGAAAGAAGGAAGCAG 60.32 55 646 
NCF4 rs1883112 CCTGTGAGAGAATGTAGTAGGG 55.6 50 CCACTTCCTTGATGTCAGTC 55.55 50 725 
RAC2 rs13058338 TGAGAACCAAGACCTGACTG 56.28 50 AAGGCTAGATCCTGTTACCC 55 50 341 
SLC23A3 rs7853758 CATCACCAAGTCTGAACTCC 55.55 50 AACCTATGAGTCTGGCAACC 56.7 50 476 
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3.7.3 Optimisation: Singleplex and Multiplex 
PCR optimisation is a crucial step in experimentation before the primers, designed in 
silico, are used routinely on patient DNA.  
Various parameters such as annealing temperature, magnesium concentration, 
additives and modification of the PCR conditions were altered to facilitate 
optimisation. Furthermore, after PCR was optimised for primers in singleplex, those 
with similar Tm’s were optimised in multiplex.  
3.7.3.1 Temperature Gradient 
The first step for PCR optimisation was a temperature gradient. This determines the 
optimum annealing temperature for each primer set and in this study a range between 
Tm-5°C and Tm+ 5°C was utilised. The annealing temperature producing the most 
specific yet highest yield of product for each primer set, visualised on an agarose gel, 
was then utilized for routine PCRs.  
 
Table 9: Conditions of PCR reaction required for optimisation of annealing 
temperature 
PCR Step Cycles Time (mm:ss) Temperature (°C) 
Initial Denaturation 1 3:00 94 
Denaturation 
30 
00:30 94 
Annealing 00:30 Tm +/- 5°C 
Extension 1:30 72 
Final Extension 1 10:00 72 
 
If the temperature gradient resulted in inadequate PCR product yield then the 
Magnesium Chloride concentration was changed to achieve optimal amplification. 
3.7.3.2 Magnesium Chloride (MgCl2) Gradient 
MgCl2 enhances the activity of Taq polymerase however while it is a valuable cofactor 
and catalyser, it may compromise specificity. Too little MgCl2 may result in no PCR 
product whereas too much MgCl2 may result in non-specific PCR products. A delicate 
balance between amplification efficiency (yield) and specificity must be maintained. 
Generally a PCR requires 1.5-2mM of MgCl2 for efficient amplification which is usually 
contained in the reaction buffer. The 5X Green GoTaq® Reaction Buffer (Promega, 
USA) was utilized for all PCR reactions and contained 1.5mM of MgCl2 per reaction. 
However, there were instances requiring additional MgCl2 for optimal amplification. 
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The MgCl2 concentration may be as high as 4mM and a gradient was established 
starting at 1.5mM (in the reaction buffer) and increased by 0.5mM increments. MgCl2 
concentrations where amplification of DNA resulted in both adequate yield and 
discernible specificity were maintained for routine PCRs. 
There may be PCR reactions that despite the altering of annealing temperature and 
MgCl2 concentrations result in persistent non-specificity or non-amplification due to 
their propensity to form secondary structures or due to inherent high GC content 114. 
An excess of these nitrogenous bases, by virtue of their three hydrogen bonds, have 
greater stability of structure and may accumulate resulting in problematic denaturation 
and truncated PCR products. Therefore, certain additives were added to increase 
specificity and efficiency. 
3.7.3.3 Additives 
Certain target regions of DNA may prove to be difficult perhaps because of GC 
content, and would therefore require addition of specific agents to the reaction mix to 
achieve amplification. Commonly used agents include: dimethyl sulfoxide (DMSO), 
Betaine, Glycerol and dithiothreitol (DTT). 
Betaine and DMSO function as PCR enhancers especially in GC rich regions where 
primer annealing is in competition with the formation of secondary structures 114 as 
previously discussed. Betaine, an isostabilizing agent, enhances denaturation and 
ensures that there is an equal contribution of both GC and Adenine-Thymine (AT) 
base pairing to the DNA duplex further increasing stability 115. DMSO facilitates 
denaturation by disrupting base pairing 115. The reducing compound, DTT, breaks 
disulphide bonds facilitating primer annealing to the template while  stabilizing the 
DNA polymerase 114. Glycerol acts as a stabilizing agent by improving the thermal 
stability of Taq polymerase 116. Some additives may be added singularly but other 
agents needed to be added in combination (i.e. DTT and Betaine) to produce a 
discernible improvement in amplification efficiency. 
While amplification efficiency is important, it should not be at the cost of specificity. 
Touchdown PCR is a technique that decreases non-specific amplification while 
increasing efficiency. 
3.7.3.4 Touchdown PCR 
Touchdown PCR is the stepwise reduction of the annealing temperature for each 
cycle (Fig.15) 114. The initial annealing temperature is approximately 5°C above the 
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annealing temperature of the primers and progressively decreases to a lower 
annealing temperature, usually in increments of 0.5°C 117. Non-specific annealing 
occurs at lower temperatures however with touchdown PCR, an initial higher 
annealing temperature translates to very specific binding of primer to template 
allowing for an accumulation of specific DNA products, before the lower temperatures 
are reached 117. At the lower temperatures, the amplification efficiency is increased 
as specificity of binding decreases, however, the accumulation of specific PCR 
products outnumbers the non-specific products 117. This technique is generally longer 
than a standard PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Diagrammatic representation of touchdown PCR adapted from 118 
The conditions of an optimised Touchdown PCR reaction are outlined in Table 10. 
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Table 10: Conditions of Touchdown PCR reaction  
PCR Step Cycles Time (mm:ss) Temperature (°C) 
Initial Denaturation 1 03:00 94 
Denaturation 1 
30 
00:30 94 
Annealing 1 00:30 Tm + 5°C 
-0.5°C per cycle 
Extension 1 00:30 72 
Denaturation 2 
30 
00:30 94 
Annealing 2 00:30 55 
Extension 2 00:30 72 
Final Extension 1 05:00 72 
    
 
3.7.4 Technique of PCR 
Target regions of DNA were amplified using multiplex PCR reactions that had been 
optimised using healthy control DNA as previously mentioned.  
Table 11: Optimised Multiplex Conditions 
Multiplex Amplification region Size of 
fragment (bp) 
Tm (°C) 
Multiplex 1 
HNMT rs17583889 325 
55 
ABCC2 rs8187710 572 
Multiplex 2 
RAC2 rs13058338 341 
56 
NCF4 rs1883112 725 
Multiplex 3 
ABCC1 rs246221 595 
65* 
ABCC2 rs17222723 761 
*Touchdown PCR with the addition of glycerol 
A total of 100ng of DNA was amplified using the conditions described below. Table 
12 shows an optimised PCR for both Multiplex 1 and Multiplex 2. Detailed protocols 
for optimized PCRs are included in the appendix (Appendix G). 
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Table 12: Prescribed reagents and concentrations for a standard PCR (Multiplex 
1 and 2) 
Reagents Stock 
Concentration 
Working 
Concentration 
Volume 
(ul) – 1x 
5X Green GoTaq® Reaction 
Buffer (Promega) 
5x 1x 5 
MgCl2 50mM 1mM 1.5 
dNTPs 5mM 200uM 1 
Forward Primer 20µM 10pmol 0.5 
Reverse Primer 20uM 10pmol 0.5 
Sterile water   15.4 
Taq polymerase 5U 0.02U 0.1 
DNA template 100ng 100ng 1 
Total   25 
 
Table 13 shows the reagents and concentrations for an optimised touchdown PCR 
with an additive for Multiplex 3. 
Table 13: Prescribed reagents and concentrations for a touchdown PCR 
(Multiplex 3) 
Reagents Stock 
Concentration 
Working 
Concentration 
Volume 
(ul) – 1x 
5X Green GoTaq® Reaction 
Buffer (Promega) 
5x 1x 5 
MgCl2 50mM 1mM 1.5 
dNTPs 5mM 200uM 1 
Forward Primer 20uM 10pmol 0.5 
Reverse Primer 20uM 10pmol 0.5 
Sterile water   15.15 
Glycerol   0.25 
Taq polymerase 5U 0.02U 0.1 
DNA template 100ng 100ng 1 
Total   25 
 
The 5X Green GoTaq® Reaction Buffer (Promega, USA) was specifically utilised as 
it contains two dyes, blue and yellow, which allows for monitoring of migration during 
agarose gel electrophoresis without the addition of a loading dye.  
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3.7.5 Agarose Gel Electrophoresis 
The success of a PCR was determined by using agarose gel electrophoresis similar 
to the technique used to assess DNA integrity as previously mentioned in the chapter. 
The multiplex PCRs were all assessed on a 3% (w/v) agarose gel electrophoresed at 
120V for 1 hour or until the line of migration was close to the end of the gel.  
Sharp, well-defined bands at the expected molecular weight, measured by a 
GeneRulerTM 100bp Plus DNA Ladder (ThermoScientific, USA) run alongside the 
samples, indicated a successful amplification. Bands that were missing, feint or non-
specific indicated an unsuccessful PCR. Amplification in the negative control indicated 
contamination of the PCR and the PCR products were not subsequently run in 
downstream applications such as genotyping and sequencing. Non-amplification or 
repeated feint bands prompted an increase in DNA template from 100ng to 200ng per 
reaction. 
Adequate PCR products were then used for downstream genotyping.  
3.8 Genotyping  
Genotyping enables the elucidation of genetic variants by interrogation of the 
genotype or DNA sequence.  
In this study, the SNaPshot® Multiplex System for SNP Genotyping Assay 
(Thermofisher Scientific, USA) on the 3130xl Genetic Analyzer (Applied Biosystems, 
USA) was utilized for 6 out of the 7 SNPs studied. RARG rs2229774 was genotyped 
using the TaqMan® SNP genotyping assay (Thermofisher Scientific, USA). 
3.8.1 Genotyping by the SNaPshot® Multiplex Assay 
3.8.1.1 Principle of Genotyping by SNaPshot® 
The SNaPshot® System for SNP Genotyping Assay has the capability of detecting 
SNPs by using single base extension and termination 119. A single oligonucleotide 
primer binds to a complementary template in the presence of DNA polymerase and 
fluorescently labelled dideoxynucleotides (ddNTPs). There is single base extension 
of the primer by the polymerase – the fluorescently labelled ddNTP (ddGTP, ddCTP, 
ddATP, ddUTP) terminates extension by virtue of the absence of a 3’-hydroxyl group 
preventing the formation of a phosphodiester bond with another nucleotide (Fig.16).  
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Figure 16: Diagrammatic Representation of the Principle of SNaPshot® 
Genotyping 119 
The incorporated ddNTP’s fluorescence is quantified on an electropherogram 
generated by automated electrophoresis and a genotype can be subsequently called 
119. 
Table 14: Labelled ddNTPs, their fluorescent dyes and colours that determine 
genotype 
ddNTP Dye Expected Colour 
Adenine (A) dR6G Green 
Cytosine (C) dTAMRATM Black 
Guanine (G) dR110 Blue 
Thymine (T) dROXTM Red 
 
The GeneMapper® software version 4.1 allows for the analysis of genotyping data 
generated by the SNaPshot® Genotyping Assay and the ABI3130xl Genetic Analyzer 
(Applied Biosystems, USA).  
Successful genotyping requires primer specificity – this was achieved by precise 
genotyping primer design described below. 
3.8.1.2 Primer Design for SNaPshot® Genotyping 
Genotyping primer design is similar to PCR primer design described earlier in the 
chapter. However there are minor modifications. 
Genotyping primers were designed by using the following databases: IDT 
OligoAnalyzer version 3.1 (http://eu.idtdna.com/calc/analyzer, date accessed 
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2014/06/24) and NCBI Nucleotide-BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch, date accessed 
2014/06/24). Either a forward or reverse primer was designed for the region amplified 
by PCR for genotyping by SNaPshot®. The genotyping assay was multiplexed, 
therefore primer lengths had to be at least 25 nucleotides long and differed by at least 
4-6 nucleotides to prevent overlap – non-homologous nucleotides were added to the 
5’ end, where necessary. The recommended annealing temperature of the 
SNaPshot® control primer is 50°C therefore the annealing temperature of the primer 
should be at least 50°C.  
The amplified region was analysed in silico, the position of the SNP noted and either 
25 nucleotides upstream or downstream of it was highlighted as a potential forward 
or reverse primer, respectively. This region of potential primer was then analysed 
using IDT OligoAnalyzer: for hairpin structures, the Tm of the secondary structures 
should not be similar to the primer Tm; for self-dimer, the ΔG should not be smaller 
than -4 and for the heterodimer, the other primers to be utilised in the multiplex should 
be analysed whereby if the ΔG is smaller than -4, the primer may be accepted and 
allowed to be assessed by NCBI Nucleotide-Blast. It is important to note that if a 
reverse primer is designed, this region must be reverse complemented resulting in 
the complement SNP being detected. 
Primers were multiplexed and therefore submitted to Autodimer software 
(http://yellow.nist.gov:8444/dnaAnalysis/primerToolsPage.do, date accessed 
2014/06/30) to ensure that the primers would not form hairpins or primer-dimers. 
Genotyping primers were not designed for the following SNPs due to failure to amplify: 
ABCB4 rs1149222; IREB2 rs17483548 and SLC23A3 rs7853758. 
Genotyping primers for the TaqMan™ SNP Genotyping Assay (Table 15) were not 
designed for RARG rs2229774 as these were pre-designed by ThermoFisher 
Scientific (Applied Biosystems, USA). 
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Table 15: Pre-designed TaqMan™ SNP Genotyping Assay  
 
GENE RS ID PRIMER CONC CONTEXT SEQUENCE 
  FORWARD  REVERSE  
     
RARG rs2229774 36uM 36uM GGCATTGGGGTGGGGACCAGGCTGC[A/G]A
GGAGTCATCCTCAAACATTTCAGG 
     
 
Table 16 shows the genotyping primers designed as outlined previously. 
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Table 16: Custom-designed Primers for Genotyping using the SNaPshot® Multiplex System (ThermoFisherScientific, Applied 
Biosystems, USA) 
1TM= melting temperature; 2GC% = percentage Guanine and Cytosine content
GENE dbSNP ID PRIMER TM1 GC%2 LENGTH 
(BASES) 
DIRECTION CHANGE CHANGE IF 
REVERSE 
ABCC1 rs246221 AGA TCC TTG GAG GAG TAC AC 53.2 50 20 Reverse . A/G 
ABCC1 rs4148350 GCA GGC AAG GCT GCT GTA ACT TAC AAT 61.6 50 28 Reverse . C/A 
ABCC1 rs45511401 TAA TCA CCT TCT CCA TCC CCG AAG 58.1 50 24 Forward G/T . 
ABCC2 rs8187710 GGC GGC ACA AGA CAA CGG GAA GAT TAT AGA GT 64.1 50 32 Forward G/A . 
ABCC2 rs17222723 GC ATT CTG GTT GGT GTC AAT CCT C  58.2 50 24 Reverse . A/T 
ACO1 rs867469 CGG CGT ACA AGT AAA GAA TAT TAC C  53.7 40 25 Reverse . C/T 
AKR1A1 rs2229540 CTA CGA TTG ATT GTG CTG CTA TCT ACG GCA  61.4 46.7 30 Forward A/G . 
AKR1A1 rs6690497 AAG GTG CTA TCT ACG GCA ATG AGC CTG A  62.9 50 28 Forward G/C . 
CAT rs10836235 TAT TAG GCG TCG GCA AGT AAA GGC CCG GCT TC 67.2 56.3 32 Forward C/T . 
CBR3 rs1056892 ATT ATC AGG TCT CAG CCC CCT CCT CCA  64.1 55.6 27 Reverse . C/T 
CYBA rs4673 ACA TCA CCA CGG CGG TCA TGT 61.6 57.1 21 Reverse . A/G 
GSTP1 rs1695 GCG ATT ACA TAC GTT GCC TCC GCT GCA AAT AC  63.8 50 32 Forward A/G . 
HNMT rs17583889 GGT CCG AAC AGC ATG GGT GAA TGT TT 61.6 50 26 Forward C/A . 
NCF4 rs1883112 GAC ATA GGT CAC AAG ACA CCC TGA TG  58.8 50 26 Forward G/A . 
RAC2 rs13058338 CAT AGT GGT CTC TGG GTT CCT TGA ATG C  60.7 50 28 Forward A/T . 
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3.8.1.3 Technique of the SNaPshot® System 
The ABI Prism SNaPshot® System (ThermoFisherScientific, Applied Biosystems, 
USA) technique consisted of three experimental procedures conducted sequentially: 
purification of PCR products, the SNaPshot® PCR reaction followed by the 
purification of the SNaPshot® PCR products before automated electrophoresis on the 
ABI 3130xl Genetic Analyzer (ThermoFisherScientific, Applied Biosystems, USA).  
Table 17 shows the reagents and volumes required for purification or “clean-up” of 
PCR products before the SNaPshot® reaction. 
Table 17: Reagents required for the purification of PCR products for genotyping 
Reagents X1 (ul) 
FastAP 1.5 
Exonuclease 1 (Exo1) 0.1 
Sterile water 13.4 
PCR product 5 
Total 20 
 
Alkaline Phosphatase (FastAP) (ThermoFisher Scientific, USA) dephosphorylates all 
blunt, 5’ and 3’ ends at 37°C and was inactivated at 75°C 120. This enzyme together 
with Exo1, was necessary for the purification of PCR products where excess dNTPs, 
unbound primers, enzymes and failed PCR products were removed to prevent 
interference of genotyping primer annealing during the subsequent SNaPshot® 
reaction. The reaction cycling conditions were 37°C for 1 hour followed by 75°C for 
15 minutes. A negative control was also purified and subject to downstream 
experiments to exclude contamination. 
Purification of PCR products was followed by the SNaPshot® PCR reaction where a 
single primer was utilized to detect a SNP (Table 18). The reaction was multiplexed 
and as a result, the corresponding primers were mixed and primer volume was taken 
from this mixture as shown below. 
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Table 18: Reagents required for the SNaPshot Multiplex Assay 
Reagents X1 (ul) Cycling Conditions 
SNaPshot Reaction Mix 1 96°C for 10s  
50°C for 5s 25 cycles 
60°C for 30s 
Hold of 4°C 
Primers 1 
Sterile water 3 
Purified PCR product 5 
Total 10  
 
This reaction was followed by a second purification of products where 1ul of FastAP 
(ThermoFisher Scientific, USA) was added to each sample including the negative 
control thereby allowing for genotyping of sequences not inhibited by excess primers 
or extraneous PCR products not bound by primer. Samples were then placed in a 
thermal cycler with cycling conditions as follows: 37°C for 1 hour followed by 75°C for 
15 minutes. 
Samples were then submitted for automated electrophoresis and the subsequent 
generation of an electropherogram and genotype. Automated electrophoresis was 
conducted on the ABI 3130xl Genetic Analyzer (Applied Biosystems, USA) and the 
reaction prepared as described below (Table 19). 
Table 19: Reagents required for the automated electrophoresis run 
Reagents X1 (ul) 
120 LIZ™ Size Standard 0.3 
Hi-Di™ Formamide 8.7 
PCR product 1 
Total 10 
 
The reaction components were denatured at 95°C for 5 minutes followed by being 
placed on an ice-block at -20°C for 2 minutes before electrophoresis could occur.  
The GeneScan™ 120 LIZ™ Size Standard (ThermoFisher Scientific, USA) utilises 
five dyes to enable sizing of small fragments (15-120 nucleotides). The size standard 
which consists of nine single-stranded DNA fragments at 15, 20, 25, 35, 50, 62, 80, 
110 and 120 nucleotides in length, are labelled with the LIZ™ fluorophore 121. The 
highly deionized Hi-Di™ Formamide (ThermoFisher Scientific, USA) enabled the 
resuspension of samples to facilitate capillary electrophoresis. 
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Figure 17: GeneScan™ 120 Liz™ Size Standard whereby nine DNA fragments 
were utilized to size small stretches of DNA to determine genotype 
Results generated by the ABI 3130xl Genetic Analyzer (Applied Biosystems, USA) 
were analysed using the GeneScan Software run on the GeneMapper (version 4.1). 
The initial analysis required the setup of an analysis method, kit, panel, bin set and 
markers were determined. These settings allowed for the peak height and quality 
which were measured in relative fluorescent units (RFU), experiment type and type of 
alleles at specific positions that would be expected to be set. Analysis of subsequent 
experiments utilised these established settings. Similarly, the accurate sizing 
standard for each sample was crucial to the calling of the alleles and subsequent 
determination of the genotype. Failed sizing quality (SQ) was often due to the sizing 
standard being inaccurately assigned and could be manually amended to allow for 
the genotype to be called (Fig.18). 
 
Figure 18: Analysis settings on GeneMapper v4.1 software allowing for 
subsequent routine genotyping calling (Red circle indicates SNP, red arrow 
indicates bin determining type and position of allele expected, red box shows 
automated allele calling) 
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Samples, despite being amplified by PCR, which failed to be accurately genotyped in 
multiplex were repeated and genotyped in singleplex. 
The second technique of genotyping utilized was the TaqMan™ SNP Genotyping 
Assay (ThermoFisherScientific, Applied Biosystems, USA) outlined below. 
3.8.2 Genotyping by TaqMan™ SNP Genotyping Assay 
3.8.2.1 Principle of Genotyping by TaqMan™ SNP Genotyping Assay 
A predesigned TaqMan™ SNP Genotyping Assay was utilized for the elucidation of 
RARG rs2229774. TaqMan™ Assays are relatively costly but have a quick turnaround 
time – this SNP (RARG rs2229774) was found to have an association with ACT in 
childhood cancer patients from a GWAS only in 2015 7 and was later included in our 
cohort. TaqMan™ assays utilize 5’ nuclease chemistry whereby a VIC® dye-labelled 
probe and FAM™ dye-labelled probe together with minor groove binding (MGB) 
technology, fluorescent dyes and target specific PCR primer pairs allow for the 
amplification and detection of polymorphisms in purified DNA samples (Fig. 19) 122. 
Probe and primer sets allow for increased specificity – specifically, MGB probes 
improve allelic discrimination due to increased binding stability between MGB probe 
and DNA template and the incorporation of a non-fluorescent quencher improves 
signal-to-noise ratios 122. The exonuclease cleavage of an allele-specific 5’ dye label 
allows for the generation of a detectable signal 122. 
 
Figure 19: Graphical representation of Taqman™ SNP Genotyping Assay 122 
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3.8.2.2 Optimisation of TaqMan™ SNP Genotyping Assay 
Genotyping utilising the TaqMan™ SNP Genotyping Assay (ThermoFisherScientific, 
Applied Biosystems, USA) only required optimisation in terms of delineating whether 
the assay allowed for amplification of sample and the ideal volume of DNA to be 
added. Therefore, control DNA was utilized for the optimisation of this assay before it 
was routinely applied to all patient samples. 
3.8.2.3 Technique of TaqMan™ SNP Genotyping 
Components of the TaqMan™ SNP Genotyping Assay (primers and probes), 
TaqMan™ Genotyping Master Mix and purified genomic DNA (1-20ng) were required 
for the detection of this SNP. TaqMan™ Assay was diluted to 20X working solution 
using 1x TE Buffer (Appendix F) and stored as multiple aliquots at -15 to -25°C in the 
dark due to their fluorescent probes being light-sensitive. 
Each reaction plate had DNA samples that were to be interrogated for the SNP of 
interest and two no-template controls (NTCs). A 96 well plate with a total reaction 
volume of 10ul was utilized (Table 20).  
Table 20: Preparation of reaction mix for the wet DNA method 122 
Reagents Volume (ul) – 1x 
  
2X TaqMan® Genotyping Master Mix 5 
20X Assay Working Stock  0.5 
Nuclease-free water 2.5 
Total volume per well 8 
  
DNA (100ng/ul) 2 
  
Total volume per well 20 
 
The 2X TaqMan™ Genotyping Master Mix was added to the 20X Assay Working 
Stock and nuclease-free water, vortexed and centrifuged. 8ul of this mixture was 
pipetted into the MicroAmp® Optical 96-Well Reaction Plate wells, covered with 
MicroAmp® Optical Adhesive Film and centrifuged to eliminate air bubbles. DNA was 
diluted with nuclease-free water to ensure a concentration of 100ng/ul – 2ul of DNA 
was added to the required well ensuring a reaction concentration of 20ng/ul. The plate 
was covered with MicroAmp® Optical Adhesive Film and centrifuged. 
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The samples were cycled on the CFX96™ Real-Time PCR Detection System (Bio-
Rad, USA) with the following conditions: enzyme activation at 95°C for 10 minutes 
followed by 40 cycles of denaturation at 95°C for 15 seconds followed by annealing 
and extension at 60°C for 1 minute.  
Data generated was analysed using the TaqMan™ Genotyper Software and results 
were represented as a scatter plot (Allele 1 [VIC® dye] vs Allele 2 [FAM® dye]) where 
each point denoted an individual well (Fig.20). The NTCs were assigned as such to 
allow for a baseline correction for each run allowing for greater accuracy of allele calls. 
 
 
Figure 20: Example of an Allelic Discrimination plot 122 
3.9 Sequencing  
Sanger sequencing 123, as the gold standard for variant detection, was employed to 
confirm genotype findings using the SNaPshot® Technique. A random sample of 5% 
of the total cohort were sequenced – a technique that is both scientifically accurate 
and economical.  
Generally statistical significance is achieved when the calculated probability (p) of the 
null hypothesis (H0) being true is less than the significance level of 5% or 1% for 
greater stringency therefore 5% of our cohort was selected for validation sequencing 
for each variant. 
3.9.1 Principle of Sequencing 
Sanger sequencing 123 also known as Direct Cycle sequencing, involves the utilisation 
of a single primer, dNTPs and fluorescently labelled ddNTPs. While dNTPs allow for 
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fragment extension by Taq polymerase, ddNTPs by virtue of an absent 3’-hydroxyl 
group will terminate further extension 123. This method ensures that with a sufficiently 
high concentration of PCR products as a starting template and a specific ratio of 
dNTPs to ddNTPs that fragments covering the entire amplicon are generated. These 
fragments all terminate with a fluorescently labelled ddNTP that can be differentiated 
by a coloured dye (Table 21). 
 
Table 21: Labelled ddNTPs, their fluorescent dyes and colours that determine 
genotype 
ddNTP Dye Colour 
Adenine (A) dR6G Green 
Guanine (G) dR110 Blue 
Cytosine (C) dTAMRATM Black 
Thymine (T) dROXTM Red 
 
After denaturation, the fragments can be separated according to size by capillary 
electrophoresis, which includes a laser that both excites and detects fluorescent 
labels. Capillary electrophoresis has the ability to discriminate between single 
nucleotide differences. The pattern of bands that result would generate a full 
sequence of the amplicon – a graphical representation called an electropherogram. 
3.9.2 Technique of Sanger Sequencing  
 
Variants were specifically amplified by primer-specific PCR and amplification 
confirmed by agarose gel electrophoresis as previously described.  
PCR products were then purified from unincorporated dNTPs and single stranded 
primers using 1ul of FastAP, 0.2ul of Exonuclease I (ExoI), 3.8ul of sterile H20 and 5ul 
of PCR product in a single total volume of 10ul. The reactions were then incubated at 
37°C for 1 hour followed by an enzymatic degradation at 75°C for 15 minutes on the 
BioRad Thermal Cycler (BioRad, USA). 
Purified PCR products were then combined with components of the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Life Technologies, USA), either the forward or 
PCR
Agarose Gel 
Electrophoresis
PCR 
Purification
Sanger 
Sequencing 
Reaction
Sequencing 
Product 
Purification
Capillary 
Electrophoresis
Analysis
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reverse primer (Table 22) and sterile distilled water to a total volume of 10ul 
specifically described in Table 23.  
Table 22: Primers utilised for the validation of genotyping results using Sanger 
sequencing 
 
GENE RS ID PRIMER DIRECTION SIZE 
(BP) 
TM 
(°C) 
NO.  OF 
SAMPLES 
ABCC1 rs246221 AGGACCTTGTCTGAAGTCAC Forward 595 56 14 
ABCC2 rs8187710 
GGTAGTAGGTTCATGGGTGT
TC 
Reverse 572 56 14 
ABCC2 rs17222723 CCTGTGAGATAGGGTGTGTT Reverse 761 60* 13 
HNMT rs17583889 GACCTGAATAAGAGCACAGC Forward 325 57 13 
NCF4 rs1883112 CCACTTCCTTGATGTCAGTC Reverse 725 56 13 
RAC2 rs13058338 TGAGAACCAAGACCTGACTG Forward 341 57 14 
RARG rs2229774 
GAGGGAGCCGGTTAGATCA
G 
Reverse 464 59 14 
*Touchdown PCR 
 
Depending on the brightness of band visualized on the agarose gel, concentration of 
the product and the volumes of both purified PCR product and BigDye ® Terminator 
Cycle Sequencing Mix could be modified. The volume of the distilled water was then 
amended accordingly allowing the total volume to remain at 10ul. 
Table 23: Reagents required for the validation of genotyping using Sanger 
Sequencing  
Reagents Concentration 
Volume 
(µl) – 1x 
BigDye ® Terminator Cycle Sequencing Mix - ~ 2 
BigDye ® Terminator Dilution Buffer 5X 2 
Forward/Reverse Primer 20uM 0.5 
Sterile distilled H20 - 3.5 
PCR Product - ~2 
Total Volume  10 
    ~ variable volume dependent on amplification of product 
 
Sanger sequencing reaction conditions include: PCR template denaturation at 98°C 
for 5 minutes followed by 35 cycles of fragment denaturation at 96°C for 30 seconds, 
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primer annealing at 55°C for 15 seconds and product extension at 60°C for 4 minutes 
on the ABI Thermal cycler. 
Sequencing product purification was achieved by using ethanol precipitation, whereby 
negatively charged DNA would precipitate in the presence of absolute ethanol due to 
its interaction with salt ions 124. The salt ions are subsequently removed by 70% 
ethanol which simultaneously maintains the DNA in it state of precipitation. Briefly, 
2.5ul of sodium acetate (0.36M, pH 5.21) and 30ul of absolute ethanol was added to 
10ul of sequencing product, vortexed and incubated overnight at -22°C. This was then 
centrifuged at 10 000 rpm for 10 minutes, the supernatant discarded and 50ul of 70% 
ethanol added to the precipitate. The sample was then centrifuged at 10 000 rpm for 
10 minutes, the supernatant discarded and air-dried for an hour. The purified 
sequencing product was then resuspended in 10ul of sterile H20. 
The purified sequencing product was then separated according to size using capillary 
electrophoresis. 5ul of the sequencing product was combined with 8ul of Hi-Di 
formamide (ThermoFisher Scientific, Applied Biosystems, USA) in a single well in a 
MicroAmp plate, denatured at 95°C for 5 minutes on a thermal cycler, snap-frozen on 
an ice-block and then loaded onto an ABI3130xl Genetic Analyzer (Applied 
Biosystems, USA). Electropherograms and product sequences were subsequently 
produced by the Genetic Analyzer for further analysis. BioEdit Sequence Alignment 
Editor, Version 7.1.3.0 125 was utilized for comparative sequence alignment. 
3.10 Statistical Analysis 
Retrospective cohort analysis, prospective cohort analysis and the analysis of 
genotypes and their association with clinical phenotypes were conducted using 
Microsoft Excel, GraphPad Prism version 5 and R programming Language version 
3.2.1 (GUI) 101. The “Genetics” package and all its ‘imports or depends’ were also 
downloaded from the Comprehensive R Archive Network (CRAN) mirror 
(https://cran.r-project.org/mirrors.html). 
Continuous variables such as age were analysed by deriving the mean and median 
and performing a Shapiro-Wilk test for normality. The Shapiro-Wilk test is a test of 
normality with the assumption that the population is normally distributed.  
Chi-square tests were used to test for significant differences in categorical variables 
and depending on the nature of both the independent and dependent variables 
(categorical, ordinal, interval or normal), either the t-test, Wilcoxon-Mann Whitney 
Test, one-way ANOVA, Kruskal Wallis or logistic regression was utilized 126,127. Chi-
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square tests were used to either compare observed data with expected data based 
on a specific hypothesis i.e. the “goodness of fit” between observed and expected 
data and/or test for independence whereby a test would show whether two attributes 
occur independently 128. Statistical significance was defined as p<0.05. The 
correlation of data was achieved by the use of a multivariable, binomial logistic 
regression model. Estimates derived from the logistic regressions were used to 
compute odds ratios where OR=1 denotes no effect to outcome; OR>1 shows 
exposure associated with increased likeliness of outcome and OR<1 shows exposure 
associated with decreased likeliness of outcome 129. 
It was determined that logistic regression would be the more robust of the two 
analyses (Chi-square vs logistic regression) based on the following rationale: chi-
square was defined as a descriptive test much like a correlation that would be suited 
to describing the strength of a relationship. Logistic regression however was defined 
as a means to model the determinants of and predict the likelihood of an outcome. 
For the purposes of this study, we wished to explicitly define dependent variables and 
make predictions (likelihood of developing ACT) and found logistic regression to be 
most statistically appropriate. 
The absence of post-treatment LVEF measures in the prospective cohort and 
subsequent change in LVEF prompted the design of a statistical model whereby the 
scoring system developed in this study allowed for inferences to be made on potential 
LVEF changes. 
Retrospective data (n=402) with two LVEF measures and subsequent change in 
LVEF; a severity score (0-4) based on clinical indicators of cardiac 
dysfunction/impairment; type of first-line chemotherapy and population group were 
used to predict post LVEF where there was only one LVEF value. This model was 
tested in the prospective cohort (n=87) where patients had two measures of LVEF for 
robustness. The predictive model was then used on the prospective sub-cohort with 
missing post chemotherapy LVEF measures (n=185). 
For single marker analyses: chi-square tests were performed using a threshold of 
p<0.05 for the comparison of population groups for genotypic distribution, minor allele 
frequencies and clinical and demographic characteristics; however, to correct for 
multiple testing, Bonferroni correction was utilised with a more stringent p-value (p< 
0.0167 for significance) 130. The rationale for using a threshold of p<0.05 was based 
on p-values for replication of previously associated variants was set to P < 0.05 based 
on the existing evidence for prior associations. 
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Linkage Disequilibrium (LD) tests and Haplotype Analysis were conducted using the 
SHEsis program and R programming Language version 3.2.1 101,131,132. Furthermore, 
markers were assessed whether they were in Hardy-Weinberg Equilibrium (HWE) 
and if in HWE then a Pearson’s chi square test was used for independence 130. Gross 
deviations from HWE may indicate genotyping errors. For LD, if D’=+ 1, then there is 
no evidence for recombination between the markers; however, a high D’ together with 
similar allele frequencies may indicate markers that are inherited together (i.e. in LD); 
if ∆2 or r2 =1 then the markers may be surrogates for each other and if ∆2 or r2 =0 then 
the markers are in equilibrium. Similarly for HWE, the Chi-square goodness of fit test 
is employed to determine if the observed population is significantly different from the 
expectations of HWE – again the significance level of p<0.05 is utilized.  
The successful utilization of the methods outlined in this chapter produced the 
experimental findings and analyses which will be described in the subsequent results 
chapter. 
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Chapter 4: Results 
4.1 Retrospective Cohort Analysis 
Data from the records of a total of 402 retrospective cancer patients who had attended 
the Oncology Clinic at GSH from 2011 - 2016 were captured on an Excel spreadsheet 
and analysed. The patients had all been treated with anthracyclines and had at least 
two measures of LVEF. 
In terms of population group (or ethnicity), the cohort comprised of 24 Caucasians 
(CA), 95 IA and 283 patients of MA; 395 of the 402 patients were females and 7 were 
males. 
A histogram (Fig. 21) was used to illustrate patient age at diagnosis.  The median age 
at cancer diagnosis was 51 years (range: 27 to 77 years). Analysis by population 
group (or ethnicity) showed that IA patients had a younger median age at diagnosis 
of 44 years, compared to their MA (52 years) and CA (51 years) groups. 
 
Figure 21: Histogram of retrospective cohort illustrating proportion of patients 
and their age at diagnosis (n=402) 
The Shapiro-Wilk test showed that age at diagnosis was not normally distributed 
(W=0.98958, p=0.006).  
Table 24 shows the demographic characteristics of the retrospective patient cohort. 
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Table 24: Demographic characteristics of the retrospective patients cohort 
(n=402) 
 
MA 
 (n=283) 
IA 
 (n=95) 
CA 
 (n=24) 
Combined 
(n=402) 
     
Sex (Female:Male) 278 : 5 93 : 2 24 : 0 395 : 7 
Median Age at 
Diagnosis (years) 
52 44 51 51 
Body Surface Area*  1.77 1.86 1.80 1.8 
     
HIV Status 
(Negative: Positive: 
Unknown) 
117 : 2 : 164 
(0.41/0.007/0.59) 
45 : 10 : 40 
(0.47/0.11/0.42) 
10 : 0 : 14 
(0.42/0/0.58) 
172 : 12 : 218 
(0.43/0.03/0.54) 
     
Tobacco Smoking 
(No: Yes: Unknown) 
168 : 107 : 8 
(0.59/0.38/0.03) 
84 : 10 : 1 
(0.88/0.11/0.01) 
12 : 11 : 1 
(0.50/0.46/0.04) 
264: 128 : 10 
(0.66/0.32/0.02) 
Hypertension 
(No: Yes: Unknown) 
165 : 118 : 0 
(0.58/0.42/0) 
62 : 33 : 0 
(0.65/0.35/0) 
16 : 8 : 0 
(0.67/0.33/0) 
243 : 159 : 0 
(0.60/0.40/0) 
Diabetes 
(No: Yes: Unknown) 
240 : 43 : 0 
(0.85/0.15/0) 
83 : 12 : 0 
(0.87/0.13/0) 
23 : 1 : 0 
(0.96/0.04/0) 
346 : 56 : 0 
(0.86/0.14/0) 
Cardiac Disease 
(No: Yes: Unknown) 
266 : 17 : 0 
(0.94/0.06/0) 
91 : 4 : 0 
(0.96/0.04/0) 
24 : 0 : 0 
(1.00/0/0) 
381 : 21 : 0 
(0.95/0.05/0) 
     
* Body surface area (BSA) in females is considered normal at approx. 1.6m2 and in males at approx. 
1.9m2 133 
The average BSA used to determine accurate treatment dose, was higher than the 
“normal” for females at 1.6m2 for all population groups and even higher for IA females 
(1.86m2). 
Clinical characteristics demonstrated that 159 patients were hypertensive (40%), 56 
patients were diabetic (14%) and that 21 had pre-existing cardiac disease (5%). Of 
the self-reported 128 smokers in the cohort (32%), CA patients were proportionally 
the highest (46%) (although the sample size was small: n=24). MA patients, 
proportionally, had the highest incidence of hypertension (42%), diabetes (15%) and 
pre-existing cardiac disease (6%), compared to IA (35%, 13% and 4%, respectively) 
and CA subjects (33%, 4% and 0%, respectively).   
Table 25 shows the type and stage of cancer for patients in the retrospective cohort. 
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Table 25: Type and Stage of Cancer of Patients in the Retrospective Cohort 
(n=402) 
Type of Cancer Stage of Cancer 
 IA IB IIA IIB IIIA IIIB IIIC IV Unknown Total 
DCIS or LCIS 9 0 19 13 11 11 0 3 1 67 
IDC 16 0 52 60 44 61 7 10 2 252 
ILC 1 0 7 2 2 8 1 1 0 22 
Inflammatory 0 0 0 0 0 0 0 0 0 0 
Invasive 2 1 2 2 1 3 0 0 0 11 
BC NOS* 1 0 3 5 1 12 0 3 0 25 
Metastatic 0 0 0 3 3 2 0 8 0 16 
Other 0 0 0 2 1 1 0 2 3 9 
Total 29 1 83 87 63 98 8 27 6 402 
*BC NOS = Breast Cancer, not otherwise specified  
The most frequently diagnosed type of cancer was infiltrating ductal carcinoma (63% 
of the entire cohort) with the majority of patients diagnosed at stage IIIB (i.e. 24% of 
all invasive or infiltrating ductal carcinoma patients). Inflammatory breast cancer was 
not diagnosed in this cohort.  
In terms of first-line chemotherapy – 138 patients (34%) were on doxorubicin and 264 
(66%) were on epirubicin. The median administered dose of doxorubicin was 
450mg/m2 (range 75 - 690mg/m2) compared to the median dose of 680mg/m2 of 
epirubicin (range 75 – 1200mg/m2). Population stratification revealed that, 
proportionately, more CA patients (42%) were on doxorubicin compared to MA (36%) 
and IA (26%) patients. Furthermore, the CA sub-cohort received higher median doses 
of doxorubicin (539mg/m2) than the MA (449mg/m2) and IA (456mg/m2) groups, 
respectively, which would seemingly place CA patients at a higher risk of ACT 
compared to their MA and IA counterparts. 
The median change in LVEF (between the two measured time-points) was a decrease 
of 3% (range: decrease of -21% to an increase of +18%) after chemotherapy. A 
significant decrease in LVEF (of ≥10%) was noted in 56 patients (56/402= 14%), yet 
only seven of these patients (7/56= 12.5%) had definitive clinical symptoms after 
treatment. Conversely, of the 79 (79/402 = 19.7%) patients with the clinical status of 
“affected” (with potential or confirmed ACT), only 56 (70.8%) had a significant LVEF 
decline. 
In terms of patient cardiac clinical status after treatment, there were 79 (19.7%) 
affected and 323 (80.3%) unaffected (normal cardiac function) subjects. Patient 
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clinical status was stratified according to population group and is illustrated below 
(Fig.22). 
 
Figure 22: Patient Clinical Status (Cardiac impairment/dysfunction: affected vs 
unaffected) of retrospective cohort after chemotherapy stratified by population 
group and illustrated as relative proportions  
Figure 22 shows minimal differences (p=0.9977), between the population groups in 
terms of patient clinical status after chemotherapy. Approximately 20% of IA subjects, 
19.8% of MA and 16.7% of CA subjects had clinical signs of CF. By using the score 
or classifier developed for this study, the delineation is illustrated in Table 26: 
Table 26: Patients classified according to their clinical manifestations and 
subsequent score 
Score Score Indication Patients’ Score 
0 Normal cardiac function 323 (80%) 
1 
Chest pain, SOB and/or palpitations without LVEF 
decline 
1 (0.2%) 
2 
Chest pain, SOB and/or palpitations with non-
significant LVEF decline 
13 (3%) 
3 
Suspected CCF and/or LV dilation and/or raised 
troponin T and/or cardiomegaly 
5 (1%) 
4 
Congestive heart failure or myocardial infarction 
and/or significant LVEF change (>10%) 
60 (15%) 
 
The severity score had a very significant effect on LVEF post chemotherapy measures 
(Table 27).  
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Table 27: The effect of severity score on LVEF post chemotherapy measures  
 Severity 0 Severity 1 Severity 2 Severity 3 Severity 4 
𝒏 323 1 13 5 60 
Effect +3.33 +6.54 −1.61 −2.03 −6.23 
The LVEF post chemotherapy is higher for severity score zero and lower for severity 
score 4. The particularly high effect for severity score 1 is due to the fact that there is 
only a single observation and this patient has higher LVEF post chemo though still in 
the normal range. 
ANOVA type II tests showed that the following variables did not have a statistically 
significant effect on the LVEF post-chemotherapy measure: age, age at diagnosis, 
sex, cancer type, cancer stage, hypertension, diabetes, cardiac disease, smoking 
status, HIV status, number of cycles for first-line chemotherapy, type of first and 
second-line chemotherapy, number of cycles for second-line chemotherapy and total 
dose of doxorubicin. However, the severity score was found to significantly contribute 
to the LVEF post-chemotherapy measure (p=2.2e-16) and the LVEF pre-
chemotherapy measure together with population group significantly contributed to the 
LVEF post-chemotherapy measure (p=0.0036). The type of first-line chemotherapy 
together with LVEF pre-chemotherapy measure did not significantly contribute to the 
LVEF post-chemotherapy measure (p=0.093). 
The LVEF pre-chemotherapy measure when combined with severity score, 
population group and type of first-line chemotherapy had a significant effect on the 
prediction of LVEF post-chemo (Table 28). 
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Table 28: Prediction of LVEF post-chemo measure using population group, type 
of first-line chemotherapy and severity score 
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− 21.95 
0 
AC 
CA 
= 1.33𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 26.89 
2 
= 1.33𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 27.31 
3 
= 1.33𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 31.51 
4 
+3.31
− 0.05𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 1.04𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 2.73 
0 
CAF 
= 1.04 𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 7.67 
2 
= 1.04 𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 8.09 
3 
= 1.04𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 12.29 
4 
+3.52
− 0.05𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 1.04 𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 2.52 
0 
EC 
= 1.04 𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 7.46 
2 
= 1.04 𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 7.88 
3 
= 1.04𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 12.08 
4 
+9.08
− 0.14𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.95𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 3.04 
0 
FEC 
= 0.95𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 1.90 
2 
= 0.95𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 2.32 
3 
0.95𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 − 6.52 4 
 
= 1.09𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 6.04 
0 
Other 
= 1.09𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 10.98 
2 
= 1.09𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 11.40 
3 
= 1.09𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 15.60 
4 
3.11 + 11.98
+ 0.68𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
−15.91
+ 0.24𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.92𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 2.51 
0 
AC IA 
= 0.92𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 2.43 
2 
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= 0.92𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 2.85 
3 
= 0.92𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 7.05 
4 
+3.31
− 0.05𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.63𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 21.73 
0 
CAF 
= 0.63𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 16.79 
2 
= 0.63𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 16.37 
3 
= 0.63𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 12.17 
4 
+3.52
− 0.05𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.63𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 21.94 
0 
EC 
= 0.63𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 17.00 
2 
= 0.63 𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 16.58 
3 
= 0.63 𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 12.38 
4 
    
+9.08
− 0.14𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.54𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 27.5 
0 
FEC 
= 0.54𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 22.56 
2 
= 0.54𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 22.14 
3 
= 0.54𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 17.94 
4 
 
= 0.68𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 18.42 
0 
Other 
= 0.68𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 13.48 
2 
= 0.68𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 13.06 
3 
= 0.68𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 8.86 
4 
3.11 + 0.50
+ 0.86𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
−15.91
+ 0.24𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 1.00𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 9.42 
0 
AC 
MA 
= 1.00𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 14.36 
2 
= 1.00𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 14.78 
3 
= 1.00𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 18.98 
4 
+3.31
− 0.05𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 9.80 
0 
CAF 
= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 4.86 
2 
= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 4.44 
3 
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= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 0.24 
4 
+3.52
− 0.05𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 10.01 
0 
EC 
= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 5.07 
2 
= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 4.65 
3 
= 0.81𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 0.45 
4 
+9.08
− 0.14𝐿𝑉𝐸𝐹 𝑝𝑟𝑒 
= 0.72𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 15.57 
0 
FEC 
= 0.72𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 10.63 
2 
= 0.72𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 10.21 
3 
= 0.72𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 6.01 
4 
 
= 0.86𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 6.49 
0 
Other 
= 0.86𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 1.55 
2 
= 0.86𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
+ 1.13 
3 
= 0.86𝐿𝑉𝐸𝐹 𝑝𝑟𝑒
− 3.07 
4 
*Grey font indicates little data and should be ignored. 
Logistic regression was then performed with patient clinical status as the outcome 
and severity score and/or classifier and additional variables listed in Table 29, as the 
predictors. 
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Table 29: Logistic Regression Coefficients used to determine Odds Ratios of 
covariates for Patient Clinical Status 
Covariates Test Statistic 
Odds 
Ratio^ p-value 
    
Age at Diagnosis 0.019 
1.00  
(0.98-1.02) 0.985 
Gender- Male -2.245 
0.18  
(0.03-0.81) 0.025* 
Population Group_CA (ref) 
Population Group_MA 
Population Group_IA 
------------ ------------ ----------- 
-0.370 
0.81  
(0.23-2.25) 0.711 
-0.369 
0.80  
(0.21-2.43) 0.712 
Hypertension 0.063 
1.02    
(0.62-1.69) 0.950 
Diabetes Mellitus -0.722 
0.78  
(0.41-1.58) 0.470 
Pre-existing Cardiac Disease -0.491 
0.77  
(0.29-2.42) 0.623 
Smoking Status 0.666 
1.2    
(0.71-2.09) 0.506 
First line Chemotherapy 2.587 
1.94    
(1.17-3.20) 0.009* 
Total doxorubicin dose 5.175 
1.008  
(1.005-1.01) 2.28e-07* 
Total epirubicin dose 5.857 
1.004  
(1.003-1.005) 4.72e-09* 
Total anthracycline dose 2.127 
1.001  
(1.000-1.003 0.003* 
Change in LVEF 8.98 
1.63  
(1.48-1.83) <2e-16* 
Score (0-4) -0.003 1.88+  0.998 
    
*statistically significant with a p-value threshold of <0.05; ^univariate odds ratios with 95% CI; +sample 
size too small for CI 
The logistic regression analyses indicate that patients on first-line chemotherapy had 
nearly twice the odds of developing the outcome (OR=1.94, 95%CI, p=0.009). HPT 
has an OR of 1 indicating no association, while smoking has an OR of 1.2, this is not 
significant. Only those predictors with a statistically significant p-value were 
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considered for the multivariable model. Predictor variables were computed in multiple 
combinations and only the change in LVEF remained statistically significant when 
computed with other variables (p value=0.000164, OR=1.7).  
4.2 Prospective Cohort Analysis 
4.2.1  Recruitment  
Of the 275 patients originally recruited in the prospective study, three were removed 
for various reasons, including a change in treatment regimen, a cerebrovascular 
accident (CVA/stroke) and the development of herpes zoster. One patient was 
recruited in the cardiology clinic after suffering a myocardial infarction due to 
chemotherapy – only the post-chemotherapy sample was procured. 
Patients deemed to have sufficient chemotherapy for quantifiable effect, despite 
regimen switches or incomplete regimen, were extensively interrogated. Thirty-seven 
patients had only one sample procured (pre-chemotherapy). Three patients deceased 
before a second sample could be procured. Seven patients either discontinued or 
switched chemotherapeutic regimen. Twenty-seven patients were lost to follow-up 
despite the majority of them completing chemotherapy. After completion of the study, 
25 patients (9.2%) were deceased due to cancer progression, CF or treatment-related 
mortality. Seventeen of the deceased patients (68%) were from GSH and eight (32%) 
were from TBH. Ultimately, 272 of the original 275 patients were genotyped and 
analysed. 
4.2.2  Procurement of Clinical Information from Patient Folders 
The median age of the prospective patient cohort was 50 years (range 25 - 77 years).  
This was comparable to the retrospective cohort (median age: 51 years, and range 
27 to 77 years). The Shapiro-Wilk test showed that age of the prospective cohort was 
normally distributed (W=0.99222, p-value =0.1641). IA patients were diagnosed at a 
median age of 44 years compared to their MA (51 years) and CA (59 years) 
counterparts. This was very similar to the data from the retrospective cohort for IA 
patients who had a median age at diagnosis of 44 years, compared to their MA (52 
years) counterparts.  The prospective cohort showed that the CA patients were 
appreciably older at diagnosis (59 years) than both the IA and MA groups 
The histogram below (Fig.23) illustrates the age at diagnosis of patients in the 
prospectively analysed cohort. 
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Figure 23: Histogram of the age at diagnosis of patients in the prospective 
cohort (n=272)  
All patients recruited in the study were female, diagnosed with breast cancer and 
anthracycline-based treatment naïve. The average BSA, used to determine accurate 
treatment dose, was higher than the “normal” at 1.6m2 for all population groups and 
to a greater degree for both CA (1.84) and IA (1.81) patients. Table 30 outlines the 
demographic characteristics of the patients in the cohort in greater detail. 
Table 30: Demographic characteristics of patients receiving anthracycline-
based chemotherapy in the prospective cohort 
 
MA 
 (n=215) 
IA 
 (n=47) 
CA 
 (n=10) 
Combined 
(n=272) 
     
Sex (Female:Male) 215 : 0 47 : 0 10 : 0 272 : 0 
Median Age at 
Diagnosis (years) 51 44 59 50 
Body Surface Area*  1.74 1.81 1.84 1.76 
HIV Status 
(Negative: Positive: 
Unk) 
193 : 5 : 17 
(0.90/0.02/0.08) 
27 : 20 : 0 
(0.57/0.43/0) 
10 : 0 : 0 
(1/0/0) 
230 : 25 : 17 
(0.85/0.09/0.06) 
Tobacco Smoking 
(No: Yes: Unknown) 
122 : 77 : 16 
(0.57/0.36/0.07) 
41 : 5 : 1 
(0.87/0.11/0.02) 
6 : 3 : 1 
(0.60/0.30/0.1) 
169 : 85 : 18 
(0.62/0.31/0.07) 
Hypertension 
(No: Yes: Unknown) 
116 : 99 : 0 
(0.54/0.46/0) 
33 : 14 : 0 
(0.70/0.30/0) 
4 : 6 : 0 
(0.40/0.60/0) 
153 : 119 : 0 
(0.57/0.43/0) 
Diabetes 
(No: Yes: Unknown) 
190 : 25 : 0 
(0.88/0.12/0) 
46 : 1 : 0 
(0.98/0.02/0) 
9 : 1 : 0 
(0.90/0.10/0) 
245 : 27 : 0 
(0.90/0.10/0) 
Cardiac Disease 
(No: Yes: Unknown) 
200 : 14 : 1 
(0.93/0.065/0.00
5) 
41 : 6 : 0 
(0.87/0.13/0) 
10 : 0 : 0 
(1.00/0/0) 
251 : 20 : 1 
(0.92/0.07/0.004) 
     
* BSA in females is considered normal at approx. 1.6m2 
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The majority of patients in the cohort were HIV negative (85%); however further 
analysis revealed that a significant number of IA patients were HIV positive (43%) 
compared to MA patients (2%) and Caucasian patients (0%). Conversely in terms of 
smoking, hypertension and diabetes, IA patients self-reported the lowest incidence – 
with smokers (11%), hypertensives (30%) and diabetics (2%) compared to MA 
patients – smokers (36%), hypertensives (46%) and diabetics (12%) and Caucasian 
patients – smokers (30%), hypertensives (60%) and diabetics (10%). 
Despite the majority of patients not having any pre-existing cardiac disease (92%), 
early measures of cardiac function before administration of chemotherapy revealed 
minor abnormalities in approximately 5% of patients. IA patients had the highest 
incidence of pre-existing cardiac disease (13%).  
Table 31 shows both the type and stage of breast cancer of all the patients in the 
cohort. 
Table 31: Type and Stage of Cancer of Patients in the Prospective Cohort 
(n=272) 
Type of Cancer Stage of Cancer 
 IA IB IIA IIB IIIA IIIB IIIC IV Unknown Total 
DCIS or LCIS 2 0 7 9 7 9 1 0 0 35 
IDC 8 2 45 53 30 42 9 2 2 193 
ILC 0 0 3 4 2 4 0 1 0 14 
Inflammatory 0 0 0 0 0 2 0 0 0 2 
Invasive 0 0 3 3 2 2 0 0 0 10 
BC NOS* 1 0 1 0 1 3 0 0 0 6 
Metastatic 0 0 1 0 2 3 0 5 1 12 
Total 11 2 60 69 44 65 10 8 3 272 
*BC NOS – Breast Cancer, not otherwise specified 
As with the retrospective cohort, the most frequently diagnosed type of cancer was 
IDC (71% of the entire cohort) with the majority of these patients diagnosed at stage 
IIB (27% of all IDC patients). Inflammatory breast cancer was diagnosed most 
infrequently at only 0.7% of the cohort, consistent with the rare presentation of this 
subtype in the general population (Table 31). 
Fifteen patients who were assessed at baseline before the administration of 
chemotherapy were found to have incidental cardiac findings (Table 32). One patient 
had an inconclusive LVEF measure.  
Of the 15 patients who were found to have some measure of cardiac 
impairment/dysfunction before the start of chemotherapy – 20% were IA and 80% of 
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were MA, approximately reflecting the relative distribution of the ethnicities in the total 
cohort. 
Table 32: Incidental cardiac findings derived from routine assessment of 
baseline cardiac function before commencement of anthracycline-based 
chemotherapy contrasted with baseline LVEF 
Cardiac Incidental Findings LVEF (%) Population 
Group 
   
Rhythm abnormality 52 IA 
Mild cardiomegaly 60 IA 
Rhythm abnormality - MA 
Aortic Regurgitation 60 MA 
Impaired relaxation indicated by diastolic filling 
pattern 
55 MA 
Left ventricular hypertrophy 70 MA 
Cardiomegaly with pericardial effusion 54 MA 
Left ventricular hypertrophy; elevated left atrial 
filling pressures; mildly dilated left atrium 
60 MA 
Wall motion impairment 55 MA 
Left ventricular hypertrophy with normal diastolic 
filling pattern 
55 IA 
Impaired relaxation of left ventricle 55 MA 
Impaired relaxation with elevated left atrial filling 
pressures 
55 MA 
Aortic regurgitation; impaired relaxation of left 
ventricle; early mild pulmonary hypertension 
60 MA 
Tricuspid regurgitation 60 MA 
Left ventricular hypertrophy 55 MA 
 
4.2.3 Statistical Analysis 
Patient status was deemed either affected or unaffected with signs or symptoms of 
ACT. There were 38 affected (14% of the cohort) and 234 unaffected patients at the 
conclusion of chemotherapy in the prospective cohort. However this clinical status 
could be considered provisional as unaffected patients may have subclinical damage 
that may manifest later. 
91 
 
 
Figure 24: Clinical status (Cardiac impairment/dysfunction: affected vs 
unaffected) of Patients stratified by Population Group in Prospective Cohort  
Clinical status (Cardiac impairment/dysfunction: affected vs unaffected) differed 
between population groups (p=0.5116), where 19% of IA patients were classified as 
affected compared to 13% of MA and 10% of CA indicating that IAs may have 
increased sensitivity to ACT (Fig.24). 
The score or classifier was established to allow for patients with missing post-
treatment LVEF (n=185) to be assessed in cardiac terms with 0 being ‘normal’ and 4 
being ‘most severely affected’.  The differences between the population groups was 
found to be statistically significant (Chi-square, p=0.036).  
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Table 33: Logistic Regression Co-efficients used to determine Odds Ratios 
using Clinical-based Covariates 
Covariates 
Test 
Statistic 
Odds Ratio^  p-value 
    
Age -0.610 
0.99       
(0.96-1.02) 
0.542 
Population Group_IA (ref) 
Population Group_MA 
Population Group_CA 
-------- -------- -------- 
1.085 
1.58       
(0.66-3.5) 
0.278 
0.677 
2.13       
(0.33-41.9) 
0.498 
Hypertension -1.184 
0.66       
(0.33-1.31) 
0.236 
Diabetes Mellitus 0.450 
1.33       
(0.44-5.82) 
0.653 
Pre-existing Cardiac Disease -0.131 
0.92       
(0.29-4.08) 
0.896 
Smoking Status 0.144 
1.06       
(0.51-2.29) 
0.886 
Change in LVEF 3.891 
1.65       
(1.34-2.25) 
9.99e-05* 
Total Dose of Anthracycline-Based 
Chemotherapy 
2.400 
1.002      
(1.0004-1.004) 
0.0164* 
Change in LVEF and Total Dose 3.769 
1.704     
(1.36-2.39) 
0.000164* 
    
*statistically significant; ^odds ratios with 95% CI 
Gender was not used as a covariate due to all the patients in the prospective cohort 
being female. 
Therefore, based on both the OR and p-values, the change in LVEF and total dose of 
anthracycline-based chemotherapy significantly increased the likelihood of 
cardiotoxicity. 
The change in LVEF as a predictor of the outcome of ACT, meant that missing LVEF 
measures needed to be addressed. A simple model was established whereby patients 
with missing variables (i.e. LVEF post-chemo) could be estimated using the clinical 
classifier/score developed during this study as well as population group and type of 
first-line chemotherapy regimen. 
Retrospective data (n=402) where two LVEF measures, together with qualitative and 
quantitative cardiac data, where available, (and scored from 0-4) was used to create 
a formula that was validated on prospective patients (n=87) with both pre and post-
chemo LVEF measures. The formula was then applied to prospective patients 
(n=185) with only one LVEF measure (pre-chemo) to predict post-chemo LVEF 
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measures. The difference between actual and predicted post-chemo LVEF measures 
is illustrated in Figure 25. 
 
Figure 25: Difference between actual and predicted post-chemo LVEF measures 
in prospective patients (n=87) – Observed LVEF measures are represented as 
open circles with predicted values colour-coded according to severity score 
A cut-off of 4% was utilized as literature indicates that measurements of LVEF 
accounting for both inter-operator variability and repeat testing on the same patient 
are acceptable if in the range of 2-4% 134.  
Therefore the proposed model indicates an 82% accuracy rate in predicting post-
chemo LVEF and can be used for missing variables (LVEF measure) for the rest of 
the prospective patient cohort.  
4.3 Patient Sample 
4.3.1 DNA isolation 
DNA was isolated from 275 patient samples using the Promega Maxwell® 16 DNA 
Purification Kit and the salting out method. The Promega Maxwell® 16 DNA 
Purification Kit had a quick turnaround time but produced low yields of isolated DNA.  
DNA was successfully isolated from 274 patients, only one patient had insufficient 
white blood cells for the isolation of DNA. All patient DNA, after being quantified using 
spectrophotometry, was stored at -20°C until required for downstream applications 
(Appendix H, Table 1). The majority of patient samples taken after chemotherapy 
were stored as buffy coats and isolated as needed. 
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4.3.1.1 Spectrophotometry for quantitation of DNA 
All DNA samples were spectrophotometrically quantified before PCR (Appendix I, Fig. 
1) and a total of 86 of the 274 patient DNA samples had concentrations less than 
100ng/ul – the optimal concentration for PCR. This was noted in anticipation of 
potential failure to amplify. 
4.3.1.2 Assessment of DNA Integrity 
The integrity of the patient DNA was assessed using agarose gel electrophoresis 
(Fig.26). Low molecular weight DNA or degraded DNA appeared as a smear on the 
gel whereas intact DNA appeared as a sharp band proximal to the loading well. 
 
  
 
Figure 26: Assessment of DNA Integrity using agarose gel electrophoresis. 
Patient DNA samples were electrophoresed at 85V for 2 hours on a 1% (w/v) 
agarose gel (Seakem® LE Agarose, Lonza, USA) stained with SYBR®Safe (Life 
Technologies, USA) and visualized under UV light. The molecular weight 
marker (MWM) used was the GeneRulerTM 100bp Plus DNA Ladder 
(ThermoScientific, USA). 
This DNA integrity gel (Fig.26) indicates that the majority of the patient DNA samples 
are utilisable for downstream applications. However the smeared band for sample 
50A (lane 4) and the feint bands for samples 63A and 64A (lanes 22 and 23) may be 
partially degraded and/or of relatively low concentration. Spectrophotometry shows 
that sample 50A (lane 4) has a sufficiently high concentration (452.16 ng/ul) therefore 
is likely to be degraded. Both samples 63A (25.1 ng/ul) and 64A (29.8 ng/ul) have low 
concentrations which explains the feint band visualized on the gel. 
Cumulatively, 22 samples had either very low concentrations and appeared on the 
gel as feint bands or were partially degraded and appeared on the gel as smears. 
Nevertheless all 22 samples were amplified using PCR – only six samples exhibiting 
1: MWM 13: 55A 
2: 49A 14: 56A 
3: 49B 15: 57A 
4: 50A 16: 58A 
5: 50B 17: 59A 
6: 51A 18: 59B 
7: 51B 19: 60A 
8: 52A 20: 61A 
9: 53A 21: 62A 
10: 54A 22: 63A 
11: 54B 23: 64A 
12: 54C 
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partial degradation and two samples with very low concentrations were problematic 
to amplify and genotype.  
4.4 Selected Genes of Interest 
Genes of interest were selected using  both a pathway-based 83 and candidate 
gene/marker approach based on previous studies 10,12,27,34,47,106,135-137. 
Initially, 19 SNPs in 15 genes described in Table 7 were selected using a candidate 
gene approach. However, after approximately 70 patients were genotyped, genotypes 
appeared to be monomorphic for some of the SNPs, therefore only seven SNPs 
(ABCC1 rs246221; ABCC2 rs17222723; ABCC2 rs8187710; HNMT rs17583889; 
NCF4 rs1883112, RAC2 rs13058338 and RARG rs2229774) that showed both 
heterozygosity and association with the cardiac phenotype were further interrogated 
for all patient samples (Table 7).
4.4.1 Gene Annotation 
The output derived from Appendix J Figure 1, allowed for both the confirmation of 
the genetic location of the SNP as well as the design of primers found later in the 
chapter (Appendix J, Figure 1). 
4.5 PCR 
4.5.1 Optimisation: Singleplex and Multiplex PCR 
4.5.1.1 Temperature Gradient 
The first PCR optimisation step was establishing a good melting temperature where 
there would be optimal yield of specific product. 
 
Figure 27: Multiplex optimisation using a temperature gradient and visualized 
by agarose gel electrophoresis. Control DNA (C18F) was amplified for ABCC1 
rs4148350 (333bp) and CYBA rs4673 (680bp) [lanes 2-6] and ACO1 rs867469 
(307bp) and ABCC2 rs17222723 (761bp) [lanes 8-14] and were electrophoresed 
at 90V for 2 hours on a 3% (w/v) agarose gel (Seakem® LE Agarose, Lonza, 
USA); MWM = GeneRulerTM 100bp Plus DNA Ladder  
1: MWM    8: NTC 
2: NTC    9: 55°C 
3: 57°C    10: 56°C 
4: 58°C    11: 57°C 
5: 59°C    12: 58°C 
6: 60°C       13: 59°C 
7: NTC    14: 60°C 
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The first multiplex involving the amplification of both ABCC1 rs4148350 (333bp) and 
CYBA rs4673 (680bp) on a temperature gradient between 57-60°C showed greatest 
specificity and efficiency at Tm=60°C (lane 6). Temperatures lower than 60°C resulted 
in non-specific amplification (lanes 3-5). The second multiplex involving the 
amplification of both ACO1 rs867469 (307bp) and ABCC2 rs17222723 (761bp) 
showed increased yield of both regions as the temperature increased, however, non-
specific amplification persisted (lanes 9-14). There was no amplification in both NTCs 
(lanes 2 and 8) therefore contamination of the PCRs were unlikely. 
 
4.5.1.2 Magnesium Gradient 
The optimisation of the concentration of magnesium to remove any non-specific 
amplification (Fig.28) 
 
Figure 28: Singleplex optimisation using a magnesium chloride (MgCl2) 
gradient and visualized by agarose gel electrophoresis. Control DNA (C18F) 
was amplified for ABCC1 rs4148350 (333bp) [top gel] and NCF4 rs1883112 
(725bp) [bottom gel] and were electrophoresed at 110V for 1 hour on a 2% (w/v) 
agarose gel (Seakem® LE Agarose, Lonza, USA); MWM = GeneRulerTM 100bp 
Plus DNA Ladder (ThermoScientific, USA); NTC= no template control 
Amplification for both ABCC1 rs4148350 (333bp) [top gel – lanes 2-9] and NCF4 
rs1883112 (725bp) [bottom gel – lanes 2-9] were optimised using an MgCl2 gradient 
with concentrations at 0.5mM (lanes 2 & 3), 1mM (lanes 4 & 5), 2mM (lanes 6 & 7) 
and 3mM (lanes 7 & 8). Amplification for both ABCC1 rs4148350 (top gel) and NCF4 
rs1883112 (bottom gel) had optimum yield and specificity at an MgCl2 concentration 
of 1-2mM (lanes 4 & 6). NTCs for each sample showed no amplification therefore 
contamination was unlikely. 
 
1: MWM  6: 2mM 
2: 0.5mM 7: NTC 
3: NTC  8: 3mM 
4: 1mM  9: NTC 
5: NTC               
 
 
 
 
1: MWM  6: 2mM 
2: 0.5mM 7: NTC 
3: NTC  8: 3mM 
4: 1mM  9: NTC 
5: NTC               
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4.5.1.3 Additives 
Alterations to the annealing temperature and MgCl2 concentration did not always 
guarantee an optimised PCR, therefore, the addition of certain additives were utilized 
to improve specificity (Fig.29).  
 
 
Figure 29: Singleplex optimisation of ABCC2 rs17222723 (761bp) using 
additives (Dithiothreitol (DTT), Betaine, Glycerol and dimethyl sulfoxide 
(DMSO)) and visualized by agarose gel electrophoresis. Control DNA (C18F) 
was amplified for ABCC2 rs17222723 (761bp) in duplicate (A & B) and were 
electrophoresed at 120V for 40 minutes on a 1.5% (w/v) agarose gel (Seakem® 
LE Agarose, Lonza, USA); MWM = GeneRulerTM 100bp Plus DNA Ladder 
(ThermoScientific, USA) 
Amplification of ABCC2 rs17222723 (761bp) showed least non-specificity with the 
addition of Glycerol (Lanes 4 & 5). The addition of both DTT and Betaine (Lanes 2 & 
3) was less successful – while the target region was amplified at a sufficiently high 
yield, there were three non-specific bands. The addition of DMSO (Lanes 6 & 7) was 
the least successful- there were multiple bands of non-specific amplification with one 
of the bands having as high a yield as the target region. This challenging PCR 
required further optimisation whereby non-specific amplification was eliminated.  
4.5.1.4 Touchdown PCR 
Touchdown PCR allows for the both the amplification of difficult to amplify regions as 
well as the elimination of non-specific products. 
Previously, the addition of glycerol showed a reduction in non-specific amplification 
however some measure of non-specificity persisted. Touchdown PCR (Fig.30), 
eliminated non-specific bands and the yield of the target PCR products was high 
(lanes 8 & 9) compared to the temperature gradient (lanes 3-6) where non-specificity 
is most apparent at lower temperatures. There was no amplification in either of the 
two NTCs indicating the absence of contamination. 
 
1:MWM           
2:DTT & Betaine A 
3:DTT & Betaine B              
4:Glycerol A 
5:Glycerol B 
6:DMSO A 
7: DMSO B 
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Figure 30: Multiplex optimisation of ACO1 rs867469 (307bp), ABCC1 rs246221 
(595bp) and ABCC2 rs17222723 (761bp) using the additive Glycerol and 
comparing a temperature gradient (59°C-62°C: lanes 3-6) to touchdown PCR 
performed at 60°C (lanes 7-9) and visualized by agarose gel electrophoresis. 
Control DNA (C18F) was amplified in a multiplex PCR for ACO1 rs867469 
(307bp), ABCC1 rs246221 (595bp) and ABCC2 rs17222723 (761bp) and were 
electrophoresed at 90V for 2 hours on a 3% (w/v) agarose gel (Seakem® LE 
Agarose, Lonza, USA); MWM = GeneRulerTM 100bp Plus DNA Ladder 
(ThermoScientific, USA); NTC = no template control 
While the annealing temperature of 62°C for a standard PCR (lane 6) also showed 
reduced non-specific amplification, the intensity of the bands which represent 
amplified target regions was greater in the touchdown PCR (lanes 8-9) indicating 
greater yield of product and therefore greater overall efficiency. Hence the 
amplification of these regions was optimised with the addition of glycerol and utilizing 
a touchdown PCR. 
4.5.2 Optimised Multiplex PCRs 
All samples (lanes 2-16) amplified specifically for both target regions – HNMT 
rs17583889 (325bp) and ABCC2 rs8187710. There was no amplification in the NTC 
therefore contamination was unlikely (Fig.31).   
 
 
 
 
Figure 31: Optimised multiplex PCR showing the amplification of HNMT 
rs17583889 (325bp) and ABCC2 rs8187710 (572bp) performed at 55°C and 
visualized by agarose gel electrophoresis. Patient DNA was amplified in a 
multiplex PCR for HNMT rs17583889 (325bp) and ABCC2 rs8187710 (572bp) and 
were electrophoresed at 110V for 1.5 hours on a 2.5% (w/v) agarose gel 
(Seakem® LE Agarose, Lonza, USA); MWM = GeneRulerTM 100bp Plus DNA 
Ladder (ThermoScientific, USA); NTC = no template control 
1: MWM           7: NTC Touchdown  
2: NTC Temp 8: 60°C Touchdown                                   
3: 59°C  9: 60°C Touchdown  
4: 60°C   
5: 61°C   
6: 62°C 
 
 
 
 
 
 
1: MWM           10: 213 
2: 205           11: 214 
3: 206           12: 215 
4: 207           13: 216 
5: 208           14: 217 
6: 209           15: 218 
7: 210           16: 219 
8: 211           17: NTC 
9: 212 
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All samples (lanes 2-16) amplified specifically and efficiently for both target regions – 
RAC2 rs13058338 (341bp) and NCF4 rs1883112 (725bp). There was no amplification 
in the NTC therefore contamination was unlikely (Fig.32).  
 
 
 
 
 
 
 
 
Figure 32: Optimised multiplex PCR showing the amplification of RAC2 
rs13058338 (341bp) and NCF4 rs1883112 (725bp) performed at 56°C and 
visualized by agarose gel electrophoresis. Patient DNA was amplified in a 
multiplex PCR for RAC2 rs13058338 (341bp) and NCF4 rs1883112 (725bp) and 
were electrophoresed at 110V for 1.5 hours on a 2.5% (w/v) agarose gel 
(Seakem® LE Agarose, Lonza, USA); MWM = GeneRulerTM 100bp Plus DNA 
Ladder (ThermoScientific, USA); NTC = no template control 
All samples (lanes 2-16) amplified specifically and efficiently for both target regions – 
ABCC1 rs246221 (595bp) and ABCC2 rs17222723 (761bp). There was no 
amplification in the NTC therefore contamination was unlikely (Fig.33). 
 
 
 
 
 
 
 
 
 
Figure 33: Optimised multiplex PCR showing the amplification of ABCC1 
rs246221 (595bp) and ABCC2 rs17222723 (761bp) performed using a 
Touchdown PCR at 60°C with the addition of glycerol and visualized by agarose 
gel electrophoresis. Patient DNA was amplified in a multiplex PCR for ABCC1 
rs246221 (595bp) and ABCC2 rs17222723 (761bp) and were electrophoresed at 
110V for 1.5 hours on a 2.5% (w/v) agarose gel (Seakem® LE Agarose, Lonza, 
USA); MWM = GeneRulerTM 100bp Plus DNA Ladder (ThermoScientific, USA); 
NTC = no template control 
 
 
 
1: MWM           10: 227 
2: 219           11: 228 
3: 220           12: 229 
4: 221           13: 230 
5: 222           14: 231 
6: 223           15: 232 
7: 224           16: 233 
8: 225           17: NTC 
9: 226 
              
 
 
 
 
1: MWM           10: 162 
2: 154           11: 163 
3: 155           12: 164 
4: 156           13: 165 
5: 157           14: 166 
6: 158           15: 167 
7: 159           16: 168 
8: 160           17: NTC 
9: 161 
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4.6 Genotyping 
4.6.1 Optimisation of the SNaPshot® Multiplex System 
Multiplex PCRs were optimised for genotyping using the SNaPshot® System 
(ThermoFisherScientific, Applied Biosystems, USA). Patient ACT 107.1NOM was 
genotyped for both HNMT rs17583889 and ABCC2 rs8187710 and found to be a C/C 
homozygote and a G/A heterozygote respectively (Fig.34).  
 
Figure 34: Electropherogram illustrating determination of genotypes for both 
HNMT rs17583889 (black peak C/C) and ABCC2 rs8187710 (blue and green 
peaks G/A) derived from GeneMapper (version 4.1 using the ABI3130xl Genetic 
Analyzer (Applied Biosystems, USA). The orange peak indicates the 
GeneScan™ 120 LIZ® Size Standard (35 nt). 
Patient ACT 257.1ANN was genotyped for both NCF4 rs1883112 and RAC2 
rs13058338 and found to be a G/A heterozygote and an A/T heterozygote respectively 
(Fig.35).  
 
Figure 35: Electropherogram illustrating determination of genotypes for both 
NCF4 rs1883112 (blue and green peaks G/A) and RAC2 rs13058338 (green and 
red peaks A/T) derived from GeneMapper (version 4.1 using the ABI3130xl 
Genetic Analyzer (Applied Biosystems, USA). The orange peak indicates the 
GeneScan™ 120 LIZ® Size Standard (35 nt) 
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Patient ACT 200.1KAR was genotyped for both ABCC1 rs246221 and ABCC2 
rs17222723 and found to be a G/A heterozygote and an A/T heterozygote respectively 
(Fig.36).  
 
Figure 36: Electropherogram illustrating determination of genotypes for both 
ABCC1 rs246221 (blue and green peaks G/A) and ABCC2 rs17222723 (green and 
red peaks A/T) derived from GeneMapper (version 4.1 using the ABI3130xl 
Genetic Analyzer (Applied Biosystems, USA). The orange peak indicates the 
GeneScan™ 120 LIZ® Size Standard (35 nt) 
4.6.2 Optimisation of the TaqMan™ SNP Genotyping Assay 
The concentration and integrity of the control DNA was adequate (124ng/ul) for the 
optimisation of the assay (Appendix H, Fig. 2). The assay was optimised by the 
utilization of varying concentrations of DNA to delineate the optimal volume of DNA 
needed for a distinct genotype to be called. 
 
Control DNA Sample (C35F) was genotyped as a heterozygote (A/G) indicated by the 
blue arrow in Figure 37. The optimal volume was determined to be 2-3ul at a 
concentration of 100ng/ul. 
 
 
Figure 37: Quantification & Allelic Discrimination Plots generated from the 
CFX™ Real-Time PCR Detection System together with the TaqMan™ Genotyper 
Software 
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4.6.3 Genotyping of patient samples 
Nineteen SNPs in fifteen genes, described in Table 7, were selected using a 
candidate gene approach. However, only seven SNPs were interrogated for all patient 
samples: ABCC1 rs246221; ABCC2 rs17222723; ABCC2 rs8187710; HNMT 
rs17583889; NCF4 rs1883112, RAC2 rs13058338 and RARG rs2229774. 
Genotypes were derived for the following number of patients: ABCC1 rs246221 
(n=270), ABCC2 rs17222723 (n=260), ABCC2 rs8187710 (n=267), HNMT 
rs17583889 (n=250), NCF4 rs1883112 (n=259), RAC2 rs13058338 (n=271) and 
RARG rs2229774 (n=273). 
4.6.4 Validation Sequencing 
Genotyping results were validated using Sanger sequencing and 5% of the entire 
selection of seven SNPs were sequenced. Statistical significance is achieved when 
p<0.05 therefore 5% was used as a threshold for validation sequencing. 
Electropherograms derived from the genetic analyser were assessed for accuracy of 
sequencing and to validate variants found when carrying out SNP genotyping (Fig. 
38). 
 
Figure 38: Representation of electropherogram (top panel), sequence coverage 
(middle panel) and sequence (bottom panel) derived from Sanger sequencing 
conducted to validate SNaPshot® genotyping assay results. Patient 249.1JAN’s 
genotyping results obtained from the SNaPshot® genotyping assay was 
validated using Sanger/Direct Cycle sequencing. The arrow on the top and 
middle panel show the location of the SNP for ABCC2 rs8187710 (572bp), Y 
indicates a heterozygote (C/T) 
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The genotyping primer designed for the SNaPshot® Assay for the detection of the 
ABCC2 rs8187710 variant was in the forward direction with expected genotypes of 
GG/GA/AA however since the reverse PCR primer was found to be optimal for 
sequencing, the resulting electropherogram trace and sequence (Fig.38) was reverse 
complemented. Therefore Patient 249.1JAN’s genotype according to SNaPshot® 
was G/A which translates to C/T which was obtained by confirmatory sequencing. 
Each region of amplification and SNP was confirmed to be correct by the utilisation of 
the nucleotide basic local alignment search tool (BLAST) 138.  
The context sequence (Fig.39) was correlated to the reverse complement sequence 
that was already amplified (Fig.38). 
 
 
Figure 39: Representation of nucleotide blast results for ABCC2 rs8187710 
validating both the target gene and corresponding SNP 
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4.7 Statistical Analysis 
4.7.1 Genotype and Allele frequencies 
Genotype counts and minor allele frequencies for each of the seven SNPs are listed 
in Table 34.  
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Table 34: Distribution of genotypes and minor allele frequencies for seven SNPs focusing on differences in population groups 
Gene 
Variants 
 **Genotypic Distribution  Minor Allele Frequencies P value# P value≠ 
 
P value+ 
 Lit81 All IA MA Caucasian Lit81 All IA MA Caucasian    
              
ABCC1 
rs246221 
934/1013/557 80/123/67 6/19/22 68/100/45 6/4/0 0.42 0.48 0.67 0.45 0.2 0.0737 
<0.0001* 
0.6951 
0.1275 
0.0009* 
ABCC2 
rs17222723 
2321/179/4 201/54/5 34/11/1 158/42/4 9/1/0 0.04 0.12 0.14 0.12 0.05 <0.0001* 
<0.0001* 
<0.0001* 
0.9566 
0.0352* 
ABCC2 
rs8187710 
2181/306/17 153/98/16 19/23/4 125/74/12 9/1/0 0.07 0.24 0.34 0.23 0.05 <0.0001* 
<0.0001* 
<0.0001* 
0.9508 
0.0285* 
HNMT 
rs17583889 
1922/516/66 206/29/15 41/0/2 157/28/13 8/1/0 0.13 0.12 0.05 0.14 0.06 0.7682 
0.0741 
0.9241 
0.6474 
0.0152* 
NCF4 
rs1883112 
938/1059/507 124/91/44 30/14/1 91/73/40 3/4/3 0.41 0.35 0.18 0.38 0.5 0.0106* 
<0.0001* 
0.3068 
0.7378 
0.0009* 
RAC2 
rs13058338 
1794/91/619 200/65/6 42/5/0 152/57/5 6/3/1 0.16 0.14 0.05 0.16 0.25 0.5561 
0.0192* 
0.9831 
0.5488 
0.0113* 
RARG 
rs2229774 
2101/367/36 217/49/5 40/7/0 168/41/5 9/1/0 0.09 0.11 0.07 0.12 0.05 0.4798 
0.9043 
0.0921 
0.8379 
0.0226* 
              
# = p-value derived from a chi-square test with a 95% confidence interval where the MAFs of all the SNPs under investigation were compared to the MAFs of these SNPs reported in the 
literature; ≠ = p values derived from a Chi-square test with 95% confidence interval where the MAFs of each population group was compared to literature; += p values after 2-way ANOVA 
with 95% confidence interval to determine whether population group MAFs are significantly different to each other  
**Genotypic Distribution: Ratios indicate homozygous major/ heterozygous/ homozygous minor allele 
106 
 
Table 34 shows that the ABCC2 rs17222723, ABCC2 rs8187710 and NCF4 
rs1883112 polymorphisms had minor allele frequencies (MAF) in our patient cohort 
that were statistically different from literature. The MAFs of all the SNPs were 
statistically different when compared between the three population groups with the 
MAFs for IAs for the following SNPs: ABCC1 rs246221, ABCC2 rs17222723, ABCC2 
rs8187710, NCF4 rs1883112 and RAC2 rs13058338 all being significantly different 
from the literature. Only ABCC2 rs17222723 and ABCC2 rs8187710 in the MA 
population were statistically significant from literature with none of the variants in the 
CA cohort being statistically different to literature.  
Hardy-Weinberg calculations indicated that both HNMT rs17583889 and NCF4 
rs1883112 are not in Hardy-Weinberg equilibrium whereas all the other SNPs that 
were included in the final analysis were in HWE (Table 35). 
Table 35: Patient population allele frequencies and Pearson’s Chi-Square test 
for HWE 
*simulated p-value based on 1000 replicates using R 
Both the D’ and r2 values were used to interpret LD – ABCC2 rs8187710 and ABCC2 
rs17222723 indicate that there was very little to no recombination between markers 
(D’=0.954) and that they were in fairly strong LD (r2=0.414). The other variants 
analysed showed some degree of recombination and very weak LD (Table 36). 
 
 
Gene Variant Alleles Allele Frequency HWE Χ2 value p-value* 
     
ABCC1 rs246221 
A 0.52 
2.61 0.12 
G 0.48 
ABCC2 rs17222723 
A 0.88 
1.01 0.4 
T 0.12 
ABCC2 rs8187710 
G 0.76 
0.01 1 
A 0.24 
HNMT rs17583889 
C 0.88 
36.86 9.99e-05 
A 0.12 
NCF4 rs1883112 
G 0.65 
12.71 4e-04 
A 0.35 
RAC2 rs13058338 
A 0.86 
0.03 1 
T 0.14 
RARG rs2229774 
G 0.89 
1.25 0.34 
A 0.11 
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Table 36: Testing for LD of genetic variants using R 101 and the SHESIS Program 
132  
Pairwise LD LD Test  
Variant 1 Variant 2 D’ Χ2 p-value N r2 
rs17583889 rs8187710 0.451 4.216 0.04* 248 0.009 
rs17583889 rs1883112 0.129 1.970 0.16 236 0.004 
rs17583889 rs13058338 0.318 1.101 0.29 247 0.002 
rs17583889 rs246221 0.143 1.192 0.27 246 0.002 
rs17583889 rs17222723 0.152 0.210 0.65 240 0.000 
rs17583889 rs2229774 0.124 7.125 0.008* 248 0.015 
rs8187710 rs1883112 0.310 8.066 0.005* 251 0.016 
rs8187710 rs13058338 0.180 0.930 0.34 263 0.002 
rs8187710 rs246221 0.160 4.746 0.03* 263 0.009 
rs8187710 rs17222723 0.954 212.547 0 257 0.414 
rs8187710 rs2229774 0.0180 0.007 0.93 265 0.000 
rs1883112 rs13058338 0.106 1.870 0.17 257 0.004 
rs1883112 rs246221 0.121 3.574 0.05* 255 0.007 
rs1883112 rs17222723 0.151 0.848 0.36 245 0.002 
rs1883112 rs2229774 0.176 3.740 0.05* 257 0.007 
rs13058338 rs246221 0.004 0.002 0.97 267 0.000 
rs13058338 rs17222723 0.026 0.307 0.58 257 0.001 
rs13058338 rs2229774 0.040 0.620 0.43 269 0.001 
rs246221 rs17222723 0.225 4.170 0.04* 259 0.008 
rs246221 rs2229774 0.116 0.959 0.33 269 0.002 
rs17222723 rs2229774 0.011 0.052 0.82 259 0.000 
 
All seven SNPs were utilised to generate both an LD plot and haplotype analysis 
(Fig.40). Figure 40 shows that cumulatively all the SNPs are not in strong LD and not 
inherited as a single haplotype. 
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Figure 40: LD plot (A) and Haplotype analysis (B) generated by the SHEsis 
program 132 using all seven SNPs 
 
4.7.2 Association testing  
Patient status was significantly associated with RARG rs2229774 (p=0.049, Chi-
square test; p=0.05, Fisher’s exact test). No association was found between patient 
status and other variants - ABCC1 rs246221 (p=0.56), ABCC2 rs17222723 (p=0.95), 
ABCC2 rs8187710 (p=0.44), HNMT rs17583889 (p=0.18), NCF4 rs1883112 (p=0.28) 
and RAC2 rs13058338 (p=0.53). 
The more accurate logistic regression was used to determine whether any of the 
variants predicted clinical status. As previously mentioned, logistic regression was 
found to be better suited to our needs due to its ability to model the determinants of 
and predict the likelihood of an outcome compared to descriptive correlation for which 
chi-square tests are most apt. None of the SNPs showed any significant association 
with patient clinical status (Table 37). 
Severity score was significantly associated with ABCC2 rs8187710 (p=0.004, Chi-
square test) and ABCC2 rs17222723 (p= 0.006, Chi-square test). However no 
association was found between patient severity score and other variants - ABCC1 
rs246221 (p=0.21), HNMT rs17583889 (p=0.72), NCF4 rs1883112 (p=0.07) RAC2 
rs13058338 (p=0.89) and RARG rs2229774 (p=0.66). 
Logistic regression models were computed firstly for genotype related to the outcome 
of status and then genotype together with total dose related to the outcome of clinical 
status. 
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Table 37: Logistic Regression Co-efficients used to determine Odds Ratios 
using Genotype to Predict Outcome 
Covariates Test Statistic Odds Ratio^ p-value 
    
HNMT rs17583889 C/A 
HNMT rs17583889 C/C 
-0.014 2.19e-07+ 0.989 
-0.015 1.17e-.07+ 0.988 
    
ABCC2 rs8187710 G/A 
ABCC2 rs8187710 G/G 
1.055 
1.98          
(0.49-6.65) 
0.291 
1.261 
2.20        
(0.57-7.05 
0.207 
    
NCF4 rs1883112 G/A 
NCF4 rs1883112 G/G 
0.671 
1.46          
(0.46-4.35) 
0.502 
-0.572 
0.75        
(0.26-1.9) 
0.568 
    
RAC2 rs13058338 A/T 
RAC2 rs13058338 T/T 
-1.105 
0.65        
(0.31-1.43) 
0.269 
-0.286 
0.73        
(0.11-14.23) 
0.775 
    
ABCC1 rs246221 A/G 
ABCC1 rs246221 G/G 
-1.037 
0.64        
(0.26-1.45) 
0.300 
-0.368 
0.83        
(0.31-2.26) 
0.713 
    
ABCC2 rs17222723 A/T 
ABCC2 rs17222723 T/T 
-0.235 
0.90        
(0.40-2.25) 
0.814 
-0.217 
0.78        
(0.12-15.34) 
0.828 
    
RARG rs2229774 G/A 
RARG rs2229774 G/G 
-0.012 1.5e-06+ 0.990 
-0.014 3.2e-07+ 0.989 
    
^odds ratios with 95% CI; +sample size too small to compute 95% CI 
Odds ratios indicate that despite the genotype, total dose had a statistically significant 
contribution to the outcome of clinical status (Table 38).  
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Table 38: Logistic Regression Co-efficients used to determine Odds Ratios 
using Genotype and Dose Covariates 
Covariates Test Statistic Odds Ratio^ p-value 
    
HNMT rs17583889 and Total 
Dose 
2.430 1.002    
(1.0006-1.004) 
0.015* 
    
ABCC2 rs8187710 and Total 
Dose 
2.553 
1.002      
(1.0005-1.004) 
0.011* 
    
NCF4 rs1883112 and Total Dose 2.163 1.002   
(1.0003-1.004) 
0.031* 
    
RAC2 rs13058338 and Total 
Dose 
2.363 1.002     
(1.0004-1.004) 
0.018* 
    
ABCC1 rs246221 and Total 
Dose 
2.355 1.002     
(1.0004-1.004) 
0.019* 
    
ABCC2 rs17222723 and Total 
Dose 
2.433 
1.002   
(1.0004-1.004) 
0.015* 
    
RARG rs2229774 and Total 
Dose 
2.247 1.002   
(1.0003-1.004) 
0.025* 
    
*statistically significant; ^odds ratios with 95% CI 
The genetic models of variants was examined in the context of their allelic frequency 
and contribution to outcome (affected cardiac status due to ACT) in Table 39. 
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Table 39: Overview of genetic variants, their genetic model and contribution to 
phenotype 
Gene 
Variants 
Minor 
Allele 
Frequency 
p-value# Covariates 
Odds 
Ratio 
p-
value
^ 
Type of 
Genetic 
Model 
 Lit Stud
y 
     
HNMT 
rs17583889 
0.13 0.12 0.7682 
HNMT rs17583889 
C/A 
2.19e-07 0.989 
Multifactorial/
Polygenic HNMT rs17583889 
C/C 
1.17e-07 0.988 
ABCC2 
rs8187710 
0.07 0.24 <0.0001* 
ABCC2 rs8187710 
G/A 
1.98 0.291 
Multifactorial/
Polygenic ABCC2 rs8187710 
G/G 
2.20 0.207 
NCF4 
rs1883112 
0.41 0.35 0.0106* 
NCF4 rs1883112 G/A 1.46 0.502 Multifactorial/
Polygenic NCF4 rs1883112 G/G 0.75 0.568 
RAC2 
rs13058338 
0.16 0.14 0.5561 
RAC2 rs13058338 
A/T 
0.65 0.269 
Multifactorial/
Polygenic RAC2 rs13058338 
T/T 
0.73 0.775 
ABCC1 
rs246221 
0.42 0.48 0.0737 
ABCC1 rs246221 A/G 0.64 0.300 Multifactorial/
Polygenic ABCC1 rs246221 G/G 0.83 0.713 
ABCC2 
rs17222723 
0.04 0.12 <0.0001* 
ABCC2 rs17222723 
A/T 
0.90 0.814 
Multifactorial/
Polygenic ABCC2 rs17222723 
T/T 
0.78 0.828 
RARG 
rs2229774 
0.09 0.11 0.4798 
RARG rs2229774 G/A 1.5e-06 0.990 
Multifactorial/
Polygenic 
RARG rs2229774 
G/G 
3.2e-07 0.989 
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Chapter 5: Discussion  
5.1 Summary of Main Findings 
“Anthracycline-induced cardiotoxicity, while dose-dependent, may be attributed to 
inherent genetic differences in treated patients” was the thesis statement specified at 
the beginning of the study. This study sought to discover differences between treated 
patients to allow for the minimisation of cardiotoxicity due to anthracycline-based 
chemotherapy.  
The risk of ACT has been estimated, according to GLOBOCAN, at 10-26% 15. The 
retrospective (79/402=19.7%) and prospective cohorts (38/272=14%) in the present 
study showed that approximately 17.35% of patients here in the Western Cape were 
likely affected with ACT. This incidence of ACT may be an underestimation since 
some patients with initial subclinical damage may later progress to irreversible cardiac 
damage and subsequent symptoms 17, and perhaps not be related back to their 
chemotherapy. The extent to which different population groups were affected with 
ACT seemed distinguishable – IAs had the highest overall incidence of ACT (20% 
and 19%), MA patients had a relatively lower incidence (19.8% and 13%) and CA 
patients had the lowest overall incidence of ACT (16.7% and 10%), in both the 
retrospective and prospective cohorts, respectively. Therefore, patient risk with regard 
to clinical co-morbidities were investigated. 
Clinical co-morbidities such as hypertension, diabetes, cardiac disease and smoking 
have previously been associated with increased risk of developing ACT 10,24,48. In the 
retrospective and prospective cohorts, the incidence of hypertension was the highest 
(40% and 43%, respectively) with pre-existing cardiac disease (5% and 7%, 
respectively) having the lowest incidence. These clinical co-morbidities were stratified 
into population group in both the retrospective and prospective cohorts; MA patients 
had the highest overall risk of developing ACT due to clinical co-morbidities with IA 
patients having a fairly low to low risk. Therefore, these risk factors were not predictive 
of the outcome of ACT. 
Previously, the type of anthracycline-based chemotherapy and dose were reported to 
be associated with ACT and therefore investigated in the Cape Town cohort 24,25,46,51. 
Patients in both cohorts were analysed for type and dose of anthracycline and it was 
found that in the retrospective cohort, CA patients were most likely to be prescribed 
doxorubicin and at higher median doses compared to their MA counterparts whereas 
in the prospective cohort, both MA and IA patients were prescribed doxorubicin at 
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higher median doses compared to their CA counterparts. Logistic regression showed 
that both type and dose of anthracyclines were significantly associated with ACT for 
both the retrospective and prospective cohorts. 
The motivation for the investigation of  genetic variants associated with 
susceptibility/resistance to ACT was for a range of reasons which included: that  ACT 
was evident at different incidences in the three local populations of  cancer patients 
receiving anthracycline-based chemotherapy; (ii) previous literature indicating 
pharmacogenetic association with ACT ; and (iii) evidence of IA women being more 
susceptible to cardiotoxicity due to ethnically variant polymorphisms pertinent to 
anthracycline metabolism 6-8,139,140. 
Prospectively recruited patients (n=272) were genotyped for seven SNPs: ABCC1 
rs246221; ABCC2 rs17222723; ABCC2 rs8187710; HNMT rs17583889; NCF4 
rs1883112: RAC2 rs13058338 and RARG rs2229774. A simple illustration of genetic 
diversity between the three local populations was evident from statistically significant 
differences of the MAFs for these markers when compared to literature – while the 
local CA patients showed no significant differences, the MA patients had 2 SNPs 
(ABCC2 rs17222723 and ABCC2 rs8187710) and the IA patients had 5 SNPs 
(ABCC1 rs246221, ABCC2 rs17222723, ABCC2 rs8187710, NCF4 rs1883112 and 
RAC2 rs13058338) with significantly different allele frequencies compared to that 
reported (generally for CA) in the literature. Furthermore, SNPs interrogated in the 
patient population had shown previous association to ACT however the only SNP that 
showed an association with patient clinical ACT status was RARG rs2229774, which  
corroborated an earlier Canadian GWAS investigating ACT in childhood cancer 7. This 
significance however was lost when the more robust logistic regression to predict 
outcome was applied.  
5.2 Retrospective Cohort Analysis 
Data analysis was performed on the entire cohort (n=402) and stratified into the local 
population groups. The recruitment sites, two government hospitals in Cape Town, 
South Africa, were attended by predominantly individuals of MA and to a lesser 
degree, IAs and CA individuals. MA refers to an admixed population of origins as 
diverse as European (including Dutch, French, German and English), Asian and 
indigenous Khoisan, whereas IA refers to a population group of native or indigenous 
Africans with various ethnicities such as Zulu and Xhosa, and CA refers to a 
population group of European origin, mentioned earlier 141. Not only does population 
stratification improve accuracy for larger scale association studies, but it may also aid 
114 
 
in delineating extreme phenotypes due to the unique genotypes of the constituent 
local populations 6,142. 
There were only seven males in this cohort – this was due to the fact that they are 
only rarely affected with breast cancer, the prevalence is reported to be approximately 
1% in the literature 14,34. 
Additional demographic factors such as age and BSA were analysed. While the 
overall median age at diagnosis for this cohort was 51 years, which was in agreement 
with South African Census statistics 143, this is comparatively younger than the 
published worldwide statistics of 65 years and older 15. The IA cohort had a median 
age of only 44 years. Young age at diagnosis in the IA patient cohort may be attributed 
to a range of factors which is outside of the scope of this research but may include 
risk factors such as delayed onset of childbirth and genetic influences where 
hereditary factors such as BRCA1/2 mutations (amongst those in other genes) may 
be a contributing factor 144,145. Similarly, BSA and by extension, body mass index 
(BMI), were found to be consistently higher than normal especially in the MA and IA 
sub-cohorts which may be attributed to two possibilities – i) ethnic differences in body 
form for local populations that do not correlate with worldwide standards, therefore 
making a universal cut-off value inapplicable, and/or ii) the possibility of the adoption 
of an unhealthier lifestyle due to e.g. urbanisation  and modernization 146,147. 
Clinical co-morbidities such as hypertension, diabetes, cardiac disease and smoking, 
shown to increase the risk of developing ACT previously, were also investigated. 
Logistic regression models based on our retrospective data did not substantiate these 
findings 24,26,36,148. Nevertheless, both MA and IA patients had higher rates of these 
co-morbidities compared to their CA counterparts which may indicate shared risk 
factors (including genetic) in these two groups (i.e. MA and IA) resulting in greater 
susceptibility to certain lifestyle-induced diseases, or perhaps due to inadequate 
access to healthcare due to socioeconomic circumstances.  
Risk factors such as type and dose of anthracycline were also assessed. The 
anthracyclines, doxorubicin and epirubicin, have different safety profiles. Due to a 
shorter terminal half-life and more rapid total body clearance 22,26,30, epirubicin is 
considered “safer” and given at increased doses. However, our analysis shows that 
neither of these agents are entirely safe – 138 patients were treated with doxorubicin 
and 37 were affected (27%) compared to 264 patients treated with epirubicin, 42 of 
whom were affected (16%). This relative (minimal) improvement (i.e. 16% versus 
27%) in ACT-affectation status warrants the investigation of alternatives such as 
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liposomal-encapsulated anthracyclines or the parallel provision of a cardio-protectant 
75,76,98. 
Patients’ clinical status in terms of ACT was either ‘affected’ or ‘unaffected’ based on 
numerous factors which included LVEF decline. It emerged that IAs at 20% may be 
marginally more susceptible compared to MA at 19.8%, with Caucasians at 16.7% 
being the relatively least susceptible. Previous evidence of ethnically variant 
polymorphisms that influence doxorubicin pharmacokinetics and pharmacodynamics 
suggest that population-based differences may be expected 6,139,140. 
Although relied on heavily in this study, LVEF, as a measure of cardiac function may 
prove to be unreliable, whereby 56/402 patients (14%) had significant decreases in 
LVEF (≥10%) yet only seven out of the 56 patients exhibited clinical signs and 
symptoms of cardiac dysfunction. Conversely, 79/402 patients (20%) were deemed 
to be clinically “affected” post-treatment (i.e. exhibiting signs of cardiac 
dysfunction/impairment) – however, only 56 out of the 79 patients had significant 
LVEF decline – a failure rate of 29%, indicating that LVEF may be ineffective as  both 
an early and sensitive measure of cardiac dysfunction, specifically ACT. Despite 
LVEF being the widely accepted measure of cardiac function, it’s lack of sensitivity 
and inherent variability has been mentioned previously 149,150 and other alternatives 
such as the measurement of global longitudinal strain as a more sensitive and 
reproducible prognostic indicator of ACT has been suggested 69,151. 
Therefore, in this study, the “unaffected” status of patients was not deemed definitive 
without an echocardiography to provide confirmation. Some measure of association 
could be lost due to the potential inaccuracy in phenotyping. In trying to circumvent 
this issue and provide clarity, the severity score or classifier was developed based on 
previous literature (CTCAE grading) and the clinical phenotype of the cohort 51-54,152. 
Logistic regression models developed using retrospective patient data pointed to the 
following factors contributing to the final phenotype: hypertension, smoking, type of 
chemotherapy (i.e. total dose of anthracyclines:  either doxorubicin, or epirubicin), and 
the change in LVEF from baseline to after chemotherapeutic administration, which 
have all been previously indicated 24,51,87,148. However, in a multivariable model, the 
only factor that showed robustness was the LVEF decline – nevertheless this still does 
not indicate its utility as an early indicator of cardiotoxicity as LVEF decline was used 
for determining clinical status and the severity score of patients. 
ANOVA type II tests showed that pre-chemo LVEF combined with population group 
contributed to the post-chemo LVEF measure which may indicate that different LVEF 
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ranges for different population groups may be more accurate in determining cardiac 
clinical status. Furthermore, when the pre-chemo LVEF was combined with severity 
score, population group and type of first-line chemotherapy, a fairly robust model of 
prediction of post-chemo LVEF emerged. This may have utility in financially-
constrained hospital settings where only one measure of LVEF (pre-chemo) is 
possible. 
5.3 Prospective Cohort Analysis 
Anthracycline-naïve patients (n=272) were prospectively recruited from both GSH and 
TBH Hospitals in the Western Cape Province of South Africa.  
Similar to the retrospective cohort analysis, patient clinical histories were extensively 
analysed. Infiltrating or invasive ductal carcinoma was found to be most frequently 
diagnosed in both cohorts (71% of the entire cohort), in accordance with worldwide 
statistics 153.The median age of diagnosis in this cohort was 50 years with the IA 
cohort again being significantly younger (44 years) compared to both the MA (51 
years) and CA (59 years) patients. The BSA of this cohort was also higher and in this 
instance, to a greater degree for IA (1.81m2) and CA (1.84m2) compared to their MA 
counterparts (1.74m2) (See Table 30). Age at diagnosis and BSA are similar to the 
trends observed in the retrospective patient cohort.  
While the retrospective cohort showed a high number of patients with unknown HIV 
status, the prospective cohort showed a higher proportion of IA women (43%) with 
HIV. This may reveal easier accessibility and increased testing which is useful for 
patient care and management. However, the differential between HIV positivity in the 
cohort (43%) and the general reported incidence of 18% in this  province is worthy of 
note154.  
The co-morbidities present in this cohort, which include hypertension, diabetes 
mellitus, cardiac disease and smoking status provided interesting insights when they 
were analysed within the population groups. IA patients were, on average, younger, 
but they were also found to be at the lowest risk for hypertension, diabetes and 
smoking. However, baseline cardiac incidental findings were highest in this group 
(13%). These cardiac incidental findings could be attributed to poor previous clinical 
care and subsequent subclinical cardiac dysfunction and/or the increased genetic 
likelihood of cardiac insufficiency 155,156. 
Incidental cardiac findings were both of interest and a confounding factor that could 
not be disregarded as they had a bearing on the outcome phenotype (cardiac status). 
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These findings ranged from the more serious left ventricular hypertrophy where ACT 
would be potentially greatest, to the lesser but still serious rhythm abnormality. 
Despite this, LVEF for all these patients were ‘normal’ allowing for treatment to be 
initiated – only one patient had an inconclusive LVEF measure and this was 
presumably in response to rhythm abnormality. 
The patient standard of care at the beginning of the study included LVEF 
measurement at both baseline (before chemotherapy) and again after three or four 
cycles of chemotherapy. However, protocol changes due to change in management 
and an overburdened healthcare system resulted in only one LVEF measurement 
(baseline) recorded for a number of the prospective cohort (68%). Furthermore, 
patient overload on the Department of Nuclear Medicine at TBH and GSH resulted in 
some patients without any LVEF measure. Chemotherapy was administered 
regardless of cardiac status (either before or after treatment) as the treatment was 
deemed to be of greater need i.e. to treat cancer compared to the potential danger of 
cardiotoxicity. This, of note, is the standard of care in most public hospitals in the 
country. 
However, the number of cardiac incidental findings in seemingly healthy patients 
(Table 32) at baseline together with significant rates of post-chemotherapy affected 
(ACT) patients (exhibiting signs of cardiotoxicity) emphasises the need for instituting 
effective measures of cardiac function and, specifically, repeated measures of LVEF. 
The model of prediction of post-chemotherapy LVEF was developed using 
retrospective patient data – notably the following variables: pre-chemotherapy LVEF, 
severity score, population group and type of first-line chemotherapy. This statistical 
model was validated in prospective patients (n=87) with no missing variables and 
allowed for a fairly utilizable estimation of post-chemotherapy LVEF with an accuracy 
of 82%. The prediction of post-chemotherapy LVEF could allow for the change in 
LVEF and subsequent clinical cardiac status (i.e. dysfunction/impairment) to be 
ascertained. This predictive model could be utilised in patients with missing secondary 
LVEF measures (post-chemotherapy LVEF) for improved patient outcomes and may 
ultimately warrant further development. 
There were 14% affected individuals in this cohort. However this may be an 
underestimation due to the likelihood of subclinical damage which can manifest later 
and both LVEF measure and clinical symptoms may not be indicative at the stage that 
patients were being assessed 56,58,106. Nevertheless, IAs may have an increased risk 
of ACT as they were proportionally most affected (19%) compared to MA (13%) and 
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CA (10%), which is also in agreement with the retrospective cohort findings and the 
literature 6,140. 
After patient history, and patient status regarding ACT, genotyping of patient DNA 
was undertaken for an association study.  Firstly, SNP MAFs for each population 
group were compared to MAFs (Reference population: ALL) derived from both dbSNP 
and Ensembl 81. The allelic frequencies of five  SNPs (ABCC1 rs246221, ABCC2 
rs17222723, ABCC2 rs8187710, NCF4 rs1883112 and RAC2 rs13058338) in IAs and 
two SNPs (ABCC2 rs17222723 and ABCC2 rs8187710) in MA patients were 
significantly different compared to literature and Ensembl 81 reiterating the need for 
the inclusion of African and/or local populations in worldwide databases 157. The MAFs 
of the investigated SNPs for the CA patients in this study were in accordance with the 
MAFs reported in both Ensembl and dbSNP (Population: ALL). Secondly, Hardy-
Weinberg Equilibrium calculations were conducted and two SNPs – HNMT 
rs17583889 and NCF4 rs1880112 were found not to be in Hardy-Weinberg 
Equilibrium in the cohort. While genotyping error is an improbable reason for these 
deviations (as confirmed by Sanger sequencing), the relatively small cohort size may 
explain this deviation. 
The variant, RARG rs2229774 was found to have a strong association with 
anthracycline-induced cardiotoxicity in a genome-wide association study conducted 
by Aminkeng et al. 7 on childhood cancer patients of both European and non-
European (including Asian, African-American and Hispanic) ancestry assessing 
cardiac function using the CTCAE grading and ECHO measures. The present study 
also found a statistically significant association of RARG rs2229774 with clinical 
status pertaining to ACT (Chi-square test, p=0.049). However, the more accurate 
logistic regression models found no association with this variant or any of the other 
variants and ACT status.  
ABCC1 rs246221 was not associated with clinical status pertaining to ACT in this 
study, however a previous study by Semsei et al. 158 found this variant to be 
associated with anthracycline-induced left ventricular dysfunction in Hungarian 
paediatric patients with acute lymphoblastic leukaemia. Aside from a different 
population and the use of ECHOs to show diminished cardiac function, patients were 
followed for a median of 6.3 years. Therefore the lack of association of this variant 
with ACT in our study may indicate that it would be worth following up on our patients 
longer term, and assessing for ACT (our patients were only followed for 1-3 years). 
Similarly, Vulsteke et al. 159 found ABCC1 rs246221 to be associated with an LVEF 
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decline of >10% in a European CA cohort of breast cancer patients treated with 
epirubicin and followed for a median of 3.62 years. While our study cohort had breast 
cancer patients, treatment with epirubicin and the outcome of LVEF decline >10%, 
our cohort consisted of mostly African-derived populations.  
Wojnowski et al. 8 found the variants NCF4 rs1883112, RAC2 rs13058338 and 
ABCC2 rs8187710 to be associated with ACT in a German patient population treated 
with anthracyclines for non-Hodgkin lymphoma (NHL), and followed up for a median 
of more than  three years, where arrhythmias and cardiac failure were classified as 
acute and chronic ACT, respectively. Again the divergent European-based population 
and longer follow up time may explain the lack of association with these variants and 
ACT in the present study. Similarly, Leong et al. 105 found an increased risk of ACT 
associated with RAC2 rs13058338 and ABCC2 rs8187710. 
The variant, ABCC2 rs17222723, had been previously associated with acute 
cardiotoxicity 83,137,160 due to its role in drug transportation of cytotoxic agents into and 
out of the cell. However, the present study failed to find an association between this 
SNP and cardiotoxicity despite its sensitivity to acute ACT. 
Similarly, the variant HNMT rs17583889, was found to have an association with ACT 
in Canadian paediatric cancer patients where cardiac function was assessed using 
both CTCAE guidelines and ECHOs 10. However, in the current study of adult women, 
this variant showed no association with ACT and this may be explained by not only 
ancestry of the population compared to our cohort but also that paediatric cases may 
have greater susceptibility to cardiac damage due to the developing heart. It has been 
shown that paediatric hearts have inadequate compensatory mechanisms for 
cardiomyocyte loss allowing cardiac damage from anthracyclines to be potentially 
progressive thereby resulting in significant morbidity and/or mortality 161. 
Furthermore as suggested in the Aminkeng et al.6 article, genetic differences in key 
genes in African populations may account for increased sensitivity to both ACT and 
CHF. Differences in MAF as shown in the study between IA patients and literature 
illustrates these genetic dissimilarities. Beyond the variants discussed in this study, 
Aminkeng et al.6 showed that CYP enzymes’, involved in the metabolism of 40-60% 
of all drugs, varied expression due to genetic differences may contribute to 
predisposition to several ADRs and poor response rates in African compared to 
European populations. The pharmacogenomic heterogeneity of African populations 
across different ethnic groups and geographical regions may contribute to differences 
in drug efficacy and safety profiles. 
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Variables that appeared to increase the odds of the outcome (patient clinical status) 
included significant LVEF decline (>10%) and total anthracycline dose (p=9.9e-05 and 
p=0.0164, respectively). The logistic regression of a multivariable model with both 
these factors was found to have an odds ratio of 1.704 and a p-value of 0.000164 
thereby indicating a strong association of LVEF change and total anthracycline dose 
to level of cardiotoxicity (i.e. patient clinical status related to cardiotoxicity). Despite 
the inadequacy of LVEF as a sensitive measure of ACT, it has some utility in 
predicting the outcome of cardiotoxicity. Similarly, the dose of anthracycline, also 
predicts the outcome of cardiotoxicity – a finding that has been supported previously 
24,51,53. 
5.4 Study Limitations 
General limitations of the study were:  
i) relatively small sample size – despite the recruitment of 272 prospective patients, 
their population stratification may have decreased statistical power of certain 
associations;  
ii) short median follow-up – the study in fulfilment of a PhD with a finite completion 
period included the recruitment of prospective patients before anthracycline-based 
treatment as well as follow-up after treatment which may have been too short a 
timeframe to assess progressive late-onset ACT;  
iii) the lack of information pertaining to lifestyle factors such as stress and exercise 
which may have had a bearing on cardiac function and/or susceptibility to 
cardiotoxicity. For example, studies indicate that aerobic exercise may mitigate 
cardiovascular dysfunction 162,163;  
iv) lack of two LVEF measures for every  patient – despite the insensitivity of the LVEF 
measure in some instances, the lack of a second measure complicated patient 
phenotyping with regard to ACT;  
v) attributing differences in genotypes to self-reported ethnicity – which may decrease 
population-specific significance . Ancestry Informative markers may have been useful 
in delineating the different population groups rather than the reliance on self-reporting 
164. The limitation of attributing differences in genotypes to self-reported ethnicity is 
that it SNPs with population-specific significance may be lost or diluted in the sub-
cohorts (stratified according to population group). Furthermore, patient follow-up at a 
later stage could reveal late-onset ACT and therefore an affected case which may 
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contribute to non-associated SNPs finding statistical significance, particularly within 
the heterogeneous local population groups. 
5.5 Recommendations 
Despite the study’s focus on the development of ACT, other issues related to patient 
health emerged. The lack of HIV status in a significant fraction of the retrospective 
cohort, is a concern given that South Africa has one of the largest epidemics in the 
world 154. As was noted in the prospective cohort – up to 43% of women in the IA sub-
cohort were HIV positive.  Although not focused on in this thesis – HIV status or 
perhaps the status of an individual’s immune system (e.g. AIDs versus non-AIDs in 
HIV positive subset) may contribute to ACT-susceptibility, and makes for a reasonable 
follow-up project with public health relevance.   
In terms of managing ACT, patients with suspected or potential cardiotoxicity may be 
at a critical point whereby reversible cardiac damage may progress  to irreversible, 
chronic or sometimes life-threatening cardiomyopathy, yet few patients were referred 
to cardiology clinics for follow-up and confirmatory ECHOs 25,60. The inherent 
variability and lack of sensitivity of LVEF as a measure of cardiac function warrants 
the consideration of alternatives such as ECHOs or tissue-doppler imaging as a truer 
measure of cardiotoxicity. We therefore recommend routine ECHOs before and after 
chemotherapy as standard of care in the government setting for improved patient 
outcomes and decreased chronic cardiac care costs.  
5.6 Future Directions 
While this study provided valuable insights into the genetic heterogeneity of our 
African populations and their increased risk of developing ACT, this is merely a good 
starting point for future work.  
Confirmed affected and non-affected (normal) patients’ DNA may be utilised for 
GWAS to determine the nuances of their susceptibility to ACT. Patients will be 
stratified according to population group, confirmed by ancestry informative markers 
and their GWAS data analysed. 
Additional patients may be recruited with the aim of improving cardiac assessment – 
ECHOs before and after treatment as well as submitting patient samples to a panel 
of biomarkers. These patients cardiac status can then be correlated to genotyping for 
the SNPs discussed in this study. Furthermore, the model developed in this study 
may be validated using actual post-chemotherapy cardiac measures.  
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While a genotypic change provides information that may be pertinent to susceptibility 
or protection, the level of expression may confer to what extent this is the case. 
Quantitative PCR may provide valuable insight/s into expression of genes associated 
with ACT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
Chapter 6: Supplementary Study – Testing of Biomarkers as 
a Measure of Cardiac Injury 
6.1 Introduction: 
Cardiac biomarkers found in blood had been initially used to detect cardiotoxicity in 
animal models and in pilot clinical studies, however they have the potential to be a 
more accurate measure of early cardiotoxicity in the routine management of patients 
17,18,22,37,69. The advantages of biomarker assays is that they are standardized thereby 
minimizing technical variability to some extent, and they are also minimally invasive 
and easily repeated.  Serial monitoring of serum biomarker concentrations have been 
proposed as a more specific and sensitive modality of cardiotoxicity detection 24,69, 
perhaps in place of LVEF (and the means of currently measuring this parameter), as 
discussed earlier in the thesis. Biomarkers that are currently being utilised in the 
assessment and detection of cardiotoxicity include: natriuretic peptides, troponins, 
and the ST2 cardiac biomarker 161,165-167, which are reviewed hereunder 
6.1.1 Brain Type Natriuretic Peptide (BNP) 
Natriuretic peptides play an important regulatory role in cardiovascular (Fig. 41) and 
renal homeostasis, as well as fatty acid metabolism and subsequent maintenance of 
body weight 168. Natriuretic peptides belong to a group of structurally similar yet 
genetically heterogeneous peptide hormones, namely: atrial, brain and C-type (ANP, 
BNP, CNP respectively) 69,168.  
 
Figure 41: Natriuretic peptides involved in Cardiac Failure 169 
All three peptides (Fig. 42) contain a 17 amino acid disulphide ring with variable C 
and T terminal regions 170. 
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Figure 42: Natriuretic peptides ANP, BNP and CNP adapted from Suzuki et al 170 
Conserved residues are shaded and the amino acids are indicated by their 
single letter code 
Specifically, B-type natriuretic peptide (BNP) is a hormone involved in cardiac 
homeostasis (natriuresis, diuresis, vasorelaxation and inhibition of aldosterone and 
renin secretion) and is preferentially expressed in response to cardiac stress or injury 
which manifests as increased filling pressures and volume overload 168,171,172.  
The prohormone, proBNP is converted to an inactive N-terminal pro B-type natriuretic 
peptide (NT-proBNP) and the active BNP 173. Mature BNP consists of 108 amino 
acids, however BNP has a cleavable signal sequence allowing for variable BNP 
fragments in circulation 168.  
Elevated levels of NT-proBNP and BNP have been associated with CF and therefore 
have been previously used as a predictive marker of this phenotype (CF) 127,173-175. 
While the increased concentration of BNP is associated with CF, these levels may be 
sensitive to other factors such as patient age, gender, renal insufficiency and obesity 
127. Evidence shows that natriuretic peptide deficiencies may contribute to both 
hypertension and diabetes 164. Previous findings indicate an inverse correlation 
between BNP levels and obesity – therefore patients with diabetes may have lower 
BNP levels 127.  
Although data is limited, the literature indicates that ethnicity may have an effect on 
BNP levels 127. Krim et al. 127 found that both Asian and Black patients had higher 
median BNP levels compared to their Hispanic and CA counterparts. Conversely, 
Gupta et al. 164 found that  African American patients’ NT-proBNP levels were below 
the limit of detection, and that this was significantly lower independent of other factors. 
It was also found that lower NT-proBNP levels were associated with the male gender, 
higher BMI, heart rate, blood glucose and diastolic blood pressure whereas higher 
NT-proBNP levels were associated with increased age, smoking, beta-blocker use 
and systolic blood pressure 164. Furthermore, a genetic basis was used to associate 
ethnicity with NT-proBNP levels 164. Genetic polymorphisms in the NPBB and Corin 
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genes, involved in NT-proBNP processing, have been suggested as plausible 
explanations for lowered NT-proBNP levels in African Americans, where these 
functional variants exist at a higher frequency 164. 
During the first three months of chemotherapy, increased levels of BNP were reported 
to be associated with abnormal LV thickness-to-dimension ratio which may indicate 
LV remodelling; in this regard, studies have shown abnormal LV structure years after 
chemotherapy 24,136.  
However Plana et al. 69 found that the association between BNP levels and LV 
function were prone to inconsistencies. 
6.1.2 Troponin T 
Cardiomyocyte damage results in the increase of circulating cardiac troponin in the 
blood allowing for plasma and serum to be utilized for biomarker testing to assess 
cardiac health 136.  Cardiac troponin T-levels are generally undetectable in healthy 
individuals but are elevated where there is myocardial injury, possibly indicating 
irreversible cardiomyocyte necrosis 24,39,136. Negative troponin concentrations have 
been shown to be indicative of low risk of cardiomyopathy – pointing to the sensitivity 
of troponin T as a measure of even early or subclinical cardiac damage which may 
allow for treatment while damage is still reversible 37,136,176.  
Troponins are proteins found in both cardiac and skeletal muscle. The troponin 
complex consists of thin filaments in striated muscle which is complexed to actin. 
There exist three types of troponins: Troponin T which is tropomyosin binding, 
Troponin I which inhibits binding between actin and myosin, and Troponin C which is 
calcium binding allowing for muscle contraction 177. 
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Figure 43: Visualization of cardiac muscle and the different Troponin 
molecules, adapted from Shave et al. 177 
Despite females reportedly having a greater risk of developing ACT, males are more 
likely to have increased cardiac troponin levels due to anthracyclines indicating that 
together with the difference in LV mass between the sexes, an attempt should be 
made to devise population and gender based Troponin T values correlated with  
cardiac assessment/function 136. Furthermore,  in addition to cardiac troponin levels 
being significantly elevated in males, especially those with irradiation near the heart, 
this biomarker was raised in correlation with higher cumulative doses of 
anthracyclines 136.  
Cheung et al. 136 were not able to elucidate if troponin release was due to 
anthracycline-induced apoptosis of cardiomyocytes or due to consistent myocardial 
injury causing troponin release into the bloodstream. 
Nevertheless, genotyping revealed that the CYBA rs4693 CT/TT genotype was 
significantly associated with increased cardiac troponin levels compared to the CC 
genotype, whereas the variants in  RAC2 (rs13058338) and NCF4 (rs1883112) had 
no association with troponin levels 136. The CYBA rs4673 CT/TT genotype has been 
associated with high sensitivity cardiac troponin levels which functionally translate to 
worse left ventricular longitudinal strain 136. 
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6.1.3 Suppression of Tumorigenicity 2 (ST2) 
The “Suppression of Tumorigenicity 2” or ST2 marker is an interleukin-33 receptor, 
part of the interleukin-1 receptor family, and is a cytokine secreted in response to 
cellular damage, particularly cardiovascular stress and fibrosis 166. While it has a 
cardiovascular role, ST2 is also involved in inflammatory and immune processes 166.  
While severe cardiotoxicity during anthracycline-based therapy may result in its early 
discontinuation, cardiotoxicity may also present years after treatment 24,41. Cardiac 
troponin T as a measure of acute cardiotoxicity, may benefit from an additional, 
sensitive biomarker such as ST2; the latter of which is a powerful predictor for death 
due to CF, and may be especially useful to detect late onset ACT 41,166.  
While careful monitoring of cardiac function, utilisation of a specific type of 
anthracycline and limiting cumulative anthracycline dose may mitigate risk of 
developing ACT, it is likely that cardiotoxicity may still occur regardless of these 
efforts. Therefore, other measures need to be utilized for the reduction or prevention 
of cardiotoxicity at the clinical level. 
This aspect of the study was to determine whether biomarkers, in this instance NT-
proBNP or BNP may serve as a more accurate measure of cardiac injury and 
cardiotoxicity.  
6.2 Materials and Methods: 
6.2.1 The Study Cohort: 
Forty-two patients from the prospective cohort with adequate biological specimen 
before and after chemotherapy were selected for the biomarker study. 
Peripheral whole blood (3ml) was collected in Greiner Bio-One Vacuette Venous 
Blood Tubes (Lavender K3EDTA) from patients which enable an intact and stable 
specimen to be collected for plasma for biomarker testing. 
6.2.2 Determination of cardiac biomarker of injury levels using 
peripheral blood 
The Biomedica® Competitive Enzyme Immunoassay (Biomedica Immunoassays, 
Austria) was used to detect level of NT-proBNPs in order to determine the extent of 
cardiac injury.  
128 
 
6.2.2.1  Principle of ELISA 
The method of Enzyme-Linked Immunosorbent Assays (ELISA) or Enzyme 
Immunoassays (EIA) dates to the 1960s and utilises the combined specificity and 
sensitivity of antibodies and/or antigens and enzymes allowing for inferences of either 
antigen or antibody concentration to be made 178-180. ELISAs can be either used to 
detect the presence of antigens specifically recognized by an antibody or vice-versa. 
A generalized ELISA consists of the following: Microtiter plates are first coated with 
antigen, unbound sites are then blocked to prevent non-specific binding, primary 
antibodies are added to the wells and finally a secondary antibody which is conjugated 
to an enzyme, is added 179. The enzyme acts as the reporter label 178. This conjugate 
usually produces a colour change when a substrate is added that ultimately indicates 
a positive result that can be more accurately quantified with an ELISA plate-reader. 
There are four types of ELISA that can be used depending on the object of the 
experiment: Direct ELISA, Indirect ELISA, Competitive ELISA and Sandwich ELISA 
179. Direct ELISAs involve antigen attachment to the microtiter plate and the addition 
of an enzyme-linked antibody, allowing for a rudimentary measurement of sample 
concentrations 179. Similarly, Indirect ELISAs involve antigen attachment to the solid 
phase, but the addition of an unlabelled primary antibody with the addition of an 
enzyme-linked secondary antibody allows for greater specificity in antibody detection 
179. Greater specificity is achieved with Competitive ELISAs whereby “competing” 
antibodies or proteins are added 179. The last type of ELISA is both sensitive, specific 
and amenable to high-throughput platforms – Sandwich ELISAs involve a solid phase 
coated with capture antigen, the addition of samples with known or unknown antigens 
in a matrix or buffer followed by the addition of an enzyme-conjugated antibody that 
allows for a quantifiable detection signal 179. 
 
 
Figure 44: Schematic illustration of the generalized principles of the four types 
of ELISAs (Image adapted from 181) 
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6.2.2.2 Technique of Detection of N-terminal pro B-Type Natriuretic Peptide (NT-
proBNP) using a Competitive ELISA 
 
Peripheral blood was centrifuged at 2500 rpm for 20 minutes at 4°C allowing for 
separation of plasma. BNP fragments are stable in plasma and serum and therefore 
centrifugation occurred soon after procurement of sample. Plasma was then stored at 
-80°C until needed. The plasma may be subjected to five freeze-thaw cycles without 
compromising sample integrity. The reliability of haemolysed blood samples in 
determining levels of NT-proBNP is disputed 182; samples which were suspected of 
haemolysis were therefore collected and recorded as such, and utilized nevertheless.  
The Biomedica assay was performed according to manufacturer’s instructions 168. The 
wash buffer, standard and control were reconstituted before use. The wash buffer was 
diluted 1:20 and both the standards (synthetic human BNP fragment at various 
concentrations (pmol/l) and control (synthetic human BNP fragment) were 
reconstituted with 200ul of distilled water for 20 min at room temperature, mixed gently 
and then stored at -25°C. A volume of 150ul of Assay Buffer was added to all wells 
except the blank in a plate coated with polyclonal anti-BNP fragment antibody followed 
by 30ul of either samples, control or standards to each well except the blank. This 
was followed by the addition of 50ul of conjugate (synthetic BNP fragment –HRPO 
with red dye) to each well except for the blank. The plate was then well covered and 
incubated overnight at 4°C in darkness. The wells were then aspirated and washed 
four times with 300ul of diluted wash buffer using an ELISA plate washer (Biotek® 
Microplate Washer, USA). A volume of 200ul of substrate [Tetramethylbenzidine 
(TMB) solution] was then added to each well and then incubated for 20 minutes at 
room temperature in the dark. Subsequently, 50ul of stop solution (Sulphuric acid, 
0.18M) was added to each well, shaken well and then placed on the ELISA plate 
reader capable of determining absorbance at 450nm with a correction wavelength at 
630nm. The stop solution can alter the pH therefore inactivating the enzyme and 
halting the reaction. The correction wavelength allows for non-specific emissions and 
interference signals to be eliminated thereby giving the correct absorbance of proteins 
of interest. The assay was performed in duplicate. 
6.2.2.3  Statistical Analysis for the determination of NT-proBNP levels 
Results were analysed by measurement of the optical density (OD) of each well. OD 
values derived from the standards were used to construct the standard curve. Raw 
data was transformed and analysed using the 4PL algorithm (GraphPad Prism 6) and 
unknown samples were interpolated using the standard curve. Sample concentrations 
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were then derived from the antilog of interpolated values. Reference ranges derived 
from the standards for the assay were specific to the run and could not be utilised 
across assay runs. 
NT-proBNP levels were assessed as transformed log values and as quartiles specific 
to population as previously done 127. 
6.3 Results: 
Incidental cardiac findings and the missing LVEF measures for some patients 
prompted a pilot study for the assessment of a sub-group of patients at baseline and 
after chemotherapy, and where blood samples were collected at these two time 
points, using a cardiac biomarker to determine if there was any cardiac injury in 
asymptomatic patients. 
6.3.1 Determination of cardiac biomarker of injury levels using EDTA-
plasma  
 
Forty two patients were assessed at both baseline and post-chemotherapy for BNP 
levels using EDTA-plasma from peripheral blood. Raw values from the ELISA were 
log-transformed and patient concentrations of NT-proBNP were inferred from the 
fourth-party logistics (4PL) Algorithm using GraphPad Prism 6 183. Multivariable linear 
regression was utilized for the association between population group (predictor) and 
biomarker levels (outcome). Covariates for the multivariable models included: 
population group, age, BMI, hypertension, diabetes and smoking status. 
6.3.2 NT-pro B-Natriuretic Peptide (NT-proBNP) concentration 
Patients were stratified according to their hypertensive status (Table 40) as 
hypertension due to ventricular stretching of the myocardium may increase the 
release of BNPs 175. 
 
 
 
 
131 
 
Table 40: Clinical, demographic and experimental information pertaining to the patients assessed for BNP levels 
Patient 
ID 
Age at 
Diagnosis 
Population 
Group 
Pre-
existing 
CD 
Diabetes Smoking Other Meds 
LVEF 
Pre 
Type of 
Chemo 
Dose 
Clinical Symptoms 
Post 
BNP Concentration 
           Pre Post 
Non-Hypertensives 
ACT217 53 MA N N Y None 57 Epi 690 Severe SOB 571.6 647.8 
ACT219 55 MA N N N None 65 Dox 420 . 363.3 281.1 
ACT220 61 MA N N N None 68 Dox 400 DECEASED OR 296.1 
ACT222 50 MA N N Y None 65 Dox 480 . 187.2 276.2 
ACT227 41 MA N N Y None 60 Dox 460 . 112.4 188.1 
ACT228 50 IA N N N None 65 Dox 400 . 227.9 562.1 
ACT229 54 MA N N N None 68 Dox 440 . 344.9 55.2 
ACT230 58 MA N N N None 67 Dox 330 . 343.8 267.4 
ACT232 69 MA N N N None 55 Epi 440 Borderline ECG 218.8 415.3 
ACT234 68 MA N N N None 55 Dox 600 . 176.2 288.1 
ACT238 52 MA N N N None 60 Dox 330 . 593.6 402.6 
ACT240 30 MA N N N None 55 Dox 285 Confirmed LVH 500.5 513.3 
ACT241 51 MA N N Y None 67 Dox 600 . 397.9 386.8 
ACT245 57 MA N N N None 60 Dox 270 Borderline ECG 161.0 113.1 
ACT246 49 IA N N N None 60 Dox 330 Potential LVH 662.0 224.3 
ACT248 44 IA N N N None 60 Dox 460 . 206.5 386.8 
ACT252 73 MA N N Y None 53 Epi 330 Confirmed Acute MI 366.3 95.8 
ACT259 43 MA N N Y None 58 Epi 840 . 895.8 440.8 
ACT260 63 MA Y Y N NIDDM meds 55 Dox 345 Chest pain 247.2 151.9 
ACT263 43 MA N N N None 60 Dox 460 . OR 95.8 
ACT264 57 MA N N N None 55 Epi 375 . 312.7 43.8 
ACT272 44 MA N N Y ARVs 69 Dox 320 . 738.4 540.8 
Hypertensives 
ACT215 62 MA N N N 
HCTZ, Atenolol, 
Enalapril, Zocar, 
Amlidopine 
73 Dox 400 . 432.9 48.5 
ACT221 63 MA N N N 
Hypertensive 
meds, 
Simvastatin 
77 Dox 420 . 290.0 175.4 
ACT223 37 IA N N N 
Amlidopine, 
ARV 
55 Epi 520 . 89.5 146.0 
ACT224 58 MA N Y N 
Hypertensive 
meds 
67 Dox 400 . 146.0 1015.6 
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Table 40 continued: Clinical, demographic and experimental information pertaining to the patients assessed for BNP levels 
ACT225 54 MA N N N 
Dispirin, 
Amlidopine 
60 Dox 380 . 159.7 217.0 
ACT226 50 MA N N Y 
Ridaq, 
Pharmapress 
67 Dox 330 
Abnormal ECG; Sinus 
Tachycardia 
93.7 465.5 
ACT231 44 MA N N Y None 65 Dox 330 . 387.8 392.3 
ACT244 47 MA N N N Ridaq 55 Epi 540 
Abnormal ECG; 
Prolonged QT 
324.2 140.9 
ACT249 56 MA N Y Y 
Ridaq, 
Pharmapress, 
Glibendamide 
58 Epi 780 . 362.3 43.1 
ACT250 43 IA N N N 
Ridaq, Atenolol, 
Zocar; 
Simvastatin, 
Enalapril 
none Dox 440 . 362.3 436.4 
ACT251 63 MA N N N Ridaq, Atenolol 60 Epi 500 Borderline ECG 187.1 129.3 
ACT253 51 MA N N Y 
TB Drug 
Regimen 1; 
Ridaq, Atenolol 
71 Dox 380 Potential MI 523.2 715.5 
ACT254 48 MA N N N Ridaq, Atenolol 66 Dox 345 . 234.5 139.0 
ACT255 63 MA N N Y 
Hypertensive 
Meds 
60 Dox 400 . 276.8 305.2 
ACT257 40 MA N N N 
Ridaq, 
Pharmapress, 
Atenolol 
65 Dox 460 . 568.6 203.2 
ACT261 67 IA N N N None 65 Dox 450 . 388.2 289.0 
ACT265 38 MA N N N Pharmapress 65 Dox 400 . 550.5 490.3 
ACT266 60 MA Y N N Atenolol 60 Dox 400 . 345.0 236.8 
ACT269 45 MA N N Y 
ARVs, 
Pharmapress 
64 Dox 360 . 132.2 496.5 
ACT273 43 MA N N N 
Ridaq, 
Pharmapress 
50 Dox 400 Potential LVH 1139.8 676.5 
*SOB = shortness of breath; ECG= echocardiogram; LVH= left ventricular hypertrophy; MI= myocardial infarction; NIDDM= non-insulin dependent diabetes mellitus; 
ARVs= antiretroviral; HCTZ =  hydrochlorothiazide;  QT = time between start of Q wave and end of T wave; TB = tuberculosis 
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6.3.3 Statistical Analysis 
Patients were analysed as a combined cohort as well as after stratification into 
population groups. The median age of this sub-cohort was 51.5 years, which, when 
stratified showed MA patients with a median age of 53.5 years compared to the 
younger IA cohort with a median age of  46.5 years. Despite the younger age of the 
IA cohort, their median BMI at 31.6 was higher and in the obese category compared 
to the median BMI of the MA cohort at 28.2 - in the overweight category. 
While the IA cohort had a higher incidence of hypertension (0.5) compared to the MA 
cohort (0.44), the MA cohort had more pre-existing cardiac disease (0.03), diabetes 
(0.08) and more smokers (0.33) compared to a zero incidence of these factors in the 
IA cohort. These risk factors have been shown to increase the likelihood of ACT 24,26,36. 
This would essentially translate to the MA cohort being at higher risk of cardiotoxicity 
and therefore likely to have higher expected levels of BNPs. However, the median 
baseline LVEF for the combined, MA and IA cohort was 60% which is in the normal 
or healthy heart range 64. 
Cumulative chemotherapeutic dose relies on type and stage of cancer as well as the 
BSA which relies on both weight and height 184. While BMI is a crude but relatable 
measure, the IA cohort with a higher median BMI received overall, a higher median 
cumulative dose of doxorubicin – i.e. 440mg/m2 compared to the MA cohort with a 
median dose of 400mg/m2 in this pilot biomarker cohort. Only one IA patient was 
administered epirubicin so a similar deduction could not be made for this drug. 
However, when both cohorts were analysed for median dose of anthracycline-based 
chemotherapy, the IA sub-cohort received a higher dose – 445mg/m2 compared to 
the MA cohort’s cumulative median dose of 400mg/m2.  
While the increased concentration of BNP is associated with CF, a major limitation of 
this measure is that BNP levels may be sensitive to other factors such as patient age, 
gender and obesity, as well as population-specific variants resulting in increased 
sensitivity to chemotherapy 127,139,140. Therefore, BNP baseline levels were stratified 
according to population group (Fig.45).  
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Figure 45: Comparison of baseline BNP concentrations in both the MA and IA 
cohorts with the exclusion of all hypertensive patients (n=40, p=0.4369, 
Unpaired t-test) 
Hypertensive patients were excluded from this analysis as hypertension may cause 
ventricular stretching which can cause increases in BNP levels (Fig. 45, Table 41) 175.  
Table 41: Comparison of median baseline BNP concentrations before the 
administration of anthracycline based chemotherapy and stratified per the type 
of chemotherapy administered, population group and hypertensive status of 
patient 
*Chi-square Test, +Not computed due to no IA, non-hypertensive patients administered Epirubicin, p-
valueboth <0.0001 therefore statistically significant, ^Only one Indigenous African patient was 
administered epirubicin 
Overall, hypertensive IA patients had higher baseline BNP levels compared to their 
MA counterparts. However, MA patients (both hypertensive and non-hypertensive 
Patient Cohort 
Type of 
Anthracycline 
BNP Concentration 
(mg/m2) 
Population 
Group 
p-value 
  Median Range   
All 
Doxorubicin 
344.4 93.7-1139.8 MA 
<0.0001* 
362.3 206.5-662 IA 
Epirubicin 
343.3 187.1-895.8 MA 
89.5^ n/a IA 
Both 
344.4 93.7-1139.8 MA  
295.1 89.5-662 IA  
      
Hypertensive 
Doxorubicin 
290 93.7-1139.8 MA 
<0.0001* 
375.3 362.3-388.2 IA 
Epirubicin 
324.2 187.1-362.3 MA 
89.5^ n/a IA 
Both 
307.1 93.7-1139.8 MA  
362.3 89.5-388.2 IA  
      
Not 
Hypertensive 
Doxorubicin 
344.9 112.4-738.4 MA 
-+ 
227.9 227.9-662 IA 
Epirubicin 
366.3 218.8-895.8 MA 
n/a n/a IA 
Both 
354.1 112.4-895.8 MA  
227.9 227.9-662 IA  
      
135 
 
combined) had higher baseline BNP concentrations compared to IA patients (Table 
41). Chi-square test analysis shows that this difference is statistically significant (poverall 
<0.0001). 
The BNP concentration of the entire cohort before and after chemotherapy is 
illustrated in Figure 46. 
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Figure 46: BNP Concentration of the entire cohort before (pre) and after (post) 
chemotherapy (n=42), (p<0.001, Chi-square Test) 
While the differences in BNP levels for the combined populations (pre vs post, both 
hypertensive and non-hypertensive) are statistically significant, Figure 46 indicates 
that anthracycline-based chemotherapy decreases BNP concentration after 
administration, which is counterintuitive.  Anthracycline-based chemotherapy is 
known to be cardiotoxic and was therefore expected to increase BNP levels rather 
than show a decrease. Therefore, the BNP concentration of the entire cohort was re-
analysed, excluding the hypertensive patients, in case the decreased BNP levels after 
chemotherapy is as a result of the use of anti-hypertensives 185,186. 
The BNP concentration of the non-hypertensive patients in the cohort were compared 
before and after chemotherapy and illustrated in Figure 47. 
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Figure 47: BNP Concentration of the non-hypertensive patients in the cohort 
before and after chemotherapy (n=21), (p<0.001, Chi-square Test) 
Despite the exclusion of hypertensive patients, there was still a uniform decrease in 
BNP levels after the administration of chemotherapy (Fig. 47). This shows that this 
trend is not due to hypertension and the use of anti-hypertensives. Therefore, as 
previously discussed (Fig. 45), stratification of the cohort into population group before 
the analysis of BNP concentration levels may allow for a more accurate analysis as 
seen in Figure 48. 
 
Figure 48:  Comparison of BNP levels at baseline (pre) and after (post) 
chemotherapy for both MA and IA patients with the exclusion of hypertensive 
patients (p<0.0001 statistically significant change from baseline to after 
chemotherapy, chi-square test for both MA and IA) 
Figure 48 demonstrated a statistically significant change from baseline to after 
chemotherapy in BNP concentration levels in both populations. While BNP levels 
decreased in the MA population after the administration of chemotherapy as it has 
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with the previous analyses (Figs.45 & 48), it shows a posttreatment increase in the IA 
cohort, indicating possible quantifiable cardiac dysfunction (Fig. 49). Furthermore, this 
pilot analysis shows that BNP levels may be ethnicity dependent and that the 
anthracycline-based chemotherapy has potential cardiotoxic effect in the IA 
population.   
This effect was interrogated further whereby pre- and post-treatment measures were 
analysed taking account of the type of anthracycline administered in each of the MA 
and IA ethnic groups.  
 
Figure 49: Comparison of BNP levels at baseline and after chemotherapy for 
both MA and IA patients with the exclusion of hypertensive patients and 
stratified into type of anthracycline-based chemotherapy administered 
Within the MA cohort, BNP levels were found to be significantly different (i.e. 
decreased) from baseline to post-chemotherapy in patients treated with doxorubicin 
and as well as in patients treated with epirubicin (p<0.0001, Chi-Square Test, Fig. 49). 
In this MA cohort, there is a trend toward BNP levels decreasing after treatment with 
doxorubicin. The MA patients scheduled for epirubicin had a higher BNP 
concentration at baseline than the patients scheduled for doxorubicin.  
Similarly, within the IA cohort, BNP levels were found to be significantly different from 
the baseline time-point to the time-point after the administration of chemotherapy in 
patients treated with doxorubicin (p<0.0001, Chi-Square Test, Fig. 48). IA patients 
scheduled for doxorubicin had slightly higher baseline BNP levels compared to their 
MA counterparts. This observation is interesting given that the IA cohort had a lower 
clinical risk in terms of co-morbidities (Table 41). The trend for doxorubicin is an 
increase of BNP levels after the administration of treatment indicating that IA may be 
more susceptible to cardiotoxic chemotherapy as previously inferred to (Fig. 48).  
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Because of the small sample size – this observation does need to be interpreted with 
caution. 
While the assessment of BNP levels at specific time-points (pre- vs post 
chemotherapy) is of value, it is important to correlate these levels with patient clinical 
status in order to ascertain if BNP concentrations are indicative of cardiac 
physiological insult or dysfunction.  
6.3.4 Correlation between Routine Measures, Biomarkers and Cardiac 
Function Decline 
As previously mentioned, a severity score was established where patients were 
stratified in terms of anthracycline-induced cardiotoxicity. The score was based on the 
Common Technology Criteria for Adverse Events v3.0 (CTCAE) which has been 
utilised previously 7,10. This score or grading was based on change in LVEF if available 
and clinical phenotype after the administration of chemotherapy. 
 
Table 42: Severity Score established using LVEF measure and patient clinical 
phenotype 
Severity 
Score 
Change in LVEF Clinical Phenotype 
0 No change  Normal  
1 No LVEF decline  Chest pain, shortness of breath, palpitations  
2 LVEF decline <10% Chest pain, shortness of breath, palpitations, 
chemotherapy dose change or decrease 
3 LVEF decline <10% Suspected CCF, LV Dilation, Cardiomegaly, 
raised Troponin T  
4 LVEF decline ≥ 10% Congestive Heart Failure, Myocardial Infarction  
 
Due to the progressive nature of cardiac dysfunction, it was necessary to take certain 
clinical characteristics beyond LVEF into account 51-54. 
Cumulatively (in both population groups), the change in BNP concentration levels 
(post – pre) was not normally distributed (W=0.938; p=0.029). The median BNP 
change is -59 pmol/l indicating that there was an overall average decrease of 59 
pmol/l from pre-chemotherapy levels to post-chemotherapy levels. In terms of the 
extremes in BNP levels change – this ranged from a decrease of 463.2 pmol/l to an 
increase of 869.6 pmol/l. 
The change in BNP was analysed in terms of clinical status of the patient after the 
conclusion of chemotherapy and the following emerged: despite there being evidence 
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of the patient having some measure of cardiac dysfunction, there was no statistically 
significant difference in change in BNP levels between the unaffected and affected 
groups (Fig. 50a, Chi-square test, p=0.426). 
 
 
Figure 50: Comparison of change in BNP based on both patient status (A) and 
severity score (B) 
Figure 50A demonstrates that despite the clinical status of patients after treatment, 
there is no difference in change in BNP levels. Figure 50B shows that while there are 
differences depending on the severity score, these differences indicate that BNP 
levels decrease in patients with a higher severity score (i.e. BNP levels after 
chemotherapy have a greater decrease in patients with signs of cardiac dysfunction) 
which is counterintuitive. 
Patients were then stratified into population group and assessed for change in BNP 
compared to their cardiac clinical status (affected vs unaffected).  
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Figure 51: Comparison of change in BNP in both IA and MA affected (yellow) 
and unaffected (green) individuals 
While there is no discernible difference in the change in BNP between affected and 
unaffected MA individuals, there is a difference between affected and unaffected IAs 
(Fig. 51).  
Furthermore, patients with baseline cardiac incidental findings (Table 43) were 
analysed together with their levels of BNP and clinical status. 
Table 43: Patients with baseline cardiac incidental findings analysed for both 
BNP levels and clinical status 
    BNP   
Patient 
ID 
Pre 
LVEF 
Cardiac 
Baseline 
HPT Pre Post Change Score Status 
ACT223 55 LVH Y 89.5 146.0 56.5 0 unaffected 
ACT232 55 
Impaired 
relaxation LV 
N 218.8 415.3 196.5 0 affected 
ACT234 55 
Impaired 
relaxation, 
elevated atrial 
filling pressures 
N 176.2 288.1 111.8 0 unaffected 
ACT238 60 
Impaired 
relaxation LV, 
aortic 
regurgitation 
N 593.6 402.6 -191.1 0 unaffected 
ACT251 60 
Tricuspid 
regurgitation 
Y 187.1 129.3 -57.8 0 affected 
ACT260 55 LVH N 247.2 151.9 -95.3 1 affected 
 
Table 43 shows patients with both baseline cardiac incidental findings and 
measurement of BNP levels before and after chemotherapeutic administration – 
despite potential diminished cardiac function, increases in BNP levels were not 
indicative of clinical status. This lack of association was illustrated in Figure 52. 
141 
 
 
Figure 52: BNP changes in patients with baseline cardiac incidental findings 
compared to their clinical status after the administration of chemotherapy 
Chi-square test for change in BNP levels compared to status (Fig. 52) showed non-
significant differences (p=0.3062). 
6.4 Discussion 
Given the inadequacy of LVEF, this prompted the validation and utilisation of BNP 
concentration as a measure of cardiac dysfunction and to improve the accuracy of 
gauging the cardiac phenotype 62,93,165. Ideally, the entire cohort would have 
undergone BNP analysis, however, the combined cost of 272 patients at two time 
points limited the study to prioritisation of those without a second LVEF measure; so 
at best the present study is a pilot. 
Data derived from our cohort of 42 patients, treated for breast cancer, indicated that, 
in general, BNP levels decrease after the administration of a cardiotoxic treatment. 
This is of interest as it can be erroneously inferred that anthracyclines may improve 
cardiac function or, more rationally, that the measurement of BNP concentration as a 
surrogate marker of cardiac function is limited. However, this trend persisted even 
after the removal of hypertensive patients (as BNP may be released in response to 
ventricular stretching of the myocardium 175), as well as when the data was further 
stratified into the type of regimen (i.e. doxorubicin versus epirubicin). It was found that 
there was a discernible and significant increase in BNP concentration for the IA cohort 
– indicating that despite the limitation of BNP levels, the cardiac effect of the 
anthracyclines may have been sufficient to show impairment in this population group.   
Although the IA cohort was relatively small, this trend may suggest that African women 
may be more sensitive to chemotherapy which is plausible considering previous 
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evidence of ethnically variant polymorphisms that influence doxorubicin 
pharmacokinetics and pharmacodynamics 127,139. 
While the lowered levels of BNP after the administration of cardiotoxic chemotherapy, 
was unexpected – numerous studies have also found conflicting results correlating 
BNP and/or NT-proBNP levels with chemotherapy 187-190.This may be explained by 
the difference in BNP versus Troponin – Troponin is released due to cardiac myocyte 
damage and/or death whereas BNPs are released due to stretching of the ventricular 
myocardium 191,192. Additionally, maintained preload reserve may explain the 
unchanged or decreased BNP levels after the administration of chemotherapy – 
compensatory mechanisms that preserve stroke volume and cardiac output thereby 
preventing excess expansion and pressure overload and subsequent release of BNP 
may explain this phenomenon 186. 
BNP levels are not only sensitive to functional genetic variants which may be 
population specific, but also to patient age, gender, obesity and hypertension 127,139,140. 
While hypertensive patients may exhibit higher levels of BNP due to ventricular 
stretching and therefore not be as informative as a predictor of cardiac dysfunction, 
hypertensive medications such as angiotensin inhibitors and βeta-blockers, may 
preserve cardiac function particularly in patients treated with a sufficiently high dose 
of the drug 69,185. It is hypothesized that the progressive nature of myocardial injury 
enabling the asymptomatic cardiac decline to become irreversible, symptomatic 
cardiac dysfunction may be slowed or even halted by the concomitant administration 
of anti-hypertensive medications 185. 
It is also likely that patients may not have left ventricular remodelling, causing systolic 
dysfunction, thereby not showing an increase in BNP levels There was a difference 
in IA patients (Fig.51), which indicated that clinically unaffected (i.e. relating to CF) 
individuals have higher BNP levels after chemotherapy compared to baseline. Against 
this background - the one affected individual who had lower BNP levels after 
chemotherapy compared to before the administration of chemotherapy – suggests 
that BNP levels are not indicative of cardiac dysfunction but could point to ventricular 
stretching without cardiomyocyte death. However, we cannot exclude ACT related to 
cardiomyocyte death using BNP levels which is more closely related to cardiac stress 
and contractile dysfunction than cardiomyocyte death, as previously discussed. 
While the correlation of BNP levels to patient clinical status proved to be inconclusive, 
the severity score, developed for increased accuracy in patient phenotyping also 
failed to show an association with BNP levels, suggesting that the BNP biomarker 
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may not be an early predictor of ACT. Furthermore, the cardiac incidental findings at 
baseline were compared to BNP levels and also showed no association despite there 
being quantifiable cardiac compromise. 
6.4.1 Study Limitations: 
Limitations related to the use of BNP analysis for the assessment of cardiac function 
include:  
i) lack of two LVEF measures for every patient – despite the insensitivity of the LVEF 
measure in some instances, the lack of a second measure complicated the correlation 
of BNP measures to cardiac function;  
ii) attributing differences in biomarker levels to self-reported ethnicity – which may 
decrease population-specific significance . Ancestry Informative markers may have 
been useful in delineating the different population groups rather than the reliance on 
self-reporting 164, and  
iii) lack of biomarker analysis for the entire cohort – although BNP had limited utility, 
data on the entire cohort may have provided more useful insight. 
iv) the use of only one blood sample at each time-point due to the patients in the study 
being outpatients, whereas previous studies used serially collected blood samples to 
determine BNP concentration 190. Therefore, as indicated previously in literature, BNP 
levels may increase in response to chemotherapy (first 72 hours) but as the damage 
may be transient, will then decrease and return to a “normal” range compared to 
persistently high BNP levels only being present in patients with irreversible cardiac 
dysfunction 187,190;  
v) The haemolysis of some patient samples were then looked at as a reason for the 
exaggerated baseline BNP levels. Haemolysis of a blood sample is defined as the 
pink or red colour of plasma or serum after centrifugation, specifically a free 
haemoglobin concentration of more than 0.3g/L 182. While haemolysis of blood was 
thought to invalidate the results of biomarker assays owing to a lag time between 
when peripheral blood was obtained up to its usage, more recent findings have 
indicated otherwise. Daves et al. 182 demonstrated that moderate haemolysis had no 
effect on the reliability of cardiac biomarker results. In vitro haemolysis occurs in 
approximately 3.3% of all routinely collected samples and is the leading cause of up 
to 70% specimen rejection, by laboratories 182. It is important to quantify the effect of 
moderately haemolysed samples on cardiac biomarker testing as it has ramifications 
on the potentially unnecessary rejection of patient specimens and the clinical 
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management of such patients pertaining to diagnosis and treatment 182. Essentially, 
the level of haemolysis needs to be gauged accurately so that severely haemolysed 
samples that may invalidate biomarker results are discarded.  
vi) Epirubicin treatment has been shown to be less cardiotoxic than doxorubicin 
treatment 2. Possibly due to the small number of patients, our sub-study failed to 
conclude on any treatment-type effect (epirubicin vs. doxorubicin). For instance, out 
of six patients in the IA cohort, only one patient was treated with epirubicin; and  
vii) the lack of an echocardiographic evaluation after chemotherapy preventing the 
correlation of BNP levels to quantitative measure – routine clinical management of 
patients in a resource-poor environment does not always include a post-
chemotherapy echocardiography. 
6.4.2 Recommendations: 
This pilot study has been inconclusive about the use of BNP as a measure of   
irreversible cardiac damage as a result of chemotherapy. However, there is every 
indication for expanding the study, especially focussing on ethnicities towards 
establishing valid population-relevant baseline measures, as well as potential 
changes and factors which influence this, including anthracycline as a 
chemotherapeutic. This would also be an opportunity to gauge whether Troponin, and 
perhaps ST2 and other biomarkers may be a better marker of early cardiotoxicity 
188,192. The excellent collaboration that has been established with the Department of 
Cardiology, here at the University of Cape Town for the preliminary study presented 
here, will facilitate the design of such a comprehensive study. 
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Chapter 7: Concluding Remarks 
Despite genotypes not emerging as a predictor of ACT in this study, the increased 
susceptibility of the IA population to ACT as well as increased BNP levels after 
chemotherapy, demands a closer look. Furthermore, the interrogation of IA patient 
genomes for novel variants of susceptibility to ACT are recommended; this requires 
building up of a substantial cohort from this population group, which would likely 
require collaboration with a number of South African health care institutions. 
Furthermore, this study illustrates the need for clinical trials for new and existing drugs 
to be conducted in Africa on local populations.  Both the present study and literature 
6,139,140 show that local populations may have both increased risk of adverse drug 
reactions and/or reduced efficacy compared to their CA counterparts whose risk is 
already established in historical clinical trials. 
The development of both the patient scoring system and statistical model to predict 
post-chemo LVEF may warrant further development and utilisation in a resource-poor 
setting. 
Findings derived from this study indicate the need for refined patient management of 
ACT in a South African population to potentially allow for treatment with minimised 
risk and event-free breast cancer survival. 
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Appendices 
Appendix A: Gene Annotation and Primer Design Protocol 
Before annotation of your genes, you will need to prepare files and your information 
will come from NCBI and Ensembl. 
It is simplest to create a gene annotation folder, and create subfolders of each gene 
of interest which will contain the files specific to that gene. 
NCBI (www.ncbi.nih.gov) 
- Navigate to the NCBI website 
- Select Gene under “All Databases” and type the gene name in the search 
box 
- Select for the Homo Sapiens in your gene search results 
- This will open a page with a “Summary” for the gene 
- Copy and Paste the gene summary  (until Genomic Context) into a Word 
Document and label it GeneName_Summary and save in the specific gene 
folder that you already created. Save and Close 
- Scroll down to Genomic Regions, Transcripts and Products and make sure 
the Reference Sequence Primary Assembly is selected and select Genbank 
where “Go to Nucleotide” is shown 
- This will open a page with the gene details followed by the sequence (the 
selected region should be sufficient for SNP genotyping purposes) 
- Copy the page from “LOCUS….” Till “//” and paste in Notepad and save in 
your gene folder as GeneName.seq 
- The SEQ file must be edited to allow for accurate annotation later so please 
do the following:  
o Note the Gene ID, the orientation of the strand and transcript ID – this 
information can be gathered from the NCBI gene page that you first 
navigated to as well as the link on that page called “SNP: GeneView” 
o SNP:GeneView will also allow you to double check the validity of your 
SNPs as well as orientation and transcript ID 
o With this information, go through the gene, mRNA, CDS, misc_RNA 
info and for those with different gene and transcript IDS, insert a 
space…for example mRNA becomes m RNA etc. Also, spaces can 
be inserted to STS if any 
o Save and close when done – this file is ready for annotation 
Ensembl (www.ensembl.org) 
- Navigate to the Ensembl website 
- Under “All Species” select Human and type the gene name in the Search 
Box next to it 
- Find the version of the gene you require and select (ie Human Gene version) 
- This will open up a page where a Transcript table is visible, find the longest 
transcript      (Note down the Gene ID (ENSG…), Transcript ID (ENST…) 
and orientation of strand for later) 
156 
 
- Select the longest transcript 
- On the left hand side of the page, click on “Export Data” which will open a 
pop-up, select the following: 
o Select GenBank format 
o Select Feature Strand 
o Select 10000 bases upstream and 10000 bases downstream 
o Under “Options for GenBank”, select only “Variation Features”, 
“Marker Features” and “Gene Information” 
o Click Next 
o Select Text 
- This will open up another page in your browser with the required information 
- Select all, copy and paste into Notepad. Save the file in your gene folder as 
GeneNamee.seq 
- Again, this SEQ file must be edited before annotation: 
o With the Gene and Transcript IDs noted earlier, go through the text 
and insert spaces to genes, mRNA, misc_RNA that are not needed 
o Save and Close 
PERLV5 
For the PerlV5 first timer: 
After installing PerlV5 on your laptop or PC 
Create a PerlV5 folder in your C drive, every time you create new NCBI and Ensembl 
gene SEQ files, add them to this folder (after editing!) 
- Click the start icon, search for cmd and select 
- This opens up the command line for Windows 
- For command line: cd.. will navigate you back a directory; to check what is in 
a directory you may type in dir 
- Navigate to the C:\> 
- You may check if your PerlV5 folder is there by typing dir so that it looks like 
this C:\>dir and press Enter 
- If your PerlV5 folder shows on the list then you may proceed further 
- Type in cd perlv5 so that it looks like this C:\>cd perlv5, press Enter 
- Type in pre-perl so that it looks like this C:\Perlv5>pre-perl, press Enter 
- The next line will look like this C:\Perlv5> 
- You are ready to annotate! 
- For NCBI:  
o For forward strand orientation (plus strand), type the following: 
o perl annotv9.pl gene.seq gene.annot s 
o it will look like this: C:\Perlv5>perl annotv9.pl gene.seq gene.annot 
s 
o Press Enter and if the next line is C:\Perlv5> then it has worked! 
o For reverse strand orientation (minus strand), type the following: 
o perl annotv9.pl gene.seq gene.annot sr 
o it will look like this: C:\Perlv5>perl annotv9.pl gene.seq gene.annot 
sr 
o Press Enter and if the next line is C:\Perlv5> then it has worked! 
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- For Ensembl: 
o For forward strand orientation, type the following: 
o perl annotv9ev2.pl genee.seq genee.annot s 
o it will look like this: C:\Perlv5>perl annotv9ev2.pl genee.seq 
genee.annot s 
o Press Enter and if the next line is C:\Perlv5> then it has worked! 
o For reverse strand orientation, type the following: 
o perl annotv9ev2.pl genee.seq genee.annot sr 
o it will look like this: C:\Perlv5>perl annotv9ev2.pl genee.seq 
genee.annot sr 
o Press Enter and if the next line is C:\Perlv5> then it has worked! 
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Appendix B: Informed Consent  
 
Consent Document 
Consent to Participate in Research: 
Good Day Madam/Sir 
Prof Raj Ramesar (Human Genetics, UCT), A/Prof H. Simonds (Radiation Oncology, 
Tygerberg Hospital) and Miss H.Naidoo (Human Genetics, UCT) will be the 
researchers on this study. Miss H.Naidoo will be using this research project to obtain 
her Doctorate. 
This study will focus on damage caused to the heart by chemotherapy and its genetic 
basis. 
You have been asked to participate in this research study by allowing us access to 
two tubes of your blood to run tests on and allow us access to your medical history so 
that we may monitor your response to treatment. Your samples will be stored securely 
in the Human Genetics Laboratory with access only to the investigators for a period 
of 3 years. At the end of the study, all samples will be destroyed. Patient samples will 
not be used for other studies unless new ethical approval is applied for and obtained. 
Your HIV status will be made available only to the researchers and will be kept 
confidential.  
Your personal and medical details will be kept confidential and you will remain 
anonymous in the study. You will not be at any risk by being part of this study and will 
not need to pay any money for the additional laboratory tests. One extra tube of blood 
at diagnosis and again after 3 cycles of chemotherapy will be taken with your routine 
blood draw at no extra risk. The unlikely risks of any blood draw include: pain, 
infection, bruising and minor bleeding after blood is taken. 
Your participation in this research is voluntary and you will not be given any 
compensation for your involvement in the study. Furthermore, you will not be 
penalized or lose benefits if you refuse to participate or decide to stop at any time. If 
you agree to participate, you will be given a signed copy of this document and 
information about the research. 
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The benefit of this study will be information on the genes responsible for damage to 
the heart when cancer patients receive chemotherapy. 
You have been informed about the study by....................................................... 
You may contact Horacia Naidoo at 021 406 6501 at any time if you have questions 
about the research. You may also contact the Human Research Ethics Committee if 
you have any concerns or queries on 021 406 6338 or email 
sumayah.ariefdien@uct.ac.za.  
The research study, including the above information, has been described to me orally. 
I understand what my involvement in the study means and I voluntarily agree to 
participate. I have been given an opportunity to ask any questions that I might have 
about participation in the study. 
Please tick if you agree to allow us to run more tests on your blood samples    
_________ 
Please tick if you agree to allow us access to your medical files   __________  
 
…………………………………………….                                …………………………….. 
Signature of Participant     Date 
 
…………………………………………….   …………………………… 
Signature of Translator (if applicable)   Date 
 
……………………………………………..   …………………………… 
Signature of Witness      Date 
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Appendix C: Ethics Approval – UCT 
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Appendix D: Ethics Approval – GSH 
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Appendix E: Ethics Approval – SUN/TBH 
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Appendix F: Reagent Preparation 
Primer Preparation: 
1x TE Buffer:  
10mM Tris added to 1mM EDTA at pH 8.0 makes up a 10x TE Buffer stock solution. 
A dilution of 1:10 with distilled water will produce 1x TE Buffer. 
DNA Isolation: 
Red Blood Cell Lysis Buffer (RBC Lysis Buffer): 
8.28g of Ammonium Chloride (NH4Cl), 079g of Ammonium Bicarbonate powder 
(NH4HCO3), 0.2ml of EDTA (0.5M, pH 7.4) made up to 1L with distilled water. 
- 0.5M EDTA: 
18.612g of EDTA in 60ml of dH20, adjust pH to 7.4 and make up to total volume of 
100ml. 
Cell Lysis Buffer: 
25ml of Tris-HCl (1M, pH 7.5), 16.7ml of 3M NaCl and 1ml of 0.5 M EDTA made up 
to 500ml with distilled water. 
- 1M Tris-HCl: 
12.1g of Tris in 60ml of dH20, adjust pH to 7.5 and make up to total volume of 100ml 
- 3M NaCl: 
17.532g of NaCl in 100ml of dH20  
- 0.5M EDTA: 
18.612g of EDTA in 60ml of dH20, adjust pH to 7.4 and make up to total volume of 
100ml  
20% SDS: 
2g Sodium Dodecyl Sulfate in 10ml of dH20 
20mg/ml Proteinase K: 
0.02g Proteinase K in 1000ul of 1mM CaOAc at pH 8 
6M NaCl: 
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35.064 g NaCl in 100ml of dH20 
Agarose Gel Electrophoresis: 
10x Tris-Borate-EDTA (TBE) Buffer: 
108g Tris, 55g Boric Acid and 7.4g EDTA (pH 8) made up to 1L using distilled water.  
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Appendix G: Multiplex PCR Protocol 
Aim of the experiment: Allow for the exponential amplification of a targeted 
sequence for SNaPshot Genotyping 
 
bp tm cond Change/exp peak  
HNMT 325 
55  C/A (black to green)     MXA 
ABCC2 rs818 572 
  G/A (blue to green)     
RAC2 341 
56  A/T (green to red)    MXB 
NCF4 725 
 G/A (blue to green)      
ABCC1 rs246 595 
60 Tchdwn, 
Gly A/G (green to blue)       
MXC 
*ABCC2 
rs172 761 
  
A/T (green to red)        
 
 
Date:            Preparation of Mastermix 
Materials: 
 Volume for 1 
reaction (µl) – 
1x 
Volume for 
mastermix 
(µl) -   x   
Volume of 
Mastermix 
(ul) –   x  
Volume of 
Mastermix 
(ul) –  x   
Taq Reaction 
Buffer (5X) 
5            (1X)    
dNTPs                     
(5mM) 
1        (200uM)    
MgCl2                                  
(50mM/ul) 
1.5       (1mM)    
F and R primer        
(20uM) 
0.5 each  
(10pmol each) 
   
Glycerol 0 or 0.25    
dH2O 14.4 or 14.15     
Taq Polymerase      
(5U/ul) 
0.1         
(0.02U/ul) 
   
DNA template          
(100ng/ul) 
2            (100ng)    
TOTAL 25    
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 DNA samples and 1 negative control (water) 
 Clean bench area with biocide; have all reagents on ice 
 Set up master-mix without DNA and remember to add Taq last 
 Add 23µl master mix to each PCR tube or plate as well as 2µl of DNA template 
 Include a control containing 2µl master-mix and 2µl of dH2O 
 Edit the machine program: 94˚C for 3min, 94˚C for 3sec, Tm = 55°C for MX1, 
2, & 3, Tm = 58°C for MX4, Tm = 60°C for MX5, , Tm = 60°C touchdown for 
MX6 and Singleplex 
 72˚C for 1min repeated for 30 cycles 
 72˚C for 10min at the end 
 Set the sample volume to 25µl and Run! 
 Once completed – remove samples of PCR products.  Use in the designated 
post-PCR areas or store in the fridge appropriately. Post PCR area= Zone 
 
Electrophoresis of PCR products for correct temp 
Materials: 
 Loading Dye - Thermoscientific (Lot No: 00148043) 
 1x TBE Tank Buffer  
 Molecular Weight Marker-Thermoscientific (Lot No: 00149428) 
 NuSieve Agarose – Lonza (ME, USA) (Lot No: 0000313053) 
 
For 3% (w/v) Agarose gel (50ml or 100ml), use 1.5g or 3g agarose respectively and 
mix into 50ml or 100ml 1X TBE Buffer respectively. Dissolve by microwave heating. 
Allow to cool, add 5ul or 10ul of SyBr Safe, pour into casting tray with a well comb 
and allow to solidify (1-2hr min). 
Immerse gel into tank buffer. Load first well with 7ul of MWM and 3ul LD or mix 200ul 
lab LD with 25ul of MWM and 125ul water and store in fridge and use 7ul in gel. Load 
7-8ul of PCR product onto gel. Electrophorese at 90V for 50-60minutes. For larger 
gels, allow for run in of samples as loading proceeds. If GoTaq Reaction buffer used 
then no LD needed. 
For the analysis:  
- Assess sharpness and specificity of band at different temps by visualizing 
under UV Doc, photograph and label. 
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Appendix H: Patient DNA Isolations 
Table 1: Patient DNA Isolations at Diagnosis and after Cycle 3 of Anthracycline-
based Chemotherapy 
    
DNA Number 
Pre-treatment 
Sample 
Post-treatment 
Sample Notes 
ACT 1.1ANN 848.62 150.69   
ACT 2.1FLO  908.33 591.97   
ACT 3.1FAI  286.03 249.69   
ACT 4.1SUK  285.79 69.73   
ACT 5.1JUL 1204.09 806.91   
ACT 6.1GER 332.81 616.3   
ACT 7.1VUY 535.19 198.97   
ACT 8.1 LYN 860.98 1509.22   
ACT 9.1HEN 1472.8 291.65   
ACT 10.1SHA 948.92 131.2   
ACT 11.1CHA 2357.47 310.74   
ACT 12.1NAD 101 374.3   
ACT 13.1NOM 1671.5 965.99   
ACT 14.1GAY 1517.7 331.52   
ACT 15.1BER 1269.04 379.99   
ACT 16.1BON 546.74 793.25   
ACT 17.1MON 285.05 144.67   
ACT 18.1CHA 385.35 835.29   
ACT 19.1CHE 949.22 426.34   
ACT 20.1MYM 1017.5 619.58   
ACT 21.1NON 1209.6 765.63   
ACT 22.1VER 929.33 562.76   
ACT 23.1SHI 748.93 577.21   
ACT 24.1MER 321.74   
Patient deceased before sample 
2 procured 
ACT 25.1MAR 927.17 587.09   
ACT 26.1RHO 284.81 108.5   
ACT 27.1LUC 916.28 180.9   
ACT 28.1NOE 1155.7   Patient defaulted 
ACT 29.1GAD 231.58 648.42   
ACT 30.1TAN 135.93 335.36   
ACT 31.1DOR     
DNA Isolation failed for sample 1; 
patient defaulted for sample 2 
ACT 32.1SHA 395.24 420.3   
ACT 33.1SYL 151.08   Chemotherapy regimen changed 
ACT 34.1NEL 307.32 328.47   
ACT 35.1NTO 1168.9   Patient defaulted 
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ACT 36.1NAT 228.77 323.22   
ACT 37.1KUL 131.21   No treatment administered 
ACT 38.1MAR 820.18 333.33   
ACT 39.1SUS 879.15 1078.84   
ACT 40.1MON 101.57 190.86   
ACT 41.1PHE 239.3   Patient defaulted 
ACT 42.1LIE  383.96   Patient defaulted 
ACT 43.1DEN  508.37 214.14   
ACT 44.1HEL  778.58 520.41   
ACT 45.1NOK  594.36 662.52   
ACT 46.1ELI  153.71 402.42   
ACT 47.1SHA  180.16 346.74   
ACT 48.1YAL  275.37   Patient defaulted 
ACT 49.1NOS  260.96 44.9   
ACT 50.1PAM  452.16 103.2   
ACT 51.1BON  54.78 92.54   
ACT 52.1ANN  45.41   Patient defaulted 
ACT 53.1DEB  81.21   Patient defaulted 
ACT 54.1BAR  229.35 53.64   
ACT 55.1MAR  332.43   Patient defaulted 
ACT 56.1FEL  55.2   Patient defaulted 
ACT 57.1OLI  24.96 73.5   
ACT 58.1DOR  78.4   Patient defaulted 
ACT 59.1JAN  28.3 149.09   
ACT 60.1MAR  155.93 54.8   
ACT 61.1LAT  102.7 120.5   
ACT 62.1THA  65.6 57.6   
ACT 63.1ELI  25.1 68.8   
ACT 64.1NOK  29.8 147.7   
ACT 65.1MAR  88.62 52.9   
ACT 66.1RAC  162.72 154.2   
ACT 67.1TES  356.67 51.1   
ACT 68.1MAR  308.62 87.4   
ACT 69.1NOB  118.7   Patient defaulted 
ACT 70.1KAR  193.1 139.02   
ACT 71.1SHI  147.3   Sample 2 stored as buffy 
ACT 72.1MON 49.6   Sample 2 stored as buffy 
ACT 73.1ALY  65.3   Sample 2 stored as buffy 
ACT 74.1RAG  176.01   Sample 2 stored as buffy 
ACT 75.1ZUK  56.42   Sample 2 stored as buffy 
ACT 76.1DEL  138.23   Sample 2 stored as buffy 
ACT 77.1CHR  190.57   Sample 2 stored as buffy 
ACT 78.1BON  95.6   Sample 2 stored as buffy 
ACT 79.1VER  82.86   Sample 2 stored as buffy 
ACT 80.1MAR  169.89   Sample 2 stored as buffy 
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ACT 81.1ELI  248.69   Sample 2 stored as buffy 
ACT 82.1PAT  69   Sample 2 stored as buffy 
ACT 83.1YVO  302.16   Sample 2 stored as buffy 
ACT 84.1EUA  67.21   Sample 2 stored as buffy 
ACT 85.1CHR  82.11   Sample 2 stored as buffy 
ACT 86.1YOL  231.57   Sample 2 stored as buffy 
ACT 87.1JOL  103.35   Sample 2 stored as buffy 
ACT 88.1TAN  225.67   Sample 2 stored as buffy 
ACT 89.1MAR  171.46   Sample 2 stored as buffy 
ACT 90.1ANT  550.46   Sample 2 stored as buffy 
ACT 91.1LIZ  340.34   Sample 2 stored as buffy 
ACT 92.1JAM  118.76   Sample 2 stored as buffy 
ACT 93.1NAZ  71.24   Sample 2 stored as buffy 
ACT 94.1AVR  47.61   Sample 2 stored as buffy 
ACT 95.1VUY  183.76   Sample 2 stored as buffy 
ACT 96.1FAG  66.63   Sample 2 stored as buffy 
ACT 97.1MAG  29.89   Sample 2 stored as buffy 
ACT 98.1AVR  21.94   Sample 2 stored as buffy 
ACT 99.1PAT  27.78   Sample 2 stored as buffy 
ACT 100.1 NOM  52   Sample 2 stored as buffy 
ACT 101.1MAR  177.93   Sample 2 stored as buffy 
ACT 102.1PAU  286.96   Sample 2 stored as buffy 
ACT 103.1INS  75.08   Sample 2 stored as buffy 
ACT 104.1NOT  57.78   Sample 2 stored as buffy 
ACT 105.1NAN  58.26   Sample 2 stored as buffy 
ACT 106.1ELL 19.51   Sample 2 stored as buffy 
ACT 107.1NOM 20.02   Sample 2 stored as buffy 
ACT 108.1CHR 72.82   Sample 2 stored as buffy 
ACT 109.1SAN 40.38   Sample 2 stored as buffy 
ACT 110.1JEA 150.19   Sample 2 stored as buffy 
ACT 111.1THE 25.68   Sample 2 stored as buffy 
ACT 112.1RUB 189.17   Sample 2 stored as buffy 
ACT 113.1JEA 117.57   Sample 2 stored as buffy 
ACT 114.1PAM 33.72   Sample 2 stored as buffy 
ACT 115.1ANN 23.25   Sample 2 stored as buffy 
ACT 116.1SHI 28.37   Sample 2 stored as buffy 
ACT 117.1VIO 62.99   Sample 2 stored as buffy 
ACT 118.1GLE 133.19   Sample 2 stored as buffy 
ACT 119.1ROW 116.77   Sample 2 stored as buffy 
ACT 120.1VAL 93.94   Sample 2 stored as buffy 
ACT 121.1MAR 91.54   Sample 2 stored as buffy 
ACT 122.1GRA 59.51   Sample 2 stored as buffy 
ACT 123.1LUL 50.23   Sample 2 stored as buffy 
ACT 124.1NCU 186.94   Sample 2 stored as buffy 
ACT 125.1SHA 105.63   Sample 2 stored as buffy 
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ACT 126.1GEO 67.88   Sample 2 stored as buffy 
ACT 127.1AME 11.15   Sample 2 stored as buffy 
ACT 128.1CHR 176.37   Sample 2 stored as buffy 
ACT 129.1AME 111.99   Sample 2 stored as buffy 
ACT 130.1MIN 121.62   Sample 2 stored as buffy 
ACT 131.1ELI 102.25   Sample 2 stored as buffy 
ACT 132.1NIC 89.01   Sample 2 stored as buffy 
ACT 133.1AMA 153.66   Sample 2 stored as buffy 
ACT 134.1ADR 103.7   Sample 2 stored as buffy 
ACT 135.1FIO 107   Sample 2 stored as buffy 
ACT 136.1JUR 93.76   Sample 2 stored as buffy 
ACT 137.1CYN 95.41   Sample 2 stored as buffy 
ACT 138.1JEA 44.63   Sample 2 stored as buffy 
ACT 139.1HEN 74.48   Sample 2 stored as buffy 
ACT 140.1URS 32.27   Sample 2 stored as buffy 
ACT 141.1MAR 42.28   Sample 2 stored as buffy 
ACT 142.1ALE 115.33   Sample 2 stored as buffy 
ACT 143.1DES 102.58   Sample 2 stored as buffy 
ACT 144.1NOK 43.19   Sample 2 stored as buffy 
ACT 145.1JAC 110.64   Sample 2 stored as buffy 
ACT 146.1ELI 52.1   Sample 2 stored as buffy 
ACT 147.1SHI 158.18   Sample 2 stored as buffy 
ACT 148.1GER 76.9   Sample 2 stored as buffy 
ACT 149.1ZEL 287.11   Sample 2 stored as buffy 
ACT 150.1KAT 47.43   Sample 2 stored as buffy 
ACT 151.1AMA 94   Sample 2 stored as buffy 
ACT 152.1ALE 40.94   Sample 2 stored as buffy 
ACT 153.1SOF 240.04   Sample 2 stored as buffy 
ACT 154.1SHA 18.09   Sample 2 stored as buffy 
ACT 155.1TAN 131.21   Sample 2 stored as buffy 
ACT 156.1LUC 37.16   Sample 2 stored as buffy 
ACT 157.1LIL 250.23   Sample 2 stored as buffy 
ACT 158.1NOM 56.89   Sample 2 stored as buffy 
ACT 159.1WIL 99.1   Sample 2 stored as buffy 
ACT 160.1MYR 5.17   Sample 2 stored as buffy 
ACT 161.1MIC 83.91   Sample 2 stored as buffy 
ACT 162.1LYN 37.72   Sample 2 stored as buffy 
ACT 163.1JOH 25.27   Sample 2 stored as buffy 
ACT 164.1EVA 68.35   Sample 2 stored as buffy 
ACT 165.1JEN 85.04   Sample 2 stored as buffy 
ACT 166.1SUS 49.55   Sample 2 stored as buffy 
ACT 167.1LUN 19.95   Sample 2 stored as buffy 
ACT 168.1RAC 39.83   Sample 2 stored as buffy 
ACT 169.1NOK 102.67   Sample 2 stored as buffy 
ACT 170.1NOV 163.38   Sample 2 stored as buffy 
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ACT 171.1NOK 688.71   Sample 2 stored as buffy 
ACT 172.1MAR 261.47   Sample 2 stored as buffy 
ACT 173.1LEA 344.45   Sample 2 stored as buffy 
ACT 174.1JOA 68.97   Sample 2 stored as buffy 
ACT 175.1JOH 281.45   Sample 2 stored as buffy 
ACT 176.1MAR 987.31   Sample 2 stored as buffy 
ACT 177.1ANN 110.75   Sample 2 stored as buffy 
ACT 178.1RAC 349.14   Sample 2 stored as buffy 
ACT 179.1NAZ 419.74   Sample 2 stored as buffy 
ACT 180.1MIC 168.29   Sample 2 stored as buffy 
ACT 181.1LAU 137.91   Sample 2 stored as buffy 
ACT 182.1THA 657.25   Sample 2 stored as buffy 
ACT 183.1WEN 96.84   Sample 2 stored as buffy 
ACT 184.1SAR 96.31   Sample 2 stored as buffy 
ACT 185.1FLO 976.93   Sample 2 stored as buffy 
ACT 186.1VER 590.32   Sample 2 stored as buffy 
ACT 187.1RUK 371.95   Sample 2 stored as buffy 
ACT 188.1LOR 75.43   Sample 2 stored as buffy 
ACT 189.1LEL 136.21   Sample 2 stored as buffy 
ACT 190.1BAD 1281.4   Sample 2 stored as buffy 
ACT 191.1PET 777.44   Sample 2 stored as buffy 
ACT 192.1NTO 313.3   Sample 2 stored as buffy 
ACT 193.1FRA 782.92   Sample 2 stored as buffy 
ACT 194.1YOL 747.9   Sample 2 stored as buffy 
ACT 195.1LOR 694.16   Sample 2 stored as buffy 
ACT 196.1JUD 560.45   Sample 2 stored as buffy 
ACT 197.1PET 183.82   Sample 2 stored as buffy 
ACT 198.1ALV 192.12   Sample 2 stored as buffy 
ACT 199.1PAT 106.45   Sample 2 stored as buffy 
ACT 200.1KAR 440.13   Sample 2 stored as buffy 
ACT 201.1NTO 66.91   Sample 2 stored as buffy 
ACT 202.1JAC 196.86   Sample 2 stored as buffy 
ACT 203.1BEA 155.92   Sample 2 stored as buffy 
ACT 204.1MUR 22.42   Sample 2 stored as buffy 
ACT 205.1ZUR 521.45   Sample 2 stored as buffy 
ACT 206.1NOA 282.67   Sample 2 stored as buffy 
ACT 207.1MAG 305.56   Sample 2 stored as buffy 
ACT 208.1RAC 233.67   Sample 2 stored as buffy 
ACT 209.1VEN 49.16   Sample 2 stored as buffy 
ACT 210.1JOH 212.56   Sample 2 stored as buffy 
ACT 211.1VER 440   Sample 2 stored as buffy 
ACT 212.1ALI 216.81   Sample 2 stored as buffy 
ACT 213.1DES 312.04   Sample 2 stored as buffy 
ACT 214.1SHI 130.27   Sample 2 stored as buffy 
ACT 215.1GER 555.82   Sample 2 stored as buffy 
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ACT 216.1FUN 646.26   Sample 2 stored as buffy 
ACT 217.1MIE 97.86   Sample 2 stored as buffy 
ACT 218.1PAT 271.82   Sample 2 stored as buffy 
ACT 219.1MAG 468.66   Sample 2 stored as buffy 
ACT 220.1MAU 199.7   Sample 2 stored as buffy 
ACT 221.1BER 413.44   Sample 2 stored as buffy 
ACT 222.1STE 201.95   Sample 2 stored as buffy 
ACT 223.1PLI 75.69   Sample 2 stored as buffy 
ACT 224.1FLO 100.25   Sample 2 stored as buffy 
ACT 225.1KAR 454.62   Sample 2 stored as buffy 
ACT 226.1SER 92.82   Sample 2 stored as buffy 
ACT 227.1LUC 243.93   Sample 2 stored as buffy 
ACT 228.1DUN 47.05   Sample 2 stored as buffy 
ACT 229.1ROS 56.45   Sample 2 stored as buffy 
ACT 230.1WIL 513.23   Sample 2 stored as buffy 
ACT 231.1ELS 634.41   Sample 2 stored as buffy 
ACT 232.1ALE 638.29   Sample 2 stored as buffy 
ACT 233.1ANI 465.57   Sample 2 stored as buffy 
ACT 234.1CHR 299.49   Sample 2 stored as buffy 
ACT 235.1ELI 267.6   Sample 2 stored as buffy 
ACT 236.1RUT 174.89   Sample 2 stored as buffy 
ACT 237.1ELI 152.36   Sample 2 stored as buffy 
ACT 238.1BEU 581.08   Sample 2 stored as buffy 
ACT 239.1BUS  1742.5   Sample 2 stored as buffy 
ACT 240.1TAR 670.17   Sample 2 stored as buffy 
ACT 241.1CAT 407.82   Sample 2 stored as buffy 
ACT 242.1EME 520.35   Sample 2 stored as buffy 
ACT 243.1CHR 696.28   Sample 2 stored as buffy 
ACT 244.1LYD 578.75   Sample 2 stored as buffy 
ACT 245.1RAC 290.01   Sample 2 stored as buffy 
ACT 246.1SUS 97.36   Sample 2 stored as buffy 
ACT 247.1ELI 263.33   Sample 2 stored as buffy 
ACT 248.1BUS 246.17   Sample 2 stored as buffy 
ACT 249.1JAN 543.42   Sample 2 stored as buffy 
ACT 250.1THA 89.19   Sample 2 stored as buffy 
ACT 251.1WEN 600.6   Sample 2 stored as buffy 
ACT 252.1JOH 306.36   Sample 2 stored as buffy 
ACT 253.1FRA 369.31   Sample 2 stored as buffy 
ACT 254.1JON 328.43   Sample 2 stored as buffy 
ACT 255.1VAN 704.44   Sample 2 stored as buffy 
ACT 256.1CAR 507.32   Sample 2 stored as buffy 
ACT 257.1ANN 705.13   Sample 2 stored as buffy 
ACT 258.1BER 497.99   Sample 2 stored as buffy 
ACT 259.1CAR 611.26   Sample 2 stored as buffy 
ACT 260.1NAO 257.88   Sample 2 stored as buffy 
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ACT 261.1FLO 570.03   Sample 2 stored as buffy 
ACT 262.1LEZ 413.59   Sample 2 stored as buffy 
ACT 263.1SUZ 59.54   Sample 2 stored as buffy 
ACT 264.1ANN 454.65   Sample 2 stored as buffy 
ACT 265.1EST 406.05   Sample 2 stored as buffy 
ACT 266.1SAR 380.05   Sample 2 stored as buffy 
ACT 267.1JOH 197.99   Sample 2 stored as buffy 
ACT 268.1CAT 503.42   Sample 2 stored as buffy 
ACT 269.1HAZ 489.64   Sample 2 stored as buffy 
ACT 270.1NOM 439.12   Sample 2 stored as buffy 
ACT 271.1MOI 657.32   Sample 2 stored as buffy 
ACT 272.1MAR 232.58   Sample 2 stored as buffy 
ACT 273.1THE 503.84   Sample 2 stored as buffy 
ACT 274.1MER 1871   Sample 2 stored as buffy 
ACT 275.1CAR 317.49   Sample 2 stored as buffy 
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Appendix I: Spectrophotometric quantitation of DNA 
 
 
Figure 1: Representation of the spectrophotometric quantitation of patient DNA 
samples (ACT 193.1FRA) using the NanoDrop ND-1000 (Nanodrop Technologies, 
USA) 
 
Figure 2: Representation of the spectrophotometric quantitation of a control DNA 
sample (C35F) before being utilized in the optimisation of the TaqMan™ Genotyping 
Assay using the NanoDrop ND-1000 (Nanodrop Technologies, USA) 
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